CanSinoBIO

2025

Environmental, Social and Governance (ESG) & Sustainability Report

CanSinoBIO

CONTENTS

About the Report

Following the principle of objectivity, standardization, transparency, and comprehensiveness, the Environmental, Social and Governance (ESG) & Sustainability Report provides a detailed disclosure of CanSinoBIO's social responsibility practices and performance in ESG and sustainability across various areas, including operations and development, environment, labor and community, and value chain.

Basis of Preparation

The Report is prepared in accordance with the *Environmental, Social and Governance Reporting Code* set out in Appendix C2 to the *Rules Governing the Listing of Securities (the Listing Rules)* on HKEX and the *SSE Environmental Information Disclosure Guidelines for Listed Companies* by Shanghai Stock Exchange, with reference to the *Guidelines No.14 of Shanghai Stock Exchange for Self-Regulation of Listed Companies-Sustainability Report (Trial)*, as well as the requirements of the GRI Standards issued by the Global Sustainability Standards Boards (GSSB).

Scope of Report

The Report involves the major research and development ("R&D") and manufacturing sites, workplaces and subsidiaries of CanSino Biologics Inc. It covers the period from January 1, 2025, to December 31, 2025, with some reviews over previous years and the forecast of 2026 when necessary. Notes will be found in the text when the data scope is inconsistent with the Report.

Source of Information

The information and cases herein were extracted mainly from the Company's statistical reports, internal communications, and other relevant documents. The financial data involved are sourced from the annual financial statement of CanSino Biologics Inc. unless otherwise specified. Other data comes from internal statistics and manual collation within the Company.

Reporting Principle

- **Materiality:** To prepare this Report, the Company follows the materiality assessment procedure to determine what and to which extent these contents should be disclosed in the Report. The results of the materiality analysis in 2025 are available in the chapter "Stakeholder Communication".
- **Quantitative:** The Report discloses the quantitative information on environmental and social aspects to present our performance in main ESG KPIs.
- **Balance:** The Report objectively discloses both positive and negative information to ensure balanced disclosures.
- **Consistency:** Data disclosed herein are for 2025 unless otherwise specified. We will prepare the future ESG report with consistent statistical methodologies according to the actual management, and disclose the comparative data for consecutive years as far as possible to help readers better understand how indicators change over time. Unless otherwise stated, the data disclosed in the Report are counted according to the unified information collection process and mechanism established by the Company to ensure comparability.

References

To facilitate presentation and reading, in the Report, "CanSino Biologics Inc." is also referred to as "CanSinoBIO", "the Company", or "we". CanSino Biologics Inc. and its subsidiaries are referred to as "the Group". The monetary unit adopted in the Report is RMB (yuan) unless otherwise specified.

About CanSinoBIO

Company Profile

Incorporated in Tianjin Economic-Technological Development Area (TEDA) West District, Tianjin in 2009, CanSino Biologics Inc. is a high-tech company dedicated to the R&D, production, and commercialization of high-quality innovative vaccines (stock code in H-share: CanSinoBIO 06185.HK, stock code in A-share: CanSino 688185.SH).

CanSinoBIO has gathered a vast array of senior scientists in the vaccine field and technical experts with extensive backgrounds in major domestic and international pharmaceutical companies. Possessing superior management capabilities and robust research and development strength, the Company is rapidly advancing the research, development, production, and social responsibility initiatives for innovative vaccines. It remains steadfast in its commitment to developing and providing high-quality vaccine products to contribute to global public health.

Technology platforms

CanSinoBIO has established five core technology platforms: adenovirusbased viral vector technology, synthetic biotechnology, protein structure design and VLP assembly, mRNA technology, formulation and drug delivery technology.

Vaccine R&D

The R&D pipeline covers multiple innovative vaccines in more than 10 disease fields such as meningitis, pneumonia, DPT, novel coronavirus (COVID-19), Ebola virus disease, herpes zoster, tuberculosis, etc.

Vaccine manufacturing

CanSinoBIO has established largescale modern vaccine industrial bases in Tianjin and Shanghai, China, and has contributed to multiple local production lines in countries and regions such as Mexico, Pakistan, and Malaysia to supply innovative vaccines in multiple locations.

Collaborations

The Company has established partnerships with Barinthus Biotherapeutics (formerly Vaccitech) and Ocugen, etc.

Under the mission of "To Provide Innovative, High-Quality and Affordable Vaccines", CanSinoBIO proactively fulfills the vision of "Innovation for a Safer World". We pursue the value of "Respect, Agility, Innovation, Superior in Quality and Engagement" to treasure the reverence and protection of life.

Culture and Value

To Provide Innovative, High-Quality and Affordable Vaccines

Innovation for a Safer World

RAISE

Respect
Agility
Innovation
Superior in quality
Engagement



Milestones in 2025

Jan.

A delegation led by the Vice Minister of Health of Türkiye visited CanSinoBIO to strengthen international cooperation under the Belt and Road Initiative, particularly in the biopharmaceutical sector. CanSinoBIO will continue to meet local and global disease prevention and control needs with more innovative, high-quality, and affordable vaccine products, advance international cooperation in public health, and contribute to global health.

Feb.

CanSinoBIO's quadrivalent meningococcal polysaccharide conjugate vaccine (MenACWY135) with CRM197 carrier, Menhycia®, received Halal certification from the Food, Drug and Cosmetics Assessment Agency of the Indonesian Ulema Council, laying an important foundation for the Company's international commercialization.

The DTcP vaccine (diphtheria, tetanus and acellular pertussis components) for infants (DTcP Infant), developed by CanSinoBIO, was officially included in the priority review pathway. To date, no such vaccine developed by a domestic vaccine manufacturer has been approved for marketing in China.

As a representative Chinese innovative vaccine company, CanSinoBIO was invited to attend the 2025 World Governments Summit in Dubai, where it shared case studies of innovation and proposed reshaping the global public health system through technological innovation and win-win cooperation.

Mar.

During the 2025 Two Sessions, Zhu Tao, a member of the National Committee of the Chinese People's Political Consultative Conference and Chief Scientific Officer of CanSinoBIO, proposed expanding vaccination across all age groups, improving the efficiency of translating pharmaceutical innovation into practical outcomes, optimizing the review and approval mechanism for combination vaccines, and supporting the global expansion of high-quality domestic vaccines.

CanSinoBIO signed an exclusive commercialization agreement for adsorbed tetanus vaccine with Grand Life Sciences Group Co., Ltd. Under the agreement, upon approval of the vaccine, the Company will authorize Grand Life Sciences to provide exclusive promotion services in Greater China, further expanding vaccine accessibility.

CanSinoBIO participated in the 2025 International Vaccine Innovation Forum. Wang Jing, Chief Business Officer, engaged in in-depth dialogue with guests and shared multidimensional solutions to support global vaccine equity, drawing on the Company's practices in localized manufacturing, public education, and demand-driven innovation.

Together with international partners, CanSinoBIO accelerated the market entry of its quadrivalent meningococcal conjugate vaccine Menhycia® into Saudi Arabia and other Middle East and North Africa markets, while also advancing joint R&D and the development of localized manufacturing systems.

Apr.

CanSinoBIO's subsidiary, CanSinoBIO (Shanghai), entered into a strategic partnership with Jenkem Tianjin, a wholly owned subsidiary of Jenkem Technology, to jointly advance a clinical research project on an mRNA vaccine for the treatment of glioblastoma multiforme (GBM), expanding capabilities in infectious disease prevention and control as well as tumor immunotherapy and other fields.

May.

The inhaled tuberculosis booster vaccine developed by CanSinoBIO received clinical trial approval in Indonesia. The Company has established a complete inhalation formulation and quality control system, upgraded the first-generation product, and added antigen components to develop this inhaled tuberculosis booster vaccine. Delivered by nebulization, the vaccine is expected to induce pulmonary immune responses, thereby helping eliminate Mycobacterium tuberculosis, control latent infection, and potentially prevent infection.

Jun.

CanSinoBIO's self-developed 13-valent pneumococcal conjugate vaccine, iPneucia® (PCV13*i*), was officially approved by the National Medical Products Administration, becoming China's first pneumococcal conjugate vaccine to use a dual-carrier system of non-toxic mutant of diphtheria toxin (CRM197) and tetanus toxoid (TT).

CanSinoBIO globally launched its three-component LNP delivery system, breaking through industry patent barriers and providing an innovative solution for mRNA vaccine and drug delivery.

CanSinoBIO was awarded the First Prize of the Tianjin Science and Technology Progress Award.

CanSinoBIO was included in the S&P Global Sustainability Yearbook (China Edition) 2025.

Milestones in 2025

Jul.

CanSinoBIO's recombinant polio vaccine received approval for clinical trials in China and may proceed with clinical studies for the prevention of polio caused by infection with poliovirus types I, II, and III.

Aug.

Dr. Yu Xuefeng, Chairman and Chief Executive Officer of CanSinoBIO, gave an exclusive live interview with Bloomberg TV, sharing the Company's high-quality innovation strategy and global market development plans.

Sep.

CanSinoBIO's self-developed 13-valent pneumococcal conjugate vaccine, iPneucia® (PCV13*i*), was shipped to the domestic market, further strengthening the Company's supply capabilities in China's vaccine market.

Menhycia® (MCV4), Asia's first quadrivalent meningococcal polysaccharide conjugate vaccine, was shipped to overseas markets, marking an important step in CanSinoBIO's international commercial expansion.

Oct.

As a representative innovative enterprise, CanSinoBIO was invited to attend the Annual Consultation of the Global Polio Eradication Initiative (GPEI), where progress in the development of its recombinant polio vaccine was included in the meeting report. According to the report, VLP technology is increasingly regarded as a key pillar in long-term vaccine safety and supply security strategies. CanSinoBIO's recombinant polio vaccine does not use any live poliovirus during production, fully aligning with long-term biosafety containment goals.

Nov.

To support international cooperation and regulatory coordination, the Tianjin Drug Administration and the Indonesian Food and Drug Authority held a meeting at CanSinoBIO. This will promote closer exchange and cooperation between Chinese and Indonesian biopharmaceutical companies in areas such as vaccine technology transfer and quality standards.

CanSinoBIO signed a licensing agreement with Panru Biotech to expand the application prospects of the three-component LNP delivery system and deepen cooperation in the mRNA technology field.

The inhaled tuberculosis vaccine initiated its Phase I clinical trial in Indonesia and enrolled its first participant.

Dec.

In recognition of its sustained commitment and outstanding performance in ESG practices, CanSinoBIO was once again named one of the "Best ESG Employers in China 2025."

CanSinoBIO's DTcP-Hib-MCV4 combination vaccine initiated its Phase I clinical trial, marking important progress in the Company's development of innovative multivalent combination vaccines.

Accolades in 2025

2025 China Best ESG Employer

Aon Group

Specialized and Innovation-driven “Little Giant” Enterprise

Ministry of Industry and Information Technology of the People's Republic of China

High and New Technology Enterprise

Tianjin Municipal Science and Technology Bureau; Tianjin Municipal Finance Bureau; Tianjin Tax Service, State Taxation Administration

First Prize of Tianjin Science and Technology Progress Award

Tianjin Municipal People's Government

Tianjin Cheetah Enterprise

Tianjin Municipal Science and Technology Bureau



Tianjin Engineering Research Center for Key Technologies in Innovative Vaccine Industrialization (Assessment Passed)

Tianjin Municipal Development and Reform Commission

Chairman's Statement

Looking back on 2025, CanSinoBIO remained true to its founding mission of "Health, Hope, Promise," making steady progress in vaccine R&D and manufacturing and in advancing global public health, with notable results. We firmly believe that sustainable corporate success must be built on a deep understanding of, and concrete commitment to, environmental, social and governance (ESG) issues. With this in mind, we have deeply embedded ESG into our corporate strategy and day-to-day operations, striving to contribute to long-term social prosperity while achieving business success.

We uphold compliance to strengthen the foundation of operations. Integrity and compliance are the unwavering cornerstones of CanSinoBIO. We adhere to the principles of openness and transparency, uphold the highest standards of business ethics, and continuously enhance the effectiveness of our compliance management system. In 2025, the Company successfully passed the surveillance audits for both the ISO 37301 Compliance Management System and the ISO 37001 Anti-Bribery Management System. This demonstrates the sound operation of our scientific management framework, which is centered on risk control and supported by process management, ensuring that all business activities are carried out steadily within a lawful and compliant framework.

We drive innovation to safeguard life and health. Advancing human health is the ultimate goal of all our work. Leveraging our five core technology platforms: adenovirusbased viral vector technology, synthetic biotechnology, protein structure design and VLP assembly, mRNA and LNP technology, and formulation and delivery technologies, we made important progress in both emerging infectious diseases and conventional diseases in 2025. We successfully developed and advanced the approval and application of multiple innovative vaccines, earning broad international recognition. Our R&D pipeline continues to expand, with the aim of providing more comprehensive and accessible health protection for people of all age groups. We firmly believe that the future of vaccine science holds immense promise, and we will continue to explore new frontiers to deliver better health solutions to the world.

We promote shared growth to build stronger momentum. Our employees are CanSinoBIO's most valuable asset, and the communities in which we operate are the foundation of our development. We are committed to building a platform that respects talent and unlocks potential, while giving back to society through concrete actions. Over the past year, we have continued to improve our training and career development systems, launching multiple initiatives designed to enhance professional capabilities and leadership skills, helping employees grow alongside the Company. In community engagement, we actively fulfilled our corporate citizenship responsibilities by carrying out philanthropy and other activities to extend health and well-being to broader communities. We believe that only by advancing together with our employees and fostering harmonious coexistence with society can we generate the strongest and most enduring momentum for development and truly create shared value for both business and society.

We advance green development and value nature's gifts. We deeply recognize the close connection between business operations and the ecological environment. We therefore remain firmly committed to a green and low-carbon development path. Internally, we have comprehensively implemented energy-saving and carbon-reduction measures, systematically advanced climate actions, and continuously reduced the environmental impact of our operations. At the same time, we are committed to working with partners across the industrial chain to explore and build more environmentally friendly and sustainable models for pharmaceutical R&D, production, and consumption, so that we can fulfill our responsibility to our shared planet.

Looking ahead, we will continue to steer with science and sail with sustainability, constantly expanding the boundaries of health through innovation, safeguarding our development journey through strong governance and compliance, bringing together the strength of employees and society through shared growth, and actively reshaping the industry ecosystem through green development. We stand ready to work hand in hand with all our partners to create a more resilient and sustainable future for public health.

ESG Governance System

As an innovation-driven vaccine company, CanSinoBIO integrates the ESG philosophy into its core development strategy. Regarding the environmental aspect, CanSinoBIO upholds the philosophy of green practices. The Company consistently optimizes production processes, aiming to reduce energy consumption and emissions and pursuing harmonious coexistence with the environment. As for the social responsibility, CanSinoBIO is deeply committed to the R&D and innovation of vaccines, actively responds to the UN's Sustainable Development Goals (SDGs), and is dedicated to providing solutions to the prevention of infectious diseases worldwide. For governance, CanSinoBIO adheres to standardized and transparent management principles, establishes and improves a sound corporate governance structure and internal control system, and ensures scientific and effective decisions. Looking ahead, we will continue to improve vaccine accessibility with innovative technologies, and strive to achieve coordinated development between the economy, society, and environment, contributing to the global healthcare.

Board Statement

The Board of CanSinoBIO has always been committed to deeply integrating the ESG philosophy into the Company's development strategies. The Board has been keeping track of ESG performance in every aspect of the daily operation to optimize the ESG management system. We have proactively responded to the expectations of various stakeholders while ensuring the realization of operational goals. The Board takes relevant social responsibilities and creates long-term values for society to lay a solid foundation for the sustainable and high-quality development of the Company.

The Board of Directors of CanSinoBIO strictly complies with the *Code of Corporate Governance for Listed Companies*, the *Environmental Information Disclosure Guidelines for Listed Companies* by Shanghai Stock Exchange, and the *Environmental, Social, and Governance Reporting Guide* of the HKEX. The Company formulated and issued the *Environmental, Social and Governance (ESG) Management Policy* to establish a standardized and effective ESG management and information disclosure system and ensure the orderly flow of ESG work.

As the highest decision-making body of the Group responsible for ESG management, the Board is responsible for overseeing and approving ESG strategies, work plans, and other key matters. The Board regularly reviews the progress of ESG goals and ensures the effective operation of the risk management system. As the supervisory and advisory body for ESG matters, the Audit Committee reviews the Company's ESG strategy and reports while reporting progress to the Board. The Company has also established a dedicated working group that collaborates with various departments and subsidiaries to ensure the enforcement of various policies. In 2025, the Board reviewed the environmental targets from the previous year to ensure their steady progress.

Each year, the Board conducts a comprehensive assessment of ESG materiality based on the Company's development to determine key directions for ESG risk management in the following year. The Company regularly reviews and updates its ESG risk management plan to promote effective alignment between risk management and business operations. Under the guidance of the Audit Committee, it continuously improves its risk management system to ensure the efficient operation of relevant mechanisms.

The Report truthfully discloses the ESG development and achievements of CanSinoBIO in 2025, which will be issued after approval from the Board on March 30, 2026.

ESG Philosophy and Strategy

CanSinoBIO integrates ESG philosophy into its core strategy, striving for sustainable development. We aim to promote ESG practices across our daily operation through four strategic pillars: Green Development, Product Responsibility, Value Creation, and Governance Enhancement.

In terms of green development, we follow a green and low-carbon development path by optimizing production management and minimizing emissions and energy consumption. Besides, we take efforts to implement efficient waste management strategies, realize strategic management of water and energy resources, and proactively address climate change, striving to achieve harmonious coexistence with the environment.

In terms of product responsibility, we strictly enforce product quality control and monitoring, continuously promote innovation and R&D, and enhance healthcare accessibility. We are committed to protecting customer rights and collaborating with international organizations, governments, and enterprises to advance the pharmaceutical industry, contributing to global health development.

In terms of value creation, we attach great importance to employee rights and benefits, striving to foster a diverse, equitable, and inclusive work environment. We provide competitive salaries and diversified growth opportunities to support the shared development of both employees and the Company. Meanwhile, we actively engage in community development and charity, responding to the health needs of various sectors and contributing to the advancement of public health.

In terms of governance enhancement, we continuously optimize our governance system, deeply integrating ESG governance with corporate governance to ensure compliant and transparent operations. We emphasize ESG management for our supply chain, collaborating with suppliers to build a transparent, honest, and mutually beneficial business environment. Committed to business ethics, we firmly oppose corruption and aims to lay a solid foundation for sustainable development.

ESG Governance System

CanSinoBIO fully integrates the principles of sustainable development into its corporate strategy and management practices, and continues to improve its governance structure and management mechanisms. CanSinoBIO has built an ESG governance structure consisting of the Board, the Audit Committee, and the ESG Working Group. The Board and the Audit Committee constitute the governance body responsible for strategy formulation and monitoring, while the ESG Working Group leads and coordinates all departments to strengthen overall ESG management. Along with that, the Company incorporates each department and business unit into the ESG governance system to leverage the capabilities of each tier and implement the philosophy of sustainable development in a comprehensive manner.



The Company has established the *Environmental, Social and Governance (ESG) Management Policy*, which defines the division of ESG management responsibilities, work content, assessment mechanisms, and information collection requirements, providing an institutional foundation for the systematic implementation of ESG-related work. The policy covers key areas including ESG principles and concepts, management responsibilities, system development, work content, and data assessment, ensuring that responsibilities are clearly assigned to the relevant departments.

In terms of risk management, we have established a comprehensive ESG risk identification and control system. The Audit Committee is responsible for overseeing and monitoring ESG risks, the Board of Directors evaluates risks and formulates response strategies, and the ESG Working Group coordinates with various departments to implement specific measures. Through regular internal audits, on-site inspections, and employee training, the Company ensures effective prevention and control of ESG risks and continuously strengthens its resilience against risk.

The Board

- Responsible for the overall supervision and review of the Company's ESG strategy, work plans, and related major matters, and for regularly evaluating progress on key ESG topics and overseeing the implementation of targets;
- Approves decisions related to ESG risks and opportunities in connection with the Company's development, ensuring the effective operation of ESG risk management and internal control systems;
- Reviews and approves the Company's annual ESG-related reports, including the ESG Report, Corporate Social Responsibility Report, and Sustainability Report.

Audit Committee

- Responsible for reviewing the Company's ESG strategy and work plans;
- Evaluates material ESG risks and opportunities;
- Approves ESG-related management policies;
- Reviews and approves the annual ESG report, including the Corporate Social Responsibility Report and Sustainability Report.

ESG Working Group

- Carries out its work under the direct leadership of the Audit Committee, and is responsible for advancing ESG-related management and practices, while reporting regularly to the Audit Committee and the Company's Executive Committee;
- Develops ESG strategies and annual work plans, and sets specific measurable targets based on ESG management and target achievement;
- Takes the lead in organizing the identification and assessment of ESG-related risks and opportunities, and prepares reports on assessment results and response measures;
- Systematically reviews and continuously improves relevant policies under each ESG topic, and coordinates across functional departments to carry out and implement ESG-related work.

Functional Department and subsidiary

- Implements relevant internal tasks in line with the Company's ESG objectives and work plans, and promotes the timely achievement of all targets;
- Completes ESG-related work such as information disclosure and project implementation;
- Strengthens communication with stakeholders, proactively understands their ESG-related expectations, and communicates the Company's ESG initiatives and performance to them.

Contribution and Response to the SDGs

Our Actions in 2025	Corresponding Chapters
CanSinoBIO remains committed to supporting community development in areas such as disability assistance, medical support, and rural revitalization, while actively contributing to public welfare initiatives.	Community Development and Public Welfare
Guided by its mission to help build a global community of health for all, CanSinoBIO honors its commitment to providing safe vaccines to the public, actively supports the Doha Declaration, and is dedicated to continuously improving the global accessibility and affordability of medicines.	Medical Health Accessibility
CanSinoBIO values gender equality and is committed to ensuring female employees have equal opportunities for promotion and career development. In 2025, women accounted for 52.47% of total employees and 44.83% of management.	Employment and Rights Protection
CanSinoBIO continues to improve its compensation, performance management, and incentive systems to ensure employees' efforts are properly recognized and rewarded, while providing a fair and competitive workplace. In 2025, 23.02% of key employees were covered by the employee share ownership plan.	Compensation and Benefits
With the vision of "Innovation for a Safer World," CanSinoBIO has long been deeply engaged in vaccine R&D and technological innovation across more than ten disease areas, and is committed to providing sustainable vaccine solutions. The Company also actively supports developing countries in building local vaccine R&D and manufacturing capabilities, contributing critical strength to the establishment of a global immunization barrier.	Local Innovation, Global Impact / Product Innovation and R&D / Medical Health Accessibility

Contribution and Response to the SDGs

Our Actions in 2025	Corresponding Chapters
Upholding its commitment to human rights and equality, CanSinoBIO is dedicated to advancing the equitable development of global health. We pay close attention to disease prevention and control needs in underdeveloped countries and regions, and through continued technology transfer and deeper local collaboration, we enhance vaccine accessibility in these areas to help build a fairer global health environment.	Local Innovation, Global Impact / Medical Health Accessibility
CanSinoBIO has established a quality management system covering the full product lifecycle and continues to optimize its pharmacovigilance and product recall mechanisms, providing the public with safe, reliable, and trustworthy vaccine products.	Product Safety and Quality
CanSinoBIO adheres to green development and systematically carries out climate risk assessment and opportunity identification. By reducing the carbon footprint of its own operations, the Company responds to climate challenges, actively supports China's carbon peaking and carbon neutrality strategy, drives industry innovation and upgrading, and captures new opportunities for sustainable development.	Green Development: Practicing Environmental Responsibility for a Low-Carbon Future
CanSinoBIO consistently upholds a business philosophy centered on compliance and accountability, and is committed to building an efficient and collaborative governance structure. The Company actively promotes board diversity and continues to uphold business ethics and integrity.	Strengthening Governance: Improving Governance Systems for Steady Development
CanSinoBIO deepens collaboration with research institutions, government authorities, international organizations, and other partners to jointly advance vaccine R&D and innovative applications. We are committed to working with all stakeholders to help build a global community of health for all and promote the development of global public health.	Local Innovation, Global Impact / Product Innovation and R&D / Medical Health Accessibility / Responsible Supply Chain

Stakeholder Communication

CanSinoBIO attaches great importance to communication with its stakeholders. We actively listen to and respond to suggestions and inquiries from all sectors of society, and continuously enhance communication transparency and engagement efficiency by further improving diversified communication channels.

Stakeholder Communication

Stakeholder	Government and regulators	Shareholders and investors	Employees	Customers and users	Suppliers and partners	Media and NGOs	Communities
Demands	• Comply with laws and regulations • Ensure product quality and safety • Accept supervision from the government and promote the healthy development of the industry • Pay taxes according to law and drive the regional economy development	• Understand the Company's operating performance, governance standards, and ensure risk control • Maintain sound operations and generate returns for investors • Ensure information disclosure is fair, impartial, and transparent	• Protect employees' basic rights and interests • Care about employees' physical and mental health and safety • Provide training and career advancement for employees • Offer generous benefit packages	• Protect consumers' basic rights and interests • Comply with business ethics • Ensure product safety and timely recall of faulty products	• Maintain good and stable partnerships • Operate with integrity and ensure product compliance • Promote sustainable supply chain	• Understand environmental pollution and emission reduction measures • Timely and effective reply to complaints • Fulfill social responsibility through public welfare initiatives	• Emphasize the impact of manufacturing and operation on the local communities • Drive local economy and help vulnerable groups • Recycle product packaging and waste to reduce environmental pollution
Responses from the Company	• Fulfill all obligations in accordance with laws and regulations • Report operational performance as scheduled • Continue to increase access to healthcare • Promote the synergy of upstream and downstream companies in the industry • Establish internal control mechanisms for compliant operation • Pay taxes according to law	• Disclose compliance information • Conduct investor communication through telephone, email, and online conversations • Annual General Meeting of Shareholders • Investor communication meetings and on-site visits	• Employee communication meeting • Employee satisfaction survey • Gather opinions and feedback from employees • Employee training • Employee benefits	• Strictly follow the quality control of vaccines • Protect customer information and optimize the compliant mechanism • Handle consumer complaints and opinions	• Regular communication • Standardized management and enforcement of contracts and agreements • Jointly fulfill social responsibilities	• Disclose data on environmental performance and set targets for environmental conservation • Establish complaint channels on the official website and social media accounts • Organize charitable activities	• Engage in charity • Regularly provide assistance in certain areas • Participate in volunteer services

Dual Materiality Assessment

In 2025, CanSinoBIO systematically conducted a dual materiality assessment of its ESG topics. The assessment was carried out across two dimensions: "impact materiality" (the Company's actual impact on society, the environment, and the economy through its performance on specific topics); and "financial materiality" (the extent to which each topic may affect the Company's business model, operations, financial position, development strategy, cash flow, financing structure, and cost of capital over the short, medium, and long term). This approach enabled a comprehensive identification of the significance of each ESG topic.

During the assessment process, the Company implemented due diligence procedures for sustainability-related topics. Across its operations and value chain, it mapped ESG-related risks and opportunities and assessed the level of impact materiality based on three factors: the likelihood of risk exposure, the severity of potential impact, and the organization's ability to respond to risk. At the same time, financial materiality was ranked by analyzing the potential impact of each topic on revenue, operating costs, asset structure, and corporate valuation. Based on the combined results of these two assessments, CanSinoBIO established the dual materiality prioritization of its ESG topics and developed the corresponding materiality matrix. In 2025, the Company identified a total of 20 topics, of which 6 were classified as topics of high financial materiality and 6 as topics of high impact materiality.



CanSinoBIO 2025 Dual Materiality Matrix



2025 Performance Highlights

Green Development

Total investment in environmental protection amounted to RMB **2.4314** million

Completed **4** environmental compliance upgrade projects.

Greenhouse gas emissions per unit floor area of production and auxiliary facilities decreased by **17.39%** year on year.

Energy consumption per unit floor area of production and auxiliary facilities decreased by **5.31%** year on year.

Air pollutant emissions per production batch decreased by **7.62%** year on year.

Non-hazardous waste generation per unit floor area of production and auxiliary facilities decreased by **38.46%** year on year.

Hazardous waste generated per production batch decreased by **11.67%** year on year.

Wastewater pollutant discharge per unit floor area of wastewater discharge facilities decreased by **76.47%** year on year.

Product Responsibility

Conducted quality supervisions and audits, with **no** major deficiencies identified

Reported **no** actual product recall

Employee coverage for quality training reached **100%**

during the year, **4** new patents were granted

bringing the cumulative total to **57**

Total R&D investment amounted to RMB **371** million, including both expensed and capitalized R&D expenditure

The Company had **273** R&D personnel

of whom **55.68%** held a master's degree or above

Supported the ***Doha Declaration on the TRIPS Agreement and Public Health***

Value Creation

Received the **"2025 Best ESG Employer in China"** award.

Women accounted for **52.47%** of total employees.

Women accounted for **44.83%** of management.

Employee training coverage reached **100%**

with average training hours per employee of **34.48** hours

Total investment in employee benefits amounted to RMB **73.12** million

Enhanced Governance

Successfully passed the surveillance audits for **both** ISO 37301 Compliance Management System and ISO 37001 Anti-Bribery Management System.

Employee participation in compliance training reached **100%**

The number of lawsuits or cases related to corruption, bribery, violations of business ethics, or unfair competition was **0**

the signing rate of *Confidentiality Agreements* and *Integrity Agreements* by suppliers was also **100%**

Obtained **three-level information system security** certification

The signing rate of the *Anti-Corruption and Business Ethics Commitment Letter* by employees was **100%**

Information security and privacy protection training achieved employee coverage **100%**

Feature

Driving Sustainable Innovation Through Building a More Resilient Global Immunization System

Guided by its mission of providing innovative, high-quality, and accessible vaccines for the world, CanSinoBIO incorporates social value and public health needs as key considerations in its R&D decision-making, while continuing to focus on areas of disease prevention and control where needs remain insufficiently addressed. We recognize that the value of innovation lies not only in achieving technological breakthroughs, but also in translating scientific advances into accessible and scalable public health solutions that deliver sustainable health improvements for people across different countries and regions. By strengthening local innovation capabilities and enhancing synergy with industrialization and commercialization capabilities, the Company continues to improve the overall performance of its vaccine products in terms of availability, affordability, and sustainable supply. In doing so, we strive to narrow regional disparities in immunization protection, expand access to high-quality vaccines for broader populations, and contribute our corporate strength to advancing global health equity and building a more resilient public health system.

Local Innovation, Global Impact

Amid the new normal of global cooperation, CanSinoBIO continues to deepen its international presence and is committed to becoming an innovation leader in global public health, leveraging Chinese technology to protect human health. With its diversified product pipeline as a starting point, the Company has established long-term strategic partnerships with collaborators in various countries, actively explored cooperation models for technology transfer, and accelerated its internationalization process. To date, supported by its five globally innovative technology platforms, CanSinoBIO has achieved multiple internationally influential milestones and built a pipeline of innovative vaccine products covering more than 10 indications. At the same time, the Company actively integrates into the global public health system and promotes the effective alignment of innovative vaccines with national immunization programs through deep participation in leading industry conferences. With internationalization as a strategic lever, CanSinoBIO is helping advance global public health to a higher level.

CanSinoBIO's Menhycia® (MCV4) Entered Overseas Markets

In September 2025, CanSinoBIO shipped its self-developed Menhycia® (MCV4), Asia's first quadrivalent meningococcal polysaccharide conjugate vaccine, to overseas markets. The vaccine has been approved for marketing in Indonesia with Halal certification. The successful overseas launch of MCV4 marked a solid step forward in the Company's efforts to build a multidimensional vaccine product portfolio in international markets. At present, the Company has completed a clinical trial in Indonesia evaluating the safety and immunogenicity of MCV4 in individuals aged 18 to 55, and is carrying out the subsequent procedures with a view to expanding the indicated population. Meanwhile, the Company is advancing market access in the Middle East and North Africa and promoting localized cooperation to improve vaccine accessibility and support sustainable development in immunization coverage and meningococcal disease prevention and control in key regions around the world.

Overseas Shipment Ceremony for CanSinoBIO's MCV4

CanSinoBIO Invited to Attend the WHO Global Annual Consultation on Polio Vaccines

In October 2025, ahead of World Polio Day, CanSinoBIO, as a representative of Chinese vaccine companies, was invited to attend the annual consultation jointly held by the Global Polio Eradication Initiative (GPEI), polio vaccine manufacturers, and national control authorities/national regulatory authorities (NCAs/NRAs). During the meeting, CanSinoBIO discussed with global experts the implementation pathways for the polio vaccine supply security framework and presented the R&D progress of its recombinant polio vaccine. Currently, the recombinant polio vaccine, which has been recommended by the World Health Organization as one of the preferred vaccines for the future eradication of polio, has completed a Phase I clinical trial in Australia and has been approved in Indonesia to conduct Phase I/II clinical trials in infants. Going forward, CanSinoBIO will continue to contribute innovative strength toward the global goal of polio eradication and support the continued improvement of the global immunization system.

CanSinoBIO Representative Speaking at the Annual Consultation on Polio Vaccines

CanSinoBIO Participated in CPHI 2025

In October 2025, CPHI, the world's largest professional pharmaceutical industry exhibition, was held in Frankfurt, Germany. CanSinoBIO participated with its self-developed products, comprehensively showcasing the Company's outstanding strengths and deep expertise in key areas including innovative pneumococcal vaccines, meningococcal vaccines, and diphtheria, tetanus and acellular pertussis (components) vaccine, while also launching innovative cooperation and business expansion in the global vaccine CRDMO field. At the event, we engaged in in-depth dialogue and strategic cooperation with pioneers from the global pharmaceutical industry, contributing Chinese expertise to global health protection.

CanSinoBIO at CPHI 2025

Refining Quality, Advancing Steadily, and Improving Efficiency

CanSinoBIO remains focused on the R&D and industrialization of innovative vaccines. Supported by the five core technology platforms it has established, the Company has built a sound system covering the entire R&D process. Through a stringent quality control system, the Company applies high standards across every stage, from raw material procurement to production process optimization, and upholds rigorous clinical trial standards to ensure the safety and efficacy of its vaccine products, while continuously advancing the clinical development and commercialization of multiple vaccines. As of the end of the reporting period, the Company had established an innovative vaccine pipeline covering multiple disease areas, with some products already approved for marketing or having entered the clinical stage, continuing to provide high-quality and accessible vaccine solutions for global public health.

R&D Innovation

Since its establishment, CanSinoBIO has consistently upheld a long-term approach and remained committed to advancing the development of innovative vaccines in China through in-house R&D. The Company has achieved a number of landmark results, including Menhycia®, Asia's first quadrivalent meningococcal conjugate vaccine; Menphecia®, a bivalent meningococcal conjugate vaccine; iPneucia®, a 13-valent pneumococcal conjugate vaccine; Convidecia®, a COVID-19 vaccine recognized by the World Health Organization; Convidecia Air®, the world's first inhaled COVID-19 vaccine; and Asia's first recombinant Ebola virus disease vaccine. Several other globally innovative vaccines and first-in-China vaccines are also in preclinical research or clinical development.

The Company is committed to building a highly qualified management and innovation team. Its core members all possess deep biopharmaceutical industry expertise and an international perspective, providing strong professional support for technological innovation and vaccine R&D. Led by a number of highly experienced senior experts and scientists, the R&D team comprised 273 employees as of the end of 2025, of whom 55.68% held doctoral or master's degrees, providing sustained momentum for vaccine development.

Supported by its five major technology platforms—adenovirus-based viral vector technology, synthetic biotechnology, protein structure design and VLP assembly technology, mRNA and LNP technology, and formulation and drug delivery technology—the Company has built a comprehensive technology R&D system. This provides a strong foundation for the development of its existing vaccine products and creates broad room for the expansion of its future innovative vaccine pipeline.

Product Assurance

CanSinoBIO has established an innovative vaccine portfolio covering more than 10 disease areas, including meningitis, pneumonia, DTaP-related diseases, COVID-19, Ebola, herpes zoster, and tuberculosis. With the core mission of developing, manufacturing, and commercializing high-quality vaccines that meet both Chinese and international quality standards, the Company is committed to addressing public health needs worldwide.

The Company's product strategy is focused on the global market: it aims to fill international gaps through globally innovative vaccines, while also achieving optimized substitution of mainstream domestic products through first-in-China vaccines. In 2025, the Company's 13-valent Pneumococcal Conjugate Vaccine, iPneucia®, was officially approved and launched, while the marketing application for Adsorbed Tetanus Vaccine was accepted. At the same time, DTcP Infant was officially included in the priority review pathway, the DTcP-Hib-MCV4 Combination Vaccine received clinical trial approval and initiated its Phase I clinical trial, and progress continued on pipeline products including the Recombinant Poliomyelitis Vaccine, Inhaled Tuberculosis Booster Vaccine, and Recombinant Zoster Vaccine, supporting the Company's long-term development and the advancement of global health.

Throughout its R&D and manufacturing processes, CanSinoBIO regards ensuring both quality and supply as a core principle. By establishing a lifecycle-wide quality management system guided by risk management and actively applying advanced technologies, the Company ensures the safety, efficacy, and consistent quality of every vaccine. Looking ahead, the Company will continue to deepen vaccine R&D, advance ongoing projects through its five major technology platforms, embrace cutting-edge technologies to improve R&D efficiency, and capture the growing demand for combination vaccines, with the goal of providing more high-quality solutions for global public health.

Progress of CanSinoBIO Vaccine Candidates



CanSinoBIO's Key Products in 2025

MCV4

Menhycia®, the first MCV4 vaccine developed in China by CanSinoBIO, filled the domestic gap in protection against meningococcal serogroups YW135 for infants and young children under two years of age, opening a new chapter in the prevention of meningococcal disease among infants and young children in China. As of December 2025, Menhycia® had been put into use nationwide, providing children across China with vaccine protection that meets globally advanced technological standards. Leveraging its innovative vaccine product Menhycia®, the Company was awarded the title of the "Tianjin Municipal Manufacturing 'Single Product Champion' Enterprise (Fifth Batch)" an honor that signifies the vaccine's leading production technology and manufacturing process in its specific market segment.

In February 2025, Menhycia® received Halal certification from the Food, Drug and Cosmetics Assessment Agency of the Indonesian Ulema Council, marking its entry into the globally recognized Muslim market and accelerating the Company's internationalization. In March 2025, the Company officially signed a vaccine cooperation agreement with a partner in Saudi Arabia to jointly accelerate Menhycia®'s entry into Saudi Arabia and other markets in the Middle East and North Africa, while also promoting joint R&D and the development of localized manufacturing systems. In February 2026, CanSinoBIO received the *Notice of Approval for Supplemental Drug Application* from the National Medical Products Administration, expanding the indicated age range of Menhycia® from "children aged 3 months to 3 years (47 months)" to "children aged 3 months to 6 years (83 months)," further broadening its protection scope and providing more comprehensive protection for more children.

MCV2

Menphecia® (MCV2) is a preventive vaccine against infections caused by Neisseria meningitidis serogroups A and C. Using CRM197 as the carrier protein, it significantly enhances vaccine quality and safety. Supported by CanSinoBIO's polysaccharide-protein conjugation technology platform, Menphecia® effectively overcomes the limitations of traditional polysaccharide vaccines, induces a stronger immune response, and provides more robust immune protection for recipients.

PCV13*i*

PCV13*i* converts polysaccharides into T-dependent antigens through covalent conjugation of polysaccharide antigens with protein carriers. This approach not only induces high levels of specific antibodies in infants under two years of age, but also generates memory B cells and immunological memory. At the same time, the Company's dual-carrier technology reduces immunosuppression when co-administered with other vaccines. In terms of manufacturing, the Company uses an animal-free fermentation medium, reducing the risks associated with animal-derived biological factors and avoiding toxic phenol residues found in traditional purification processes. In June 2025, PCV13*i* (iPneucia®) was officially approved, and the first domestic shipment was completed in September 2025.

PCV24

PCV24 covers the major prevalent pneumococcal serotypes. It uses covalent conjugation of polysaccharide antigens with protein carriers, together with dual-carrier technology. It is intended for use in individuals aged two months and above, with a minimum age of six weeks, to prevent infectious diseases caused by 24 pneumococcal serotypes. Development and validation have been completed for the purified polysaccharides of all 24 serotypes, the manufacturing process for the polysaccharide-protein conjugate bulk, and the finished product formulation. In January 2026, PCV24 was approved by the National Medical Products Administration of China to proceed with clinical trials.

PBPV

PBPV is a globally innovative pneumococcal vaccine designed based on pneumococcal surface protein A (PspA), a highly conserved protein expressed by almost all pneumococcal strains. Unlike existing PPV23 and PCV13 vaccines, PBPV is not serotype-specific and therefore offers broader serotype coverage, with a coverage rate of at least 98% of pneumococcal strains. This feature enables it to effectively prevent the occurrence of serotype replacement. In addition, PBPV has a simpler manufacturing process, making it easier to scale up production and maintain quality control. In its Phase I clinical trial, PBPV demonstrated a favorable safety profile, with no Grade 3 adverse reactions or special safety risks observed. Based on the preliminary Phase I results, the Company is evaluating and planning the next stage of PBPV development.

Tdcp Adolescents and Adults

CanSinoBIO's Tdcp Adolescents and Adults is intended for people aged six years and above and is designed to provide booster immunization against DPT . This vaccine has already been widely included in routine immunization programs in major developed countries, but no comparable product has yet been approved in China. If successfully launched, it is expected to fill a gap in the domestic market. As of December 2025, the vaccine had completed its Phase III clinical trial, and the Company has been preparing the drug registration application materials.

DTcP Infant

CanSinoBIO's DTcP Infant is an innovative component DTcP vaccine. The vaccine uses a process in which each antigen is purified separately and then formulated in defined proportions, ensuring consistency and more stable product quality. To date, no other domestically developed component DTaP vaccine has been approved in China, and CanSinoBIO's DTcP Infant is positioned as a domestically developed and manufactured product. In addition, the development of this vaccine lays the foundation for the further development of Tdcp Adolescent and Adult vaccines and combination vaccines based on DTcP. In February 2025, DTcP Infant was officially included in the priority review pathway by the National Medical Products Administration.

DTcP-Hib-MCV4 Combination Vaccine

The DTcP-Hib-MCV4 combination vaccine developed by CanSinoBIO is a multivalent combination vaccine that combines MCV4, DTcP Infant, and the freeze-dried Haemophilus influenzae type b conjugate vaccine (Hib vaccine). By reducing the number of injections required, it helps address issues related to vaccine administration complexity and cost. It not only reduces discomfort for infants and saves time for parents, but also improves vaccination efficiency for public health authorities and lowers the risk of side effects. In 2025, CanSinoBIO received the *Notice of Approval for Drug Clinical Trial* issued by the National Medical Products Administration for the DTcP-Hib-MCV4 combination vaccine, and initiated its Phase I clinical trial in December. The clinical approval of this combination vaccine represents not only a breakthrough for a single product, but also an important milestone in CanSinoBIO's strategic expansion in the field of innovative multivalent combination vaccines.

Recombinant Zoster Vaccine

The clinical trial product for the recombinant zoster vaccine developed by CanSinoBIO is manufactured using internationally advanced production processes and a quality management system that meets international standards, with no animal-derived ingredients used throughout the entire process, significantly enhancing product safety. Preclinical study data show that this vaccine is comparable to Shingrix, a recombinant subunit adjuvanted zoster vaccine developed by a multinational pharmaceutical company, in stimulating humoral immunity, while demonstrating significantly superior systemic cellular immune responses, indicating the potential for strong protective efficacy. In November 2023, the vaccine initiated a Phase I clinical trial in Canada to evaluate the safety and preliminary immunogenicity of both intramuscular injection and inhalation routes of administration. As of the end of the reporting period, the Phase I trial had been completed, and the Company is evaluating and planning the next stages of development.

Recombinant Polio Vaccine

CanSinoBIO's recombinant polio vaccine is developed using protein structure design and VLP assembly technology and is expected to make an important contribution to global polio control and eradication. During production, the vaccine does not rely on live virus, significantly reducing biosafety risk and offering the prospect of good safety and immunogenicity. Compared with conventional live attenuated and inactivated polio vaccines, the recombinant polio vaccine, due to its unique technological advantages, has been recommended by the World Health Organization as one of the preferred vaccines for future polio eradication. In December 2024, the vaccine initiated a Phase I/II clinical trial in a targeted infant age group in Indonesia. In July 2025, it received approval for clinical trials in China for the prevention of polio caused by infection with poliovirus types I, II, and III.

Adsorbed Tetanus Vaccine

The adsorbed tetanus vaccine is produced using an animal-free fermentation medium, offering improved safety. Its industrial-scale manufacturing process has been established and shown to be stable. This vaccine is mainly intended for the prevention of non-neonatal tetanus, and its drug registration application has already been accepted. In March 2025, the Company and Grand Life Sciences jointly announced that they had entered into an exclusive commercialization agreement for the adsorbed tetanus vaccine.

Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector)

Building on the technological accumulation from the development of the inhaled COVID-19 vaccine, the Company has established a complete inhalation formulation and quality control system, upgraded the first-generation product, and added antigen components to develop the inhaled tuberculosis vaccine (adenovirus type 5 vector). Delivered through inhalation, the vaccine is expected to induce pulmonary immune responses, thereby helping clear Mycobacterium tuberculosis, control latent infection, and potentially prevent infection. In May 2025, the vaccine received clinical trial approval from the Indonesian Food and Drug Authority (BPOM). In November 2025, the Phase I clinical trial was launched in Indonesia to evaluate the safety and immunogenicity of a single dose of the inhaled tuberculosis vaccine (adenovirus type 5 vector) in adults aged 18 to 49.

01

Green Development

Upholding Environmental Protection Concept for a Low-Carbon Future

CanSinoBIO deeply integrates the concept of green operations into its daily work and long-term planning, and continues to improve its environmental management system under the guidance of China's "dual carbon" goals. We have established mechanisms to address climate change, continuously optimized our energy mix, improved resource utilization efficiency, and systematically controlled pollutant emissions, steadily reducing the impact of our operations on the environment and pursuing harmonious development with nature.

Addressing Climate Change

CanSinoBIO pays close attention to the long-term risks and opportunities arising from climate change and incorporates them into its decision-making processes and business planning. Aligned with the International Financial Reporting Standards Sustainability Disclosure Standard No. 2 – Climate-related Disclosures issued by the International Sustainability Standards Board (ISSB), we have established a systematic management and disclosure mechanism across four dimensions: governance, strategy, risk management, and metrics and targets. By focusing on improving energy efficiency and optimizing emissions management across production and operations, we continue to strengthen operational resilience and are committed to promoting a low-carbon transition across both our own operations and our value chain in support of decarbonization efforts.

Governance

CanSinoBIO has established a sound governance structure for climate change-related matters and systematically advances climate action and energy-saving efforts through clearly defined roles and responsibilities. The Board of Directors assumes the highest level of oversight and decision-making responsibility for ESG and climate-related issues and comprehensively oversees related risks and opportunities. The Audit Committee is responsible for advancing environmental management and following up on the implementation of targets, while the ESG Working Group under it is responsible for specific implementation and target setting. In addition, the Company has established an Energy Conservation Leadership Group, headed by the Chief Executive Officer and with the Chief Operating Officer serving as deputy head, with participation from the heads of various business and functional departments, to coordinate and advance the implementation of climate-related actions. During the reporting period, the Company has not yet incorporated climate-related considerations into its compensation policy. It is planned to establish relevant provisions in 2026.

Organization Chart of CanSinoBIO's Energy Efficiency Leading Group



Guided by laws and regulations such as the *Energy Conservation Law of the People's Republic of China*, and benchmarked against standards including the *Energy Management Systems — Requirements with Guidance for Use (GB/T 23331-2020)*, CanSinoBIO has formulated internal management policies such as the *Regulations of Energy Management, the Energy Management Guidelines, and the Regulations of Gas Fired Boiler Production and Operation*, laying a solid foundation for comprehensively improving energy efficiency and achieving green and low-carbon development. In 2025, we successfully passed the on-site assessment on dual control of energy consumption organized by government authorities and submitted our self-inspection report, with further progress made in energy audit work.

Climate Strategy

CanSinoBIO systematically conducts climate risk assessments and opportunity identification, formulates response plans around both physical risks and transition risks, and clarifies the potential opportunities climate change presents for business development, thereby driving industry innovation and industrial upgrading and capturing new opportunities for sustainable development.

Scenario Selection

CanSinoBIO is committed to scientifically and effectively identifying the climate-related risks and opportunities it faces. In accordance with domestic and international standards such as IFRS S2, and taking into account both external macro requirements and the Company's own strategic planning, we have defined three time horizons—short term (2025–2026), medium term (2027–2030), and long term (2031–2040)—and selected climate scenarios aligned with our business in order to systematically identify the degree of impact and evolution pathways of climate-related risks and opportunities at different stages.

For the analysis of climate-related physical risks, with broad reference to ISSB recommendations and industry best practices, the Company selected SSP1-2.6 (low-emissions scenario) and SSP5-8.5 (high-emissions scenario) from the Shared Socioeconomic Pathways (SSPs) applied by the Intergovernmental Panel on Climate Change (IPCC) in its Sixth Assessment Report as the physical climate scenarios. For the analysis of climate-related transition risks, the Company selected the International Energy Agency (IEA)'s Net Zero Emissions Scenario (NZE) and Stated Policies Scenario (STEPS) to simulate different climate pathways and their potential impacts on global energy demand and energy structure.

Assessment Methodology and Conclusions

The Company uses an integrated assessment methodology that combines qualitative and quantitative analysis to evaluate climate risks. On the qualitative side, the Company refers to historical events and focuses on assessing the actual impact of climate risks on business processes such as raw material procurement, production, warehousing, and transportation, while also analyzing the Company's response capabilities when facing specific climate events. On the quantitative side, the Company primarily evaluates the potential financial impact of climate risks, including possible asset losses, business interruption costs, and the investment required for response measures, thereby quantifying the financial materiality of such risks. By cross-validating quantitative data with qualitative judgment, the Company is able to classify and prioritize risks more scientifically, providing clear and reliable decision-making support for the subsequent development of targeted risk management strategies and action plans.

Based on the results of scenario analysis, the Company has tagged assets exposed to various risks and aggregated the number of high-risk assets under each risk category. A relatively high proportion of the Company's assets are exposed to extreme heat (exceeding 50% under both climate scenarios). The Company has systematically implemented measures to mitigate and address the impacts of these risks.

Based on the assessment, among climate-related physical risks, extreme heat was identified as having relatively high financial materiality. Among climate-related transition risks and opportunities, carbon pricing, R&D, and innovative products were identified as having relatively high financial materiality.



Climate-Related Physical Risks

Risk Type	Risk Description	Response Measures	Time Horizon	Financial Impact Trend	Current Financial Materiality
Extreme cold	• Increased energy demand: Greater heating capacity is required to maintain stable temperatures in laboratories and production workshops, resulting in higher energy costs. • Frozen pipelines: Pipelines in the water treatment system may freeze, affecting production activities.	• Optimize the energy management system and improve equipment energy efficiency; enhance power supply assurance and staggered scheduling mechanisms. • Strengthen winter inspections of outdoor pipelines, add heat tracing systems to prevent freezing, and establish a sound emergency response mechanism.	Medium and long term	Increase in operating costs	Low
Extreme heat	• Increased energy demand: Greater use of ventilation, cooling, and related equipment leads to higher energy consumption and operating costs. • Impact on operational stability: Peak electricity demand may lead to unstable power supply, affecting production activities. • Increased refrigerant demand: To maintain appropriate temperatures, more consumables such as dry ice and ice packs are required during vaccine transportation.	• Prioritize the purchase of low-energy-consumption cooling equipment to reduce energy use, and adopt a "one in operation, one on standby" approach to avoid production interruptions caused by overheating. • Purchase generators to respond adequately to unstable power supply and ensure the operation of cold storage facilities and refrigerators.	Short, medium, and long term	Increase in operating costs	Low
Typhoons / cyclones	• Increased asset losses: May cause damage to building roofs and walls, as well as the detachment of outdoor air conditioners, fans, and other fixed assets.	• Strengthen the inspection and maintenance of outdoor pipelines and fans, and reinforce components that are prone to damage or detachment to prevent damage in high-wind conditions.	Short, medium, and long term	Fixed asset losses; increase in operating costs	Low
Extreme precipitation	• Increased asset losses: May cause indoor and outdoor flooding, resulting in the loss of certain fixed assets. • Logistics and transportation delays: Heavy rainfall may worsen road and shipping conditions, causing transportation delays and affecting logistics timeliness.	• Use a warehouse within a warehouse model for finished products and key raw materials to prevent water ingress and leakage at the source and ensure the safe storage of vaccine products. • Equip facilities with sufficient emergency supplies such as sandbags and water pumps, and formulate emergency response plans to ensure timely drainage during rainfall events. • Optimize shipping cycles and transportation routes to reduce the impact of precipitation on product transportation.	Short, medium, and long term	Fixed asset losses	Low
Drought	• Restricted water access: May lead to interruption of municipal water supply or insufficient water pressure, requiring the purchase of external water resources or purified water, thereby increasing operating costs. • Higher procurement costs: Concurrent heat and drought may reduce the output of certain biomass raw materials such as corn and sucrose, thereby increasing procurement costs.	• Strengthen water recycling systems and actively identify and promote water-saving production processes to reduce water use.	Medium and long term	Increase in operating costs	Low

Climate-Related Transition Risks

Risk Type	Risk Description	Time Horizon	Financial Impact Trend	Current Financial Materiality
Tightening energy conservation and emissions reduction policies	Under the dual carbon goals, increasingly stringent energy conservation and emissions reduction policies may affect the Company in multiple ways and require it to increase investment in energy conservation and emissions reduction in order to meet higher environmental standards.	Short and medium term	Increase in operating costs	Low
Carbon pricing	Carbon pricing mechanisms may require the Company to pay higher carbon taxes or purchase carbon emission allowances, while also driving up the prices of traditional fossil energy sources and thereby increasing expenditures in production, warehousing, transportation, and other processes. The Company will gradually implement an internal carbon pricing mechanism in response to evolving external circumstances.	Medium and long term	Increase in operating costs	Low
Failure of technology innovation and R&D	Large-scale investment is required for clean energy technologies, high-efficiency production equipment, and low-carbon process upgrades, which may increase funding pressure. At the same time, the application of new green technologies involves uncertainty. If the technologies are not sufficiently mature or are poorly suited to market needs, the effectiveness of the transition may be affected.	Long term	Increase in R&D expenditure	Low
Stakeholder feedback	If the Company fails to comply with disclosure requirements or performs poorly in climate management, it may face negative feedback from stakeholders including regulators, investors, customers, and consumers, which could damage its reputation.	Medium and long term	Decrease in revenue	Low

Climate-Related Transition Opportunities

Opportunity Type	Opportunity Description	Time Horizon	Financial Impact Trend	Current Financial Materiality
Improved resource utilization efficiency	By improving production processes and increasing energy efficiency, such as optimizing steam, water, and electricity systems, the Company can reduce resource consumption per unit of product and lower energy and resource procurement costs.	Medium and long term	Decrease in operating costs	Low
Use of renewable energy	By increasing the use of renewable energy, the Company can reduce its reliance on fossil fuels and mitigate their impact on production costs. At the same time, government incentive policies for renewable energy projects provide favorable conditions for the construction and use of clean energy facilities such as photovoltaic systems and solar street lighting at the Company's sites.	Short and medium term	Decrease in operating costs	Low
R&D and innovative products	By developing vaccines to prevent climate-related diseases, the Company can strengthen its professional position in addressing the health impacts of climate change, gain the trust of public health institutions, healthcare professionals, and patients, and drive revenue growth from related products.	Medium and long term	Increase in revenue	Medium
Entry into new markets	By meeting market access requirements in different regions for product carbon footprints and carrying out cooperation, the Company can capture incremental share in emerging markets and thereby increase revenue. In addition, participating in international sustainable healthcare initiatives through low-carbon certified products will help the Company integrate into the global public health procurement system.	Long term	Increase in revenue	Low

Risk Management

CanSinoBIO integrates climate change risks into its existing ESG risk management framework and has established a management process covering risk identification and assessment, risk warning, and emergency response management, thereby effectively enhancing the organization's climate resilience.

Risk Identification and Assessment

Regularly identifies and assesses potential climate-related risks, and analyzes the extent of their possible impacts.

Risk Warning

Has established a dynamic monitoring and early warning mechanism for extreme weather and natural disasters to ensure that information can be reported in a timely manner and preventive measures can be promptly initiated.

Emergency Management

- Has formulated a series of emergency response plans, including the *Emergency Management Procedures on Water Cut-offs, Water Leaks, and Industrial Steam Shutdown*, the *Environmental Emergency Response Plan*, and the *Response Plan for Heavy Pollution Weather*, systematically enhancing its emergency response capabilities to ensure energy and resource supply during sudden environmental incidents;
- Regularly inspects relevant emergency equipment and facilities and conducts simulation drills to ensure their effective operation.

CanSinoBIO incorporates energy-saving and carbon-reduction actions into its daily management. In 2025, the Company placed particular focus on optimizing energy management for two newly constructed buildings, and a series of energy-saving improvement measures are being steadily implemented as planned.

Key Energy-Saving and Carbon-Reduction Measures of CanSinoBIO

Electricity

- Adopted high-efficiency energy-saving lighting and promoted the use of solar streetlights to reduce lighting-related electricity consumption;
- Implemented refined control of cleanroom systems, optimized operating parameters according to seasonal conditions, and adjusted equipment operating modes to conserve electricity resources;
- Actively promoted cross-departmental collaboration in dedicated energy-saving initiatives for office areas. By optimizing the operation and management of electricity-consuming equipment such as lighting, air conditioning, and computers, and by clarifying energy-saving responsibilities for each area, the Company effectively reduced avoidable energy consumption. In 2025, office lighting electricity consumption was reduced by approximately 10,000 kWh;
- The Tianjin plant completed the transition of all power supply to the 35kV substation, which improved power supply reliability and created the conditions for more accurate electricity data collection and real-time monitoring, further enabling systematic power management.

Steam

- Replaced self-built gas-fired boilers at the plant with municipal steam supply;
- Implemented a condensate waste heat recovery project to convert waste heat generated during production into usable thermal energy;
- Strengthened maintenance and insulation measures for the heat distribution network to reduce heat loss during transmission.

Gasoline

- Strictly controlled approval for official vehicle use and optimized travel routes to reduce fuel consumption;
- Gradually procured new energy official vehicles to reduce the proportion of gasoline-powered official vehicles.

Diesel

- Optimized the operating strategy for diesel-powered vehicles such as trucks to reduce diesel consumption.

Metrics and Targets

To systematically advance its low-carbon transition, CanSinoBIO has established energy-saving and carbon reduction targets and continues to track various related indicators.

CanSinoBIO's Energy-Saving Target

Using 2023 as the base year, reduce energy consumption per unit floor area of production and auxiliary facilities by **10%** by 2030.

CanSinoBIO's Carbon Target

Using 2023 as the base year, reduce total greenhouse gas emissions per unit floor area of production and auxiliary facilities by **10%** by 2030.

Energy Consumption of the Group in 2025

Indicator	Unit	2025 Data
Direct Energy Consumption		
Natural Gas	m^3	876,092.00
Gasoline	L	54,708.00
Diesel	L	1,547.00
Indirect Energy Consumption		
Purchased Electricity	kWh	40,057,792.00
Purchased Steam	tons	70,312.00
Total Energy Consumption	MWh	123,601.88
Energy Consumption per Unit Floor Area of Production and Auxiliary Facilities	MWh/m^2	1.07
Refrigerant (Tetrafluoroethane) Consumption	kg	54.00

Greenhouse Gas Emissions of the Group in 2025

Indicator	Unit	2025 Data
Total Greenhouse Gas Emissions (Scope 1 and Scope 2)[1]	tCO_2e	43,873.91
Greenhouse Gas Emissions per Unit Floor Area of Production and Auxiliary Facilities[2]	tCO_2e/m^2	0.38
Direct Greenhouse Gas Emissions (Scope 1)		
Natural Gas	tCO_2e	1,915.77
Diesel	tCO_2e	4.09
Gasoline	tCO_2e	118.53
Refrigerants	tCO_2e	82.62
Indirect Greenhouse Gas Emissions (Scope 2)		
Purchased Electricity	tCO_2e	21,254.66
Purchased Steam	tCO_2e	20,495.95

[1] The greenhouse gas inventory includes carbon dioxide, methane, nitrous oxide, and hydrofluorocarbons, mainly arising from purchased electricity, purchased steam, fuel consumption, and refrigerant use. Greenhouse gas emissions are presented in carbon dioxide equivalent and were calculated in accordance with the *Guidelines for Accounting Methods and Reporting of Greenhouse Gas Emissions for Enterprises — Power Generation Facilities (2022 Revision)* issued by the Ministry of Ecology and Environment of the People's Republic of China, and the *2006 IPCC Guidelines for National Greenhouse Gas Inventories* issued by the Intergovernmental Panel on Climate Change (IPCC). The emission factor for purchased electricity was calculated with reference to the *2023 Electricity Carbon Dioxide Emission Factor* published by the Ministry of Ecology and Environment of the People's Republic of China. The Company is progressively advancing the management of its Scope 3 greenhouse gas (GHG) emissions and plans to initiate the identification, inventory, and integration of indirect emissions across its value chain. Moving forward, the Company will gradually refine the statistical and management mechanisms for Scope 3 emissions in line with its operational realities. Following the establishment of consistent statistical scopes, reasonable calculation methodologies, and accurate and reliable results, the Company intends to make external disclosures in a timely manner.

[2] Excluding the floor area of the Company's projects under construction and R&D projects.

Environmental Management

CanSinoBIO has defined environmental protection matters covering all of the Company's operating sites and business activities, and has made corresponding commitments to ensure that environmental management measures are effectively implemented and that environmental performance continues to improve.

Environmental Management System

CanSinoBIO complies with national laws and regulations such as the *Environmental Protection Law of the People's Republic of China*, the *Water Pollution Prevention and Control Law of the People's Republic of China*, the *Law of the People's Republic of China on Prevention and Control of Noise Pollution*, and the *Law of the People's Republic of China on Prevention and Control of Air Pollution*, and has established an environmental management system with reference to standards such as the ISO 14001 Environmental Management System and the ISO 50001 Energy Management System. The Company strictly follows internal policies such as the *Environmental Management System* and the *Management System for Environmental Protection Equipment and Facilities*. In 2025, we revised the *Environmental Monitoring and Control Procedures*, further clarifying monitoring items, frequency, and division of responsibilities, and strengthening the systematic monitoring and continuous improvement of environmental performance, operational control, and compliance.

CanSinoBIO's Environmental Protection Commitments

- Comply with national laws, regulations, and government requirements, and establish a scientific, reliable, and systematic environmental management system;
- Introduce green energy, implement energy-saving projects, and recycle and reuse resources to achieve energy conservation and emissions reduction;
- Adhere to a prevention-first approach, identify environmental factors in products, processes, equipment, and facilities, and achieve effective environmental factor control and pollution prevention through inspection, maintenance, and monitoring;
- Provide assistance, guidance, and audits on environmental protection for the business activities of customers, contractors, and suppliers;
- Promote environmental awareness among employees, advocate environmental protection concepts, and encourage employees to participate in environmental protection activities.

CanSinoBIO has established the *EHS Targets and Accountability Management System* and the *EHS Rewards and Penalties Management System*, incorporating EHS performance, including environmental performance, into the performance appraisal system for both teams and individual employees, and designating it as a veto indicator in performance evaluation. This means that if an employee's performance in EHS does not meet the Company's standards, the employee's overall performance appraisal result will be deemed unsatisfactory. In this way, the Company enhances employees' attention to EHS performance, strengthens the specific implementation of EHS responsibilities, and advances the full achievement of its EHS objectives.

For all operating sites and business activities, the Company regularly conducts internal and external evaluations and audits of the environmental management system. We actively cooperate with environmental inspections conducted by local government authorities at our operating sites and implement corrective actions based on inspection results, with rectification reports prepared accordingly. In 2025, in line with regulatory requirements for the management of heavy pollution weather, we prepared response plans, completed voluntary emissions reduction actions and the relocation of environmental protection equipment, and ensured that responsive environmental protection measures were fully implemented and delivered sustained results.

The Company regards improving employees' environmental awareness as an important part of sustainable development and effectively promotes green concepts through a combination of systematic training and themed practical activities.

Environmental Training

One special training session on hazardous waste management and one special training session on the environmental management system were organized.

Environmental Activities

The Company carried out an employee awareness campaign for World Environment Day and organized a Tree Planting Day activity.

CanSinoBIO's Employee Tree Planting Day Activity

CanSinoBIO's operations do not involve any areas designated as ecological protection red lines. Through full-process environmental impact control, the Company keeps its impact on ecosystems and biodiversity within an acceptable range and effectively fulfills its responsibility for ecological protection. No environmental violations or environmental incidents occurred during the year, and the Company did not receive any environmental administrative penalties.

In 2025, CanSinoBIO invested a total of RMB **2.4314** million in environmental protection management

completed **4** environmental compliance upgrade projects

Environmental Risk Management

CanSinoBIO has established a comprehensive environmental risk assessment mechanism and conducts a full risk assessment every three years to systematically identify, analyze, and control potential environmental risks arising from its production and operations. Based on the results, the Company formulates targeted prevention and emergency response plans, thereby standardizing the routine management and response processes for environmental risks. In 2025, the environmental risk assessments for Rongsheng Building and the industrialization plant remained valid, and no major environmental risk incidents occurred.

The Company fully takes into account the geographical factors of its major operating sites and the impact of environmental protection policies, and effectively responds to risks such as emergency production restrictions during heavy pollution weather. Although, as a biopharmaceutical enterprise, the Company's pollutant emissions from daily operations are relatively low and its direct impact on the regional atmospheric environment is limited, we consistently attach importance to compliant operations and are committed to strictly implementing all emissions reduction directives issued by the government during emergency response periods. By formulating and continuously improving internal emergency response plans, the Company ensures that it can respond quickly whenever relevant alerts are activated and actively fulfill its environmental protection responsibilities.

The Company has established an emergency management structure for heavy pollution weather, including a dedicated emergency office and a heavy pollution weather response leadership group directly led by the Chief Operating Officer, which is fully responsible for the unified coordination and command of emergency response efforts to ensure the efficient operation of the response mechanism. In 2025, we updated the *Environmental Emergency Response Plan*, developed an independent emissions reduction plan for heavy pollution weather, and strengthened our emergency supply support capabilities. At the same time, we carried out six environmental emergency drills, effectively enhancing employees' risk awareness and emergency response capabilities, ensuring that response actions remained efficient and orderly and mitigating the negative environmental impact of sudden environmental incidents.

Emergency Drill for Hazardous Chemical Leakage

To ensure that hazardous chemical leaks can be handled promptly and properly, CanSinoBIO organized a dedicated emergency drill for hazardous chemical leakage. Participants simulated the operational procedures for each key stage in accordance with the emergency response plan, comprehensively testing and enhancing the personnel's emergency handling capabilities and process compliance in the event of a hazardous chemical leak.

CanSinoBIO's Emergency Drill for Hazardous Chemical Leakage

Resource Use

CanSinoBIO focuses on refined resource management, comprehensively improves resource use efficiency, and practices the principles of the circular economy. In terms of water resource management, the Company continued in 2025 to follow its established water consumption target and actively implemented multiple measures to ensure that its 2030 target can be achieved on schedule.

CanSinoBIO's Water Consumption Target

Using 2023 as the base year, reduce water consumption per unit floor area of production and auxiliary facilities by **10%** by 2030.

CanSinoBIO's Water Conservation Measures

- Water is sourced through the municipal water supply, ensuring stable access to suitable water sources, with no use of groundwater;
- Parameters of water-using equipment are adjusted, and the water supply network within the plant is regularly maintained and upgraded to reduce water waste.

Statistics on the Group's Resource Use in 2025

Indicator	Unit	2025 Data
Municipal Water Supply	tons	446,517.00
Water Consumption per Unit Floor Area of Production and Auxiliary Facilities	tons/m^2	3.16
Packaging Materials Used	tons	102.00
Packaging Material Intensity[3]	tons/batch	0.85

[3] The amount of packaging materials used corresponds to 120 product batches. Other products did not require packaging materials during production, sales, or other processes.

Waste Management

In its daily operations, CanSinoBIO fully implements the principles of green manufacturing and applies systematic controls over wastewater, waste gas, solid waste, and noise generated during R&D, manufacturing, and operations, so as to reduce the environmental impact of its operations. The Company follows the *Regulations on Waste Gas Management* and the *Regulations on Wastewater Management*, and in 2025 further revised and improved the *Hazardous Waste Management Procedures*, strengthening the refined management of hazardous waste such as discarded vaccines. By continuously improving internal standards and operating procedures, we ensure that the discharge and control of all pollutants comply with applicable national and local environmental regulations.

To continuously improve the systematic management of waste and strengthen internal controls, CanSinoBIO regularly engages third-party institutions to conduct emissions audits, verify the accuracy of environmental data, assess the effectiveness of management processes, and identify potential areas for improvement.

Wastewater Management

The Company strictly complies with relevant regulatory requirements such as the *Integrated Wastewater Discharge Standard (DB12/356-2018)* to ensure that all wastewater meets applicable discharge standards. To further improve the reliability of the wastewater treatment system, in 2025 the Company completed two upgrades to its wastewater treatment station, including system optimization of the wastewater lift pumps. These improvements not only effectively enhanced emergency discharge capacity under high-load operating conditions, but also significantly reduced suspended solids emissions. In addition, the Company added five groundwater monitoring wells, forming a more comprehensive groundwater monitoring network and systematically strengthening its long-term capability to monitor and protect the surrounding water environment.

CanSinoBIO's Pollutant Discharge Information in 2025

Major Pollutants	COD, Ammonia Nitrogen
Discharge Method	Discharged into the municipal sewage pipeline network
Number of Discharge Outlets	1
Discharge Concentration	COD: 45.32 mg/L; Ammonia nitrogen: 4.91 mg/L
Excess Discharge	None
Applicable Discharge Standard	COD: 500 mg/L; Ammonia nitrogen: 45 mg/L
Approved Total Discharge	COD: 42.59 tons; Ammonia nitrogen: 1.48 tons

CanSinoBIO's Wastewater Target

Using 2023 as the base year, reduce pollutant discharge per unit floor area of wastewater discharge facilities by **10%** by 2030.

Waste Gas Management

To further reduce the intensity of waste gas emissions, in 2025 the Company simultaneously put into operation 19 sets of high-efficiency activated carbon waste gas treatment facilities in newly built projects, strengthening the systematic collection and purification of waste gas. Through facility upgrades and operational optimization, the actual emission concentrations of the major pollutants in the Company's waste gas are now consistently below the limits required by national and local regulations.

CanSinoBIO's Waste Gas Emission Target

100% compliant waste gas emissions.

Waste Management

Waste generated by CanSinoBIO during production and R&D mainly includes hazardous waste such as contaminated materials, organic and inorganic waste liquids, laboratory animal-related waste, expired chemical reagents, discarded vaccines, and solid hazardous waste, as well as general waste such as kitchen waste and domestic waste. The Company places emphasis on source reduction and intelligent management and control, while also promoting the recycling and reuse of resources to continuously reduce waste generation.

CanSinoBIO's Waste Management Measures

Waste Category		Treatment Measures	Waster Reduction Measures
Hazardous Waste	Laboratory waste liquids and empty reagent bottles	Stored in a dedicated hazardous waste temporary storage area after registration.	• Provide training for all employees to reinforce the principles of solid waste classification and reduce the mixing of general waste with hazardous waste. • Optimize laboratory and production processes and reduce excess preparation of chemical reagents to reduce waste generation at source. • Procure an integrated hazardous waste management machine to enable more comprehensive automatic data collection and platform synchronization, achieving full-process traceability management.
	Biological waste	Biological waste containers are affixed with special labels and, after autoclaving or disinfection, are collected and treated together with other hazardous waste.	
	Contaminated materials	Collected uniformly using designated hazardous waste packaging bags.	
Non-hazardous Waste	Domestic waste and kitchen waste	Entrusted to qualified third-party institutions for disposal.	

CanSinoBIO's Waste Target

Using 2023 as the base year, reduce the amount of hazardous waste disposed of per product batch[3] by **10%** by 2030.

[3] Hazardous waste disposed of per product batch = hazardous waste disposal volume / total number of product batches produced.

Key Emissions Performance Indicators of the Group

Emissions Category	Indicator	Unit	2025 Data
Wastewater	Total wastewater discharge	tons	269,989.00
	Chemical oxygen demand	tons	2.55
	Suspended solids	tons	0.94
	Ammonia nitrogen	tons	0.10
	Total wastewater pollutant discharge	tons	3.59
	Wastewater pollutant discharge[4] per unit floor area of wastewater discharge facilities	tons/m²	0.00004
Waste Gas	Total waste gas emissions	m³	574,446,672.00
	Non-methane hydrocarbons	tons	2.28
	Nitrogen oxides	tons	1.16
	Particulates	tons	0.08
	Waste gas pollutant emissions per product batch	tons/batch	0.0109
Non-hazardous Waste	Total non-hazardous waste generated	tons	51.00
	Non-hazardous waste generated per unit floor area of production and auxiliary facilities	tons/m²	0.0008
Hazardous Waste	Total hazardous waste generated	tons	170.77
	Hazardous waste generated per product batch	tons/batch	0.53

[4] Wastewater from all plant areas of the Company is centrally collected and treated at the same wastewater treatment station, and discharge intensity is calculated based on the floor area of the wastewater discharge facilities.

02

Product Responsibility

Upholding Quality Excellence and Leading Vaccine Innovation

CanSinoBIO firmly believes that high-quality products are the core pillar of the Company's sustainable development. We continue to improve our product quality management system, uphold independent innovation in R&D, effectively protect customer rights and interests, and are committed to providing patients and customers with outstanding and accessible products and services.

Product Safety and Quality

CanSinoBIO has established a product quality system covering the entire product lifecycle. Supported by rigorous quality inspection and certification processes, we continue to advance the development of a quality culture, helping multiple biologics move smoothly from clinical trials to commercial production, while providing ongoing support and empowerment to global partners.

Governance

CanSinoBIO strictly complies with international standards including the *Good Manufacturing Practice (GMP)*, the *WHO Good Manufacturing Practices for Pharmaceutical Products*, and the *EU GMP*, while also benchmarking against regulatory requirements such as *FDA*[5] *GMP*. Using ICH guidelines as the framework and incorporating technical standards such as the *Chinese Pharmacopoeia (2025 Edition)* and the *European Pharmacopoeia (10.0 Edition)*, the Company revised internal policies including the *Quality Manual* and the *Deviation Management Procedures*. In 2025, the Company updated the *Supplier Management Procedures* to incorporate suppliers of materials and services involving GXP activities into the lifecycle quality management system, further strengthening supply chain quality control and providing stronger support for the overall product quality system.

Clinical quality is the foundation for ensuring the scientific rigor and reliability of clinical trials. The Company strictly follows relevant regulations such as the *Good Clinical Practice (GCP)* and the *Guidelines for Quality Management of Vaccine Clinical Trials (Trial)*, implements stringent quality control throughout the entire clinical operations process, and continues to improve its standard operating procedure (SOP) system for clinical trials. As of the end of the reporting period, the Company had a total of 124 current and effective SOPs in its clinical operations quality system, including 18 management procedures and 106 operating procedures. In 2025, the Company added 16 new SOPs and revised or upgraded 62 SOPs, with a focus on improving key areas including quality management, product management, document drafting standards, monitoring procedures, statistical data management, and ethics and genetic resources management. These efforts further strengthened the standardization and controllability of the entire clinical trial process and laid a solid foundation for improving the quality of clinical research.

[5] The Food and Drug Administration.

Strategy

CanSinoBIO regards product safety and quality as the fundamental strategic cornerstone of the Company's development and a non-negotiable red line in its operations. We have established and continued to operate a strategic governance mechanism, using the *Annual Strategic Risk Management Plan* as an input and driving the coordinated enhancement of strategic objectives and organizational capabilities through strategy cascading, organizational alignment, and closed-loop monitoring. Through this approach, we are committed to transforming the highest quality standards into a manageable and traceable core organizational capability embedded throughout the entire value chain.

Impact, Risk and Opportunity Management

The Company has established a quality management system covering the entire product lifecycle and implements systematic controls across key stages including R&D and design, raw material procurement, manufacturing, and product release. For core management objects such as suppliers, laboratories, plant facilities, and production workshops, we have formulated clear management standards and operating procedures. By strengthening source control and process supervision, we safeguard product quality and safety and reduce quality risks.

End-to-End Product Quality Management

End-to-End Product Quality Management at CanSinoBIO

Material Quality Management

System establishment	In accordance with relevant national sampling and testing standards, standardized sampling procedures have been established for raw materials, excipients, and packaging materials to ensure standardized sampling operations and accurate sample quantities. In 2025, the *Material Supplier Management Procedures* were revised, supplier grading was adjusted in accordance with the *Supplier Management Procedures*, and additional provisions were introduced, including management of material classification assessment criteria and grade requirements for pharmaceutical excipients.
Audit management	A comprehensive material supplier management system has been established, with detailed files systematically created and maintained for key material suppliers, along with a regular audit mechanism covering written reviews, on-site inspections, remote audits, and third-party assessments. In 2025, based on production needs, backup suppliers were screened and audited for suppliers with compliance risks, supply risks, or a relatively high number of complaints. In addition to suppliers for commercialized products, audits were expanded to include suppliers of materials for R&D products and certain suppliers of high-risk sterile consumables. To meet the needs of Muslim markets, Halal-related audits of suppliers were also added. At the same time, to provide more flexible material support for the Company, several domestic material suppliers were newly introduced, and corresponding audit plans were developed for these domestic suppliers.
Risk control	A risk assessment system for production consumables has been established, under which identified high-risk consumables are subject to strict pre-release controls to reduce potential quality risks during production use.
Digital management	The SAP system has been deployed to enable digital management of material release labels. Automated workflows reduce manual operations, lower the error rate, and improve the efficiency and accuracy of material management.

Production Process Control

System development	A sound production quality management system covering the entire process and a complete SOP documentation system have been established, covering key control areas including personnel, equipment, processes, and the environment, to ensure standardized and regulated operation throughout production.
Accountability	By formulating clear departmental function statements and job descriptions, production safety and quality responsibilities have been fully incorporated into the annual performance management system. A graded assessment mechanism has also been established to continuously strengthen quality awareness and production safety accountability among all employees.
Environmental control	Relevant regulations for aseptic production are strictly implemented, and aseptic control measures are fully applied throughout the production process. An environmental monitoring system (EMS) with real-time alarm functions has been deployed to enable continuous monitoring, automatic recording, and secure storage of environmental parameters, ensuring timely warning and handling of abnormalities.
Commercial production site management	Differentiated monitoring plans have been developed for the production areas of marketed products, with monitoring frequency and inspection mechanisms determined based on risk assessment results. Management focuses on consistency in document execution, completeness of deviation investigations, effectiveness of CAPA, and the systematic nature of change assessments.
Clinical manufacturing site management	In view of the characteristics of the clinical manufacturing stage, dedicated site monitoring priorities and inspection plans have been formulated to ensure the compliance of manufacturing activities and the reliability of data during the clinical stage.
Digital management	An online production process control system has been deployed to enable intelligent production execution, process visualization, digital equipment control, and integrated information management. In 2025, the QMS system went live, converting the management of changes, deviations, and CAPA from paper-based control to QMS-based system management.
Technical optimization	Continuous research has been carried out to optimize production processes, including scientific adjustment of culture medium formulations and bulk preparation process parameters. Through technological innovation, the Company improves production efficiency, systematically reduces operational quality risks, and ensures the efficiency and reliability of the manufacturing system.

Laboratory Management

Accountability	A full-staff laboratory safety accountability system has been established, clearly defining the safety responsibilities and operating requirements of each laboratory staff member, ensuring that chemical and biosafety protection levels fully meet management requirements.
Process control	A full-process sample management system covering sampling, receipt, testing, sample retention, and destruction has been implemented. Standardized controls have been established for instrument and equipment use, standard substances, sample management, and testing procedures to ensure the accuracy and reliability of testing results.
Digital management	Information systems such as LIMS (Laboratory Information Management System) and CDS (Chromatography Data System) have been deployed to enable digital management of laboratory testing processes. In 2025, an electronic testing workflow for water system monitoring was established in the LIMS system, comprehensively improving compliance and traceability in testing work.

Distribution Management

System establishment

The Company continuously improves its distribution quality management system covering the entire process, including initial customer qualification review, vaccine inbound and outbound management, warehouse management, cold-chain transportation and validation, and complaint handling.

Logistics network development

The Company continues to improve its international and domestic logistics and distribution systems. Entrusted storage sub-warehouses have been established in multiple key regions across China, and the transport network layout has been optimized in collaboration with core trunk-line carriers to improve overall delivery efficiency and timeliness. As of the end of the reporting period, the Company had 7 domestic and international logistics service providers and had established 11 regional vaccine warehouses in Guangdong, Zhejiang, Chongqing, Jiangxi, Guangxi, Shaanxi, and other regions. Logistics service providers are managed through annual quality audits, monthly business reviews, and quarterly quality communication to ensure compliant product storage and transportation quality. All logistics service providers completed quality audits and filing procedures, with a 100% pass rate in qualification review.

Transportation validation

In accordance with the annual validation plan and business needs, domestic and international transportation validation was carried out in 2025 for finished products and bulk solutions to ensure product transportation quality.

Release Management

Routine management

A full-process management system has been established covering the release of intermediates/bulk solutions, self-inspection release of finished products, and market release after passing inspection by the national statutory institution. The Company focuses on monitoring production procedure compliance and material release status to ensure that each stage meets quality standards.

Release procedures for raw materials, excipients, and packaging materials

Strict inspection procedures are applied to raw materials, excipients, packaging materials that directly contact pharmaceutical products, and critical production consumables. Only after passing inspection are inspection reports issued and release completed, thereby safeguarding production quality and compliance at the source.

Technical Feasibility Assessment

Routine monitoring

Daily monitoring of the production workshop environment is continuously carried out to ensure that environmental parameters remain compliant with relevant standards during production operations, thereby safeguarding production stability and product quality consistency.

Digital management

Information systems are used to collect and analyze production condition data for clinical trial materials, providing a scientific basis for technology transfer and marketing registration applications. Based on data analysis, technical feasibility reports are issued to support efficient coordination between R&D and production.

Batch Release Management

System establishment	The full batch release process has been systematically reviewed, with each stage analyzed one by one. Dedicated improvement measures have been developed for optimizable steps to shorten the overall release cycle.
Batch release application	After completion of first-stage release for each product batch, a batch release application is submitted to the National Institutes for Food and Drug Control of China. In 2025, all batch release work was completed and delivered on schedule, with a 100% batch release pass rate.
Product testing	Product samples taken by provincial drug regulatory authorities, together with relevant documentation, are submitted to designated testing institutions. After passing inspection, the second-stage release procedure is completed and the products are approved for marketing and sale.
Capability building	The Company continuously consolidates feedback received from official drug testing institutions during batch release, conducts high-frequency issue analysis and abnormal trend analysis, improves the quality and efficiency of responses, and organizes targeted special training. In 2025, the median batch release duration decreased by 11% compared with 2024.

Document and Training Management

Document management	In 2025, the DMS (Document Management System) went live for the R&D segment. All GMP documents are now managed within the DMS, enabling full-process control and version management of GMP system documents, graded control over record distribution and retrieval, and full traceability through barcode technology, effectively ensuring the standardization and consistency of quality management activities.
Training management	In 2025, the TMS (Training Management System) was used to enable full-process progress tracking and management for all types of training, ensuring that document training coverage reached 100%. The system applies version control and approval management to training materials such as courseware and examination papers, ensuring data integrity, reliability, and traceability, and making the training management process fully compliant with regulatory requirements.

CanSinoBIO always places vaccine quality and safety first and has established a full-process control mechanism covering deviation identification, graded assessment, corrective and preventive actions, and closed-loop management. We implement strict monitoring of deviation events such as production process abnormalities, equipment failures, and operational errors, and ensure that all corrective and preventive measures are effectively implemented through regular review and trend analysis. For any batch that may affect product quality, the Company strictly enforces its quality veto mechanism and takes measures such as suspending production or refusing release, thereby fundamentally preventing reduced vaccine potency or safety risks arising from production deviations.

Quality Testing and Certification

CanSinoBIO has established a quality monitoring system covering the entire product lifecycle. From incoming inspection of process water, raw materials, excipients, and packaging materials, to in-process control of intermediates, bulk solutions, and semi-finished products, and finally to release testing of finished products, we have established systematic quality control checkpoints at every critical stage, enabling end-to-end quality traceability and assurance from source to final product.

Lifecycle Quality Testing of CanSinoBIO's Products



CanSinoBIO has established a data-driven quality monitoring system. Through real-time monitoring and systematic trend analysis of testing indicators across the entire process, the Company achieves dynamic tracking and early warning of product quality status. For abnormal events identified during testing, including out-of-specification (OOS) and out-of-trend (OOT) results, the Company has established clear management procedures to conduct root cause investigations into abnormal fluctuations that still meet quality standards, and to fully document the handling process and closed-loop outcomes of unexpected events. In addition, the Company strictly complies with regulatory requirements by implementing standardized retention sample management for each batch of marketed products and conducting periodic stability studies to continuously verify product quality compliance throughout the shelf life and ensure ongoing conformity with registered standards.

CanSinoBIO's Handling Process for Abnormal Events, OOS, or OOT Results

Identification and Reporting	If abnormal data arise during laboratory testing, the testing personnel must report the matter to the department head and the OOS administrator within 24 hours, while preserving the relevant records and site conditions.
Preliminary Assessment	The department head conducts a preliminary assessment of the abnormality, determines the nature of the event, such as laboratory operation, system error, or product quality-related issue, and decides the next investigation pathway.
Laboratory Investigation	If the abnormality is initially determined to have been caused by laboratory operations, an internal laboratory investigation is initiated to analyze the cause in depth, implement corrective actions, and document the investigation results.
Product Quality Investigation	If the abnormality may involve product quality, the event is transferred to the production and warehousing departments for further investigation to identify the root cause and develop and implement corrective and preventive actions.
Annual Quality Review	All abnormal events are systematically reviewed each year to assess investigation progress, categorize and summarize root causes, and conduct trend analysis, providing a basis for the continuous improvement of the quality management system.

To enhance the professionalism and relevance of self-inspections, the Company has established a diversified assurance mechanism for self-inspection. The Company continuously monitors high-frequency deficiencies identified in official inspections in China and overseas, identifies key risk points in light of product and process characteristics, and organizes targeted internal audits accordingly. At the same time, it reviews issues identified in previous external audits and converts them into standardized self-inspection checklists, thereby improving the efficiency and depth of self-inspection work. On the basis of internal self-inspections, the Company also actively brings in external professional support by inviting industry experts, including former GMP inspectors from China and former inspectors from PIC/S member countries, as well as qualified third-party institutions, to conduct independent audits. Through these external perspectives, the Company obtains objective and professional assessment opinions, providing important support for the continuous optimization of its quality management system and the enhancement of its compliance standards. In 2025, CanSinoBIO steadily advanced various quality supervision and audit activities, with no critical deficiencies identified.

CanSinoBIO's Quality Supervision and Audit Activities in 2025

Internal

- 4 internal quality audits were conducted, covering the full product lifecycle, including R&D and manufacturing sites. The audits covered multiple key areas, including quality management, production management, quality control, product release, material management, plant facilities and equipment management, validation management, product shipment and recall, and pharmacovigilance. As of the end of the reporting period, 93% of the corrective actions had been completed.
- 5 clinical trial audits were conducted, involving 5 clinical trials and 3 products. The audits were conducted in accordance with relevant laws, regulations, guidelines, clinical trial protocols, and site SOPs, including the *Vaccine Administration Law of the People's Republic of China*, the *Declaration of Helsinki*, and *Good Clinical Practice* (GCP). Through on-site inspection, document review, and researcher interviews, the audits covered site qualifications, researcher qualifications and training, facilities and equipment, informed consent, screening and enrollment, vaccination visits, blood collection visits, sample management, product management, SAE management, and emergency management. As of the end of the reporting period, all on-site corrective actions had been completed.
- 3 audits were conducted on clinical monitoring service providers and clinical trial statistical data service providers.

External

In 2025, the Company underwent 14 audits by drug regulatory authorities, including 9 by domestic drug regulatory authorities and 5 by overseas drug regulatory authorities, including Halal certification-related audits. No critical deficiencies were identified.

In 2025, CanSinoBIO obtained GMP certification from Mexico.

On-Site Audit of Overseas Clinical Trial Projects

In March and June 2025, to ensure the quality of the Phase I & II clinical trial of the Recombinant Polio Vaccine in infants and young children conducted in Indonesia, CanSinoBIO successfully implemented and completed two independent overseas on-site special audits by engaging qualified and approved service providers. All issues identified during the audits were effectively clarified and addressed, demonstrating the Company's execution capabilities in cross-regional clinical quality management.

On-Site Audit of Overseas Clinical Trial Projects

In 2025, the key progress made by CanSinoBIO in quality testing collaboration included the following:

- The Company coordinated with the First Supervision Office of the Tianjin Drug Administration to carry out the destruction of nonconforming vaccine products, establishing an effective mechanism for the supervised destruction of vaccines and ensuring closed-loop management throughout the entire vaccine lifecycle.
- The Company engaged in multiple rounds of communication with regulatory authorities and the resident regulatory office regarding method transfer for new laboratories added to the Quality Control Department, identified relevant risks, and developed transfer strategies and plans, with the transfer work proceeding in an orderly manner under the guidance of the regulatory authorities.
- The Company entrusted the Tianjin Institute for Drug Control with third-party testing of packaging materials, strengthened technical exchanges and communication with the institute, and conducted technical discussions on changes to the requirements for raw materials, excipients, and packaging materials in the 2025 edition of the *Chinese Pharmacopoeia*.

Product Recall

The Company has established and implemented internal policies including the *Nonconforming Product Management Procedures*, *Vaccine Traceability System Management Procedures*, and *Marketed Product Recall Management Procedures*, thereby building a bidirectional traceability mechanism from source to end user to ensure precise control over the origin and distribution of every product batch.

In 2025

the Company reported **no** actual product recall incidents.

CanSinoBIO's Product Recall Process

When a potential safety hazard or quality incident is identified, the Quality Assurance Department immediately initiates a risk assessment procedure to evaluate the necessity of a recall.

Issue Identification and Assessment

Where further verification is required following the preliminary assessment, the Company establishes a cross-functional special investigation team to systematically analyze the source of the safety hazard, the scope of impact, and the risk level.

Formation of Investigation Team

Based on the investigation results, the Distribution Quality Department drafts the recall plan. After review and approval by the Quality Assessment Committee, the Quality Assurance Department formally submits the recall plan and relevant supporting documents to the drug regulatory authorities.

Development and Approval of Recall Plan

Upon approval by the regulatory authorities, a graded recall is initiated according to the product risk level. The business department is responsible for customer notification and communication, the Commercial Supply and Distribution Department coordinates return logistics and warehouse management, and the Quality Assurance Department regularly reports recall progress to the regulatory authorities.

Recall Implementation

After the recall action is completed, the recall implementation team prepares a summary report, comprehensively reviewing the recall process, cause analysis, and improvement measures, and reports it during the annual management review to support continuous system optimization.

Recall Summary and Analysis

All recalled products are subject to supervised destruction in accordance with standard procedures to ensure complete elimination of risk materials, with full destruction records retained to achieve closed-loop management of safety risks.

Destruction and Disposal

CanSinoBIO continuously enhances its organizational emergency response capability and cross-functional coordination efficiency through routine product recall simulation drills. We develop drill scenarios based on real-world situations to strengthen the team's ability to make rapid decisions and execute standardized procedures under emergency conditions, ensuring precise and efficient response and handling in the event of an actual recall.

Quality Culture Development

CanSinoBIO always regards quality culture development as a core pillar of its corporate growth and continuously promotes the integration of quality awareness into every aspect of the Company's operations. The Company has established accountability policies, including the *Responsibilities of the Head of Quality Management* and the *Responsibilities of the Qualified Person*, which clearly define the specific quality management responsibilities of each level of position. Achievement of quality objectives is also incorporated into the performance appraisal system, forming a quality management mechanism with clear accountability and effective incentives.

The Company has established a quality training system covering all positions. By improving dedicated procedures such as the *GMP Training Management Procedures for Personnel* and the *Training Management Procedures for Sampling Personnel*, the Company ensures that training for key positions is conducted in a standardized manner. The training system covers multiple dimensions, including onboarding orientation, pre-job training, on-the-job development, annual GMP refresher training, and external professional development, enabling targeted training for employees at different levels and in different functions. In 2025, CanSinoBIO provided quality training to all employees and contractors involved in pharmaceutical R&D, manufacturing, and quality management to ensure that they met the skill requirements for their roles and were able to continuously update and improve the knowledge and skills needed to perform their duties competently.



CanSinoBIO's Quality Training System

Induction Training

New employees are required to complete systematic training within three months of joining the Company, covering the Company's quality and safety system, data integrity requirements, and relevant rules and regulations. Training content includes basic GMP knowledge, workplace safety requirements, and vaccine administration regulations, ensuring that employees fully understand the Company's quality management policy and fundamental requirements.

Pre-Job Training

New employees and employees transferring to new positions are required to complete the training and assessment set out in the relevant job training matrix and may assume their posts only after their job qualifications have been confirmed. The job training matrix is divided into four stages:

- General training: For all employees, including training on basic laws and regulations and general GMP documentation;
- Department-level general training: For the center or department to which the position belongs, covering GMP management document training related to departmental responsibilities;
- Job knowledge and competency training: Covering management procedures and standard operating procedures relevant to the position;
- Operational skills training: For positions with hands-on operational requirements, including specialized skills training and assessment.

Development Training

Through continuing education, special training on document revisions, online course learning, and external expert lectures, the Company continuously expands employees' professional knowledge and enhances their overall business capabilities and industry perspective.

Annual GMP Training

Annual refresher training is provided to all employees engaged in pharmaceutical manufacturing and quality management. Company-level and department-level training plans comprehensively cover the latest laws and regulations, updates in professional technology, and key job skill requirements, ensuring continued compliance with GMP requirements and the Company's quality system standards.

In 2025

the annual GMP training was carried out successfully. A total of **15** company-level training sessions were conducted, achieving **100%** coverage of personnel involved in GMP manufacturing and quality management, with **7,936** cumulative attendances. At the department level, **398** training sessions were conducted, with **9,157** cumulative attendances.

Special Quality Training

In 2025, the Company organized a series of special training sessions on key quality topics, with a total of six sessions conducted. Training topics covered core industry issues including water for pharmaceutical uses, PCV product knowledge, lyophilization processes, and key points of GMP inspections. Delivered through a combination of online and in-person formats, the training covered multiple key functional departments, including the Manufacturing and Technical Operations Center, the Quality Center, and the General Management Office. These sessions enhanced the professional understanding and compliance capabilities of personnel in relevant positions and provided strong support for the sound operation of the Company's quality system.

Special Training Session

Special Training Delivered by External Experts

In October 2025, CanSinoBIO invited industry experts with extensive international regulatory experience to deliver a special training session themed Regulatory Inspection Readiness. The training focused on FDA audit procedures and inspection requirements, systematically covering the use of inspection-readiness tools, logistics coordination, strategic planning, and key considerations. It helped relevant teams comprehensively strengthen their practical capabilities in responding to high-standard international regulatory inspections and laid a foundation for compliant operations in the Company's global development.

External Experts Training Session

Metrics and Targets

CanSinoBIO has established a product quality target system consisting of key indicators, major indicators, and commercial indicators to comprehensively guide and evaluate the optimization of its quality management system. We regularly review progress against these targets, drive continuous improvement in quality performance, and ensure the effective implementation of the Company's quality strategy.

Key Indicators

Quality system review targets: including pass rates for internal and external system audits, timeliness of closed-loop management for deviations, changes, CAPA, and OOS, and on-time product release rate;

Production process management targets: including product delivery achievement rate, filling process yield, and intermediate product quality pass rate;

Product quality feedback and handling targets: including timeliness of customer complaint handling, and the timeliness and compliance of product recall response.

Major Indicators

System operation assurance targets: including completion rate of the annual training plan, supplier audit coverage rate, completion rate of internal self-inspections, and execution rate of preventive equipment maintenance;

Product safety monitoring targets: mainly including the effectiveness of pharmacovigilance system operation and the timeliness of adverse reaction reporting.

Commercial Indicators

Supply chain and distribution quality targets: mainly covering quality control requirements related to commercial circulation, such as temperature control compliance during product storage and transportation, and completeness of logistics information traceability.

Product Innovation and R&D

CanSinoBIO regards product R&D as a core driver of sustainable development. We continuously advance product upgrades, expand our product pipeline, build a high-caliber scientific research team, and reinforce our industry-leading strengths.

Governance

Leveraging coordination between internal controls and external regulation, CanSinoBIO promotes the implementation of high standards in innovative R&D and continuously enhances R&D quality and compliance. The Company follows domestic and international pharmaceutical regulatory laws, regulations, and standards, including the *Drug Administration Law of the People's Republic of China*, the *Vaccine Administration Law of the People's Republic of China*, the *Good Manufacturing Practice for Drugs – Appendix for Investigational Products (Trial)*, the *Guidelines for Quality Risk Management of Co-line Drug Production*, and *ICH Q10: Pharmaceutical Quality System*, and has established multiple internal management policies accordingly. In 2025, we further revised and added documents such as the Management Procedures for Public Video Training in R&D and the Management Procedures for External Cooperation in R&D, providing clearer guidance on external R&D collaboration procedures and the management responsibilities of relevant parties.

The Company has established a Research Center and a Product Development Center to coordinate and manage R&D activities. The Research Center is responsible for early-stage vaccine research, pharmacodynamic and toxicological evaluation of pipeline products, antibody preparation, and coordination of external scientific research collaborations. The Product Development Center is responsible for formulating product development plans and strategies, building and expanding platform capabilities, conducting project initiation and pilot-scale CMC work for vaccines and gene products, and establishing a product development management system to implement the Company's R&D strategic objectives.

At the same time, the Company places great importance on the development of R&D talent. Backed by a strong team of master's and doctoral degree holders with deep expertise in biopharmaceuticals, the Company continues to provide technical support and innovative momentum for expanding its R&D pipeline. As of December 31, 2025, the Company had 273 R&D personnel, of whom 55.68% held a master's degree or above.

the Company had

273 R&D personnel

of whom

55.68% held a master's degree or above

Strategy

In 2025, CanSinoBIO established an R&D strategy centered on "addressing unmet clinical and public health needs worldwide." By analyzing vaccine demand arising from climate change, international public health priority lists, and the policy, medical, competitive, and commercial landscape, we ensure that our R&D strategy combines scientific foresight, public value, and commercial sustainability.

To maintain strategic agility, we have established a dynamic closed-loop management system. Through quarterly mechanisms, we continuously monitor changes in the external environment and incorporate annual targets into the strategic review process for tracking and recalibration. This has enabled us to build an end-to-end management system of "global needs insight – systematic analysis – strategic cascade and capability building – dynamic execution, review, and iteration," ensuring that our innovation strategy remains responsive to change and continues to drive the Company steadily toward its long-term vision.

Impact, Risk and Opportunity Management

CanSinoBIO continues to optimize its project management processes to support R&D innovation. The Company has established a standardized, visualized, and process-based project management system to comprehensively improve the efficiency of R&D project management and ensure the orderly advancement of all R&D tasks. By establishing a project experience database, the system enhances the transparency of R&D knowledge and experience, and through modules including project initiation, planning, knowledge management, and risk management, it enables refined control over the entire project lifecycle. In addition, project teams regularly hold project meetings to conduct technical presentations and discussions on key challenges, enabling the timely identification and resolution of issues and risks arising during the R&D process and ensuring efficient and smooth R&D operations.

R&D Progress

Guided by market demand and focused on the prevention of human diseases, CanSinoBIO has built an innovative vaccine R&D system covering major infectious disease prevention and control. The Company's R&D pipeline is comprehensively established, covering more than ten disease areas, including meningitis, pneumonia, DTP, COVID-19, and Ebola virus disease. In 2025, the Company further deepened its R&D innovation system and achieved technological breakthroughs in multiple frontier areas. The Company established an AI-assisted antigen design platform and applied AI in early-stage R&D projects for antigen structure and function prediction. At the same time, it accelerated the IND application process for innovative combined vaccines, with related projects now having entered the clinical research stage. In addition, by introducing advanced technologies such as cell chips, the Company is gradually promoting alternatives to animal testing in non-clinical research, further improving R&D efficiency and scientific rigor.

While continuing to uphold independent R&D, we also actively promote the academic dissemination of innovative achievements and industry exchange. In 2025, we published a total of 8 high-quality academic papers in leading international journals.

In 2025, CanSinoBIO published several important research findings in the internationally recognized medical journal Vaccines, including:

- *Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials*
- *An Evaluation of the Safety, Immunogenicity, and Protective Efficacy of a Combined Diphtheria-Tetanus-Acellular Pertussis, Haemophilus influenzae Type b, and ACYW135 Meningococcal Conjugate Vaccine in Murine and Rat Models*
- *A single-dose mRNA vaccine protects mice from lethal Crimean-Congo hemorrhagic fever virus infection*

Academic Exchange and Collaboration

CanSinoBIO places great importance on academic exchange and collaboration. By proactively connecting with high-quality resources from universities and research institutions in China and abroad, the Company actively builds regular, interdisciplinary internal academic salon platforms to promote the translation of academic insights into industrial innovation.

Highlights of CanSinoBIO's Academic Exchange Activities in 2025:

- As the only invited Chinese biopharmaceutical company, attended the 2025 World Governments Summit, shared innovation practice cases, and discussed the latest developments of artificial intelligence in the biopharmaceutical field with participants;
- Participated in the WHO Global Annual Consultation on Polio Vaccines, where the Company discussed implementation pathways for the polio vaccine supply security framework with global experts and introduced the R&D progress of the Recombinant Polio Vaccine;
- Was invited to attend the 6th International Vaccine Innovation Forum, where the Company showcased its breakthrough progress in the field of tuberculosis vaccines, highlighting the far-reaching impact of China's biopharmaceutical industry on global public health;
- Hosted Professor Adrian Hill from the University of Oxford and his delegation for in-depth exchanges on the progress of novel vaccine R&D, jointly exploring international cooperation and innovation pathways in infectious disease prevention and control technologies;
- Participated in the 3rd Tsinghua Forum on Infection and Immunity, jointly organized by Tsinghua University and Beijing Children's Hospital, National Center for Children's Health, where the Company introduced the latest progress of its innovative vaccine technology platforms and promoted integrated innovation in medical treatment and disease prevention.

Professor Adrian Hill from the University of Oxford Visiting CanSinoBIO

In addition, we are committed to fostering a positive internal academic ecosystem for R&D. By establishing regular cross-departmental communication mechanisms and organizing themed academic seminars on a regular basis, we have created an open, collaborative atmosphere of mutual learning and joint progress, promoting collaborative innovation and the efficient advancement of R&D. In 2025, the Company organized a total of 8 internal academic salons, with multiple experts from China and abroad invited to share their insights, attracting a cumulative total of 796 participants and further enhancing the team's academic perspective and R&D capabilities.

Academic Salon Event

CanSinoBIO actively participates in the development of industry associations. In 2025, as a representative enterprise in vaccine, CanSinoBIO participated in the establishment of the Tianjin (Binhai New Area) Biomanufacturing Pilot Platform Alliance. Jointly initiated by 12 key enterprises and research institutions in the field of biomanufacturing, the alliance adheres to the principles of "market orientation, collaborative innovation, resource sharing, and win-win cooperation." Relying on four core platforms—fermentation, cell, nucleic acid, and vaccine—it supports Tianjin in building a globally influential biopharmaceutical innovation hub. The Company will provide pilot-scale services for enterprises in innovative drugs, biosimilars, vaccines, gene therapy, and cell therapy, covering areas such as stability testing for new drugs, bioanalysis, and vaccine bulk and formulation development. Supported by intelligent equipment and data analysis, these services will improve R&D efficiency and provide professional support for the translation of high-barrier biopharmaceutical technologies.

Intellectual Property Management

CanSinoBIO continues to improve its intellectual property management system and has established an organizational structure centered on the Intellectual Property Management Committee, with clear management responsibilities assigned to each department and project team. We strictly comply with laws, regulations, and standards including the *Patent Law of the People's Republic of China*, the *Copyright Law of the People's Republic of China*, the *Anti-Unfair Competition Law of the People's Republic of China*, and the *Enterprise Intellectual Property Management Standard*, and have formulated multiple internal policies, including the *Intellectual Property Management Policy*, *Intellectual Property Emergency Response Plan*, *Copyright Management Procedures*, *Trademark Management Procedures*, *Patent Management Procedures*, and *Technical Secret Management Procedures*. These ensure standardized operation across all aspects of the creation, utilization, protection, and management of intellectual property, while respecting and safeguarding intellectual property rights.

The Company has built a foundation for internal intellectual property management through digital tools and standardized processes, and has made risk prevention and control more proactive and routine through global patent landscaping and freedom-to-operate (FTO) analysis, thereby supporting strategic global patent deployment.

Highlights of CanSinoBIO's Intellectual Property Management Measures

Digital Full-Process Management

Established and implemented the Invention Disclosure Management (IDM) system and a standardized intellectual property due diligence (IP-DD) process:

- The IDM system is deeply integrated with the project management system, enabling systematic identification, categorized management, and effective protection of various invention disclosures.
- The standardized IP-DD process defines the objectives and scope of due diligence at each stage, enhancing project teams' awareness and capability in managing intellectual property risks.

Risk Identification and Mitigation

- Continued to advance patent landscaping to clarify key R&D directions, identify infringement risks at an early stage, and proactively adopt avoidance measures and formulate response plans.
- Conducted global FTO (freedom-to-operate) analyses. Based on patent landscape insights, the Company provides tailored commercial strategy recommendations to effectively control infringement risks.

International Patent Portfolio Development

- Carried out systematic patent portfolio development in major pharmaceutical markets including China, the United States, Europe, and Japan.
- Advanced international patent protection for core technology platforms such as adenovirus vector vaccines, mRNA vaccines, and polysaccharide-protein conjugate vaccines, covering major pharmaceutical markets worldwide.

The Company fosters a strong culture of innovation and has established incentive mechanisms such as the *Patent and Invention Reward Procedures*, under which eligible innovative achievements are recognized through both honorary and financial rewards, including patent awards and rewards for contributions to technical secrets, thereby stimulating employees' innovative potential.

We regularly organize intellectual property training and exchange activities and invite industry experts to provide in-depth interpretations of intellectual property laws, regulations, and practical case studies, so as to enhance intellectual property protection awareness among all employees. During the year, we invited experts from the Tianjin Center of Patent Examination Cooperation of the China National Intellectual Property Administration, the Tianjin Third Intermediate People's Court, and the Binhai New Area Intellectual Property Protection Center to visit the Company and conduct on-site presentations and interactive exchanges on key topics including the examination of the "three patentability requirements," the protection of technical secrets and trade secrets, the fast-track patent pre-examination process, and the priority system.

Performance Highlight:

In 2025, the Company organized a total of **9** intellectual property training sessions, with **160** cumulative attendances.

At the same time, we actively undertake government-led intellectual property projects and participate deeply in industry co-development and collaborative exchange. In 2025, the Company participated in three intellectual property-related conferences in the pharmaceutical industry, engaging in in-depth discussions with industry experts and peers and keeping pace with the latest domestic and international laws, regulations, and industry trends, thereby helping enhance the effectiveness of its intellectual property strategy implementation.

Highlights of CanSinoBIO's Intellectual Property Collaboration in 2025:

- Completed 10 patent customs record filings;
- Building on the completion in 2024 of the DTaP product patent landscape analysis and high-value patent cultivation project, the Company further advanced the comprehensive patent layout for this product in 2025, and with the support of the fast-track pre-examination mechanism, the relevant patents were successfully granted;
- Applied for and was successfully selected as the Tianjin Vaccine Industry Intellectual Property Operation Center;
- Participated in the China Intellectual Property and Innovation Summit (CIPIS) and delivered a speech as a company representative.

Metrics and Targets

The Company continues to strengthen R&D investment and talent development and organized employees to participate in Tsinghua University's in-person training program on the application of large AI models, enhancing the team's capabilities in applying frontier technologies and innovation. In 2025, a total of four R&D-related video training sessions were conducted, with a cumulative duration of 83.5 hours and 161 total participants.

Highlights of CanSinoBIO's Innovation and R&D Performance

Indicator	Unit	2025 Performance
R&D Investment	RMB 100 million	3.71
Cumulative Number of Patent Applications	cases	93
Cumulative Number of Patents Granted	cases	40
Cumulative Number of Overseas Patents Granted	cases	21

Clinical Trial Ethics

Throughout the process of R&D and innovation, we always place clinical trial ethics at the core of our management. We strictly comply with relevant regulations and ethical principles, protect the rights, interests, and safety of trial participants, and attach importance to laboratory animal welfare, striving to achieve respect for and protection of both human health and animal well-being.

Clinical Trial Ethics

CanSinoBIO has established a Scientific Ethics Review Committee, which is fully responsible for all science and technology activities involving ethics across the Company and its subsidiaries, including R&D, testing, manufacturing, data utilization, and external collaboration. To ensure the effectiveness of clinical trial ethics management, the Scientific Ethics Review Committee holds regular training meetings to clarify its scope of responsibilities and review procedures, thereby promoting the formation of a normalized ethics oversight mechanism.

The Company strictly follows international ethical principles such as the *World Medical Association Declaration of Helsinki* and laws and regulations such as *Good Clinical Practice for Pharmaceutical Products*, and has revised and implemented multiple internal management policies, including the *Research Center Standard Operating Procedures for Project Initiation, Preparation, Review and Submission of Ethics Materials*, to ensure that clinical trials proceed in an orderly manner within a safe, compliant, and ethically sound framework.

The Company has established a full-lifecycle clinical trial ethics protection mechanism covering the preparation stage, implementation stage, and post-trial summary stage, thereby ensuring the standardization and systematic management of clinical trial activities.

Before the Trial

Protection of Autonomy and the Right to Be Informed

During clinical trials, the Company strictly implements the informed consent process to ensure sufficient and clear two-way communication between researchers and participants, thereby safeguarding participants' autonomy.

Informed Communication	Researchers provide participants with a full explanation of key information, including the purpose of the trial, procedures, potential benefits, and risks, to ensure that participants fully understand the trial and have the right to ask questions. Participants voluntarily decide whether to participate based on complete information. Where minors such as infants and young children are involved in a trial, informed consent must be obtained from their guardians. To help children better understand the trial, researchers prepared educational animations. For adult participants, especially elderly participants, researchers used plain language and local dialects where appropriate to ensure that the informed consent process was fully effective.
Signing of the Informed Consent Form	Researchers sign the ethics committee-approved *Informed Consent Form* with participants on a one-to-one basis. The form sets out in detail key information such as the basic details of the clinical trial, the trial purpose, the trial procedures participants are required to follow, participants' obligations, the investigational nature of the trial, possible risks or inconveniences, expected benefits and the possibility of no benefit, compensation and treatment measures for trial-related injury, possible compensation for participation, confidential handling of personal data, and the principle of voluntary participation. In accordance with GCP and relevant regulatory requirements, an age-appropriate *Informed Consent Form* has been specifically designed for child participants aged 8 and above, in order to respect and obtain the child's own wishes. If a child is under the age of 8 at enrollment and turns 8 during the trial, the informed consent process must be repeated and the age-appropriate *Informed Consent Form* must be signed.
Protection of the Right to Freely Participate and Withdraw	The Company ensures that participants who refuse to participate or withdraw from the trial at any stage will not face any form of discrimination or retaliation, and fully safeguards their access to medical treatment and lawful rights and interests.

During and After the Trial

Participant Privacy Protection

The Company strictly complies with privacy-related laws, regulations, and ethical standards, and adopts stringent protective measures in the collection, storage, and use of personal information. In accordance with the clinical trial protocol, researchers assign each participant a study code, using the code in place of personal information to ensure that participants' identities are not directly disclosed in externally provided materials. When clinical trial results are published, participants' identity information remains confidential, minimizing the risk of privacy leakage to the greatest extent possible.

Adverse Event Management

Prevention of Adverse Events	Through management measures such as monitoring and auditing, the Company ensures that researchers conduct regular follow-up on AEs in accordance with the trial protocol, and carry out case-by-case investigation and full-course follow-up for SAEs[5] (Serious Adverse Event), while strictly recording and reporting individual cases in accordance with laws and regulations. Through close monitoring and early warning mechanisms, the Company identifies safety signals in clinical trials in a timely manner and works together with the investigator team to address safety risks, thereby safeguarding the health and rights of participants.
Handling of Adverse Events	Clinical trial researchers have all established SAE response plans and signed green-channel agreements with local medical institutions capable of providing treatment, ensuring that such channels remain open. During the conduct of clinical trials, professional medical staff from these institutions are stationed on-site and take rapid response measures based on participants' actual conditions to protect participant safety and health. All clinical trial projects initiated for enrollment in 2025 were covered by human/drug clinical trial liability insurance, providing insurance protection for all enrolled participants against expected and unexpected adverse events.

To continuously enhance employees' awareness of clinical trial ethics, we provide training in various formats, including online courses and in-person seminars, organize study sessions on the latest industry guidelines and policy documents, and incorporate new regulatory requirements such as the "protection of trial participants' rights and interests" and "informed consent" into the annual key training plan. In 2025, the Clinical Operations Center delivered a special in-person training session on the *Declaration of Helsinki (2024 version)* for all staff, focusing on the key revisions and core requirements to ensure that clinical trial practices comply with the latest international ethical principles. Following the release of the new version of *Good Clinical Practice (GCP)*, the Company also organized online learning sessions featuring expert interpretation of the revised content.

[5] Serious Adverse Event, SAE

Animal Experiment Ethics

CanSinoBIO attaches great importance to laboratory animal ethics and welfare and conducts animal experiments in accordance with strict ethical standards. The Company has established a Laboratory Animal Ethics Committee, which is responsible for reviewing the Application Form for Laboratory Animal Welfare and Ethical Review and overseeing animal experiment ethics. In accordance with national standards such as *Laboratory Animal Environment and Facilities (GB 14925-2023)*, the Company has formulated and implemented internal management policies including the *Laboratory Animal Management Procedures*, *Feed and Bedding Management Procedures*, *Changing Procedures for Animal Facility Personnel*, *Standard Operating Procedures for Environmental Management of Animal Facilities*, *Standard Operating Procedures for the Entry and Exit of Items into and out of Animal Facilities*, and *Standard Operating Procedures for Laboratory Animal Quarantine*, providing clear guidance for ethical animal experiment practices. At the same time, the Company proactively accepts external oversight and conducts annual inspections of the animal facility environment and facilities to ensure that animal housing conditions and experimental equipment continue to meet regulatory requirements.

To meet the Company's future animal experiment needs and support preclinical research for innovative vaccines, the Company built a new modern animal experiment center. On the original basis, the experimental facility area was expanded to twice its previous size, and through scientifically designed spatial layout, both experimental efficiency and animal welfare assurance were improved. In 2025, the center completed the annual review of its *Laboratory Animal Use License*, ensuring that all experimental activities continue to be carried out under strict ethical principles and animal welfare standards.


实验动物使用许可证

许可证号：SYXK（津）2024—0017

单位名称：康希诺生物股份公司

法定代表人：Yu xuefeng

设施地址：天津经济技术开发区西区新桂路16号动物实验中心二、三层

适用范围：普通环境：兔
屏障环境：大鼠、小鼠、豚鼠

2024年12月13日

Laboratory Animal Use License

The Company follows the 3R principles of laboratory animal protection—Reduction, Refinement, and Replacement—and fully implements laboratory animal care measures through actions such as increasing pilot testing and improving housing conditions, thereby effectively protecting animal welfare.

CanSinoBIO's Animal Welfare Measures in 2025

Promoted optimization of animal testing

Successfully developed and applied potency test methods for tetanus and diphtheria vaccines included in the *European Pharmacopoeia*. By optimizing pilot study design and grouping strategies, the number of laboratory animals used was reduced by 50%;

Improved animal housing conditions

Built a new modern animal experiment center and expanded housing area by 2,000 square meters, effectively reducing housing density; adopted a fresh-air system and a low-density housing model, and updated cages to comprehensively ensure the quality of the animals' living environment;

Strengthened environmental monitoring management

Established dedicated positions responsible for the operation of the Environmental Monitoring System (EMS) and improved the alarm response mechanism to ensure that laboratory animals remain in a suitable living environment;

Enhanced care for laboratory animals

Established a memorial monument for laboratory animals and held the first Laboratory Animal Memorial Day event in April 2025, reflecting respect and care for laboratory animals.

The Company has established a regular training system on laboratory animal ethics and provides dedicated training to relevant personnel on a routine basis. In 2025, through a combination of online and in-person formats, we organized systematic learning for all relevant parties, including internal employees, cleaning staff, and suppliers, covering core content such as the 3R principles, *Laboratory Animal Environment and Facilities (GB 14925-2023)*, and the *Guidelines for Ethical Review of Laboratory Animal Welfare (GB/T 35892-2018)*. Training coverage reached 100%.

Customer Service and Pharmacovigilance

CanSinoBIO is committed to fostering a healthy and transparent communication environment, actively listening and responding to customer needs. We have established a comprehensive customer communication and service mechanism and continuously optimized our pharmacovigilance system to effectively safeguard customer rights and ensure medication safety.

Service Assurance

CanSinoBIO consistently prioritizes the customer by establishing efficient and accessible diversified communication channels to listen to opinions, feedback, and inquiries from vaccine recipients, their families, and healthcare professionals. The Company has established a dedicated customer service team to provide efficient responses and complete problem resolution, offering customers a professional and welcoming service experience throughout the entire process. For 2025, the Company has set targets to increase the Net Promoter Score (NPS) for phone and official WeChat account customer services to 50% and 35% respectively, continuously strengthening customer trust and enhancing the service experience.

In 2025, we conducted a customer satisfaction survey to gain deeper insights into customer needs. The survey focused primarily on two major dimensions "effectiveness of problem resolution" and "overall service evaluation", covering customers who called regarding product services during the year, achieving a customer satisfaction rate of 99.41%.

achieving a customer satisfaction rate of

99.41%

CanSinoBIO's Customer Communication Channels

CanSinoBIO's hotline for vaccine products and services: 400-922-2099

An analysis of incoming inquiry content and caller identities revealed that families of potential vaccine recipients accounted for 13.15%, and product inquiries accounted for 58.29%, reflecting a high level of public attention to vaccination and product quality and providing clear direction for the precise optimization of subsequent customer service content.

During the reporting period, the service hotline received a total of 1,460 calls, achieving an overall response rate of 99.93% and a total completion rate of 100%.

Email for reporting adverse reactions: cansinoPV@cansinotech.com

In 2025, the email for reporting adverse reactions received a cumulative total of 3 adverse event reports submitted by vaccine recipients and other healthcare professionals.

Official WeChat account

In 2025, the total number of communications handled through the official account backend reached 927, with a response rate within 15 minutes of 96.17% and a total completion rate of 100%.

CanSinoBIO continuously optimizes its customer complaint management system to ensure high efficiency in complaint response and resolution. The Company has revised and implemented the *Management Procedures for Complaints of Marketed Products*, comprehensively standardizing the entire product complaint handling process. This encompasses a collaborative handling mechanism among the medical, pharmacovigilance, distribution quality, and marketing departments, establishing a standardized consensus document. The Company has established a Pharmacovigilance (PV) – Customer Service Project Communication Group, formulating clear, personalized response scripts and solutions to enhance communication professionalism. Simultaneously, the Company strengthens its data security management system by setting customer information access permissions, strictly preventing information leakage risks, and safeguarding customer privacy and information security.

CanSinoBIO's Customer Complaint Handling Process

Receive customer complaints

Provide feedback to the Distribution Quality Department within 24 hours, and the Distribution Quality Department will take urgent response measures within 24 hours upon any complaint.

The Quality Assurance Department organizes investigation teams to determine whether a complaint event is valid, and the type and level of substantiated complaints.

Organize relevant departments to conduct investigations and follow up with corrective actions based on the investigation results.

The Distribution Quality Department monitors the investigation progress and communicates the findings back to the customer.

Resolve complaints within 30 calendar days.

In 2025

all complaints from the customers were effectively settled, with a complaint closing rate of **100%** for several consecutive years.

CanSinoBIO's AEFI Handling Process

Data collection

Collect information on AEFI from different sources and preliminarily analyze and process them. In 2025, we officially launched the AEFI reporting mini-program, enabling the sales team to report information instantly to the professional pharmacovigilance team via mobile devices. This significantly shortened the overall response time from event occurrence to the initiation of a scientific evaluation.

Incidents evaluation

Type data in the safety database, and evaluate the anticipation, severity, and relevance of the incident

Follow-up investigation

Further follow-up or investigation of incidents required by the Company

Incident reporting

For reports meeting the criteria for AEFI reporting, report to the district or county-level Center for Disease Control and Prevention where the recipient is located within the timeframe required by regulations. If necessary, simultaneously report to the district or county-level health administrative department and medical products administration department where the event occurred.

Subsequent handling

We review product safety information regularly, conduct signal detection, and validate identified suspicious signals. For validated signals, we carry out signal assessments, hold signal evaluation meetings, and make decisions based on these evaluations. This helps us identify potential safety risks promptly and implement risk minimization measures to ensure a balance between risks and benefits.

We carry out handling procedures for cases requiring compensation, including obtaining investigation and diagnosis reports, organizing internal medical assessments, supporting medical appraisal and insurance compensation, and providing compensation in accordance with regulatory requirements.

CanSinoBIO consistently regards the protection of vaccine recipients' rights and interests as a primary responsibility. Strictly complying with the relevant provisions of the *Vaccine Administration Law of the People's Republic of China*, the Company purchases compensation insurance for adverse events following immunization for all marketed vaccines. The Company formulated the *Handling Process for Insurance Compensation of Adverse Events Following Immunization*. In 2025, we optimized the cooperation mechanism with insurance companies and introduced an independent and professional insurance brokerage agency to manage the compensation process. This makes the compensation process more transparent, enhances compliance and risk control capabilities, and maintains the credibility and sustainability of vaccination programs. The Company strictly adheres to the *Collecting Process for Suspected Adverse Events Following Immunization*, the *Handling Process for Suspected Adverse Events Following Immunization*, the *Measures for Compensation for Adverse Events Following Immunization*, and relevant provincial and municipal regulations. We systematically conduct the collection, handling, and reporting of cases, implement insurance compensation or humanitarian compensation in accordance with laws and regulations, and proactively assist government departments and relevant units in ensuring the proper accommodation and subsequent support of vaccine recipients and their families.

CanSinoBIO's AEFI Compensation Procedure

Adverse reactions occur in vaccine recipients following immunization

Cases are reported to the vaccination site or the Center for Disease Control and Prevention (CDC)

The CDC organizes an expert panel for investigation and diagnostic assessment to reach a conclusion

The Company accepts the investigation and diagnostic conclusion and provides appropriate compensation to the vaccine recipient through an insurance provider.

Pharmacovigilance

CanSinoBIO continuously improves its pharmacovigilance management system in compliance with national laws and regulations such as the *Drug Administration Law of the People's Republic of China*, the *Vaccine Administration Law of the People's Republic of China*, the *Administrative Measures for the Reporting and Monitoring of Adverse Drug Reactions*, the *Specifications for Pharmacovigilance Quality Management*, and local guidelines such as the *Pharmacovigilance Quality Management Guidelines for Pharmaceutical Marketing Authorization Holders in the Beijing-Tianjin-Hebei Region (Trial)*. In 2025, taking into account past inspections, internal audit results, and the latest legal and regulatory requirements, the Company revised and implemented multiple internal management systems. These include the *Pharmacovigilance Management System*, the *Pharmacovigilance Quality Management System*, the *Regulation for Pharmacovigilance Management during Clinical Trials*, and the *Major Safety Incidents Handling Procedures*.

In accordance with the *Constitution of the Drug Safety Committee*, the Company has clarified a pharmacovigilance management structure comprising the "Drug Safety Committee (hereinafter referred to as the 'Safety Committee') – CEO – the head of pharmacovigilance, the Pharmacovigilance Department, and relevant departments". The Drug Safety Committee serves as the highest decision-making body. The CEO is the responsible person for the Company's product safety, while the head of pharmacovigilance is tasked with formulating the overall management system and objectives, as well as supervising the implementation and execution of pharmacovigilance-related work across various departments. To ensure the orderly conduct of pharmacovigilance work, the Safety Committee convenes a regular meeting on a semi-annual basis and holds ad hoc meetings for specific events as needed to prevent and control product safety risks. In 2025, the CanSinoBIO Drug Safety Committee convened a total of two regular meetings and one ad hoc Drug Safety Committee meeting.

CanSinoBIO has established a pharmacovigilance system and a supporting quality management system covering the full life cycle across non-clinical stages, clinical stages, and post-marketing stages. This ensures the standardized implementation of pharmacovigilance operations and safeguards the safety of vaccine recipients.

Pharmacovigilance Management Structure



Pharmacovigilance Management Measures

Quality Objectives

Established six pharmacovigilance quality objectives to standardize operational processes, clarify work directions, and enhance management efficiency. In 2025, the pharmacovigilance quality objectives were fully achieved.

Pharmacovigilance System

Introduced the Deep-PV global pharmacovigilance system to achieve full data source coverage and real time monitoring, supporting the collection, evaluation, and reporting of safety information. Ensure system data security and scientific validity through access control, permission management, audit trails, and e-signatures.

Launch of Literature Retrieval System

Based on an automated literature monitoring system, comprehensively cover authoritative scientific evidence in both Chinese and English, and strictly execute the "system preliminary screening and manual review" process to ensure the scientific reliability of adopted information.

Safety Signal Management

Formulated signal management strategies based on product safety profiles and regulatory requirements to standardize the signal detection process. In 2025, CanSinoBIO conducted a total of 15 signal detections involving products such as Convidecia® / Convidecia® Air®, Menphecia®, Menhycia®, iPneucia®, and the Ad5-EBOV, with no explicit signals detected. Furthermore, prospectively explored the application of artificial intelligence in the intelligent monitoring of vaccine safety signals (testing phase) to enhance the proactiveness and accuracy of risk warnings.

Data Exchange

Regularly exchange safety data with relevant internal departments and partners to achieve unified management of product safety data and consistency in safety awareness.

The Company regularly conducts internal audits and external regulatory inspections for pharmacovigilance, continuously identifying and promptly rectifying potential risks to ensure the compliant and efficient operation of the system. In 2025, the Company completed one internal audit of the pharmacovigilance system and underwent one "five in one" in depth inspection of the pharmacovigilance system by the National Medical Products Administration and the Tianjin Medical Products Administration. All inspection results met the requirements, and all identified issues have been fully rectified. In 2026, the Company plans to initiate a special audit of pharmacovigilance data system suppliers to ensure that all product safety data possess compliance, reliability, and traceability.

CanSinoBIO continuously conducts internal and external pharmacovigilance training and cooperative exchanges, dedicating itself to enhancing the professional capabilities and practical proficiency of itself and its partners in the field of pharmacovigilance. In 2025, CanSinoBIO conducted a total of 24 pharmacovigilance training sessions.

Highlights of CanSinoBIO's Pharmacovigilance Training Sessions and Exchanges in 2025

Internal Training System

- Launched foundational courses via the E-Learning system to achieve full staff coverage of basic pharmacovigilance knowledge;
- New sales employees are required to complete specialized training combining online and offline modules along with in-class assessments upon onboarding to ensure training effectiveness;
- Conducted regular in-depth professional training for core teams such as pharmacovigilance and medical affairs to consolidate professional capabilities in medical assessment, data analysis, and scientific judgment.

External Training Participation

Regularly participated in multiple external training sessions organized by the National Medical Products Administration, institutes for advanced study, and relevant regulatory authorities, covering key areas including risk management, compliance and quality, and international pharmacovigilance.

International Capacity Building

Collaborated with PATH[6] to conduct a series of overseas pharmacovigilance training sessions covering individual case safety report processing, signal detection, audit and inspection, and pharmacovigilance agreement management, laying the foundation for the Company to build an international pharmacovigilance system.

Industry Standard Formulation

Proactively partnered with industry associations to spearhead the formulation of industry assessment reference standards for nervous system and blood system related AEFIs, providing solid industry professional support for regulatory decision making.

Academic Exchange and Sharing

As an industry representative of Chinese innovative vaccine enterprises, was invited to share experiences at the CMAC Medical Conference and Exhibition (CMAC) and the Drug Information Association (DIA) Pharmacovigilance and Risk Management Forum.

International Cooperation Agreements

Signed pharmacovigilance agreements with multiple overseas partners in compliance with Chinese and local regulations, covering individual case reports, periodic safety update reports, and risk management plans, while continuously communicating to enhance partner capabilities and jointly ensuring product safety and accessibility.

[6] PATH, an international nonprofit organization founded in 1979 dedicated to improving global health through innovation, especially in developing countries. Since the 1980s, PATH has operated projects in China to promote the international standardization of pharmaceutical technologies and products.

Responsible Marketing

CanSinoBIO has established a marketing risk management system covering the entire marketing process and actively applies digital and intelligent supervision tools to ensure all marketing activities strictly comply with domestic and international laws, regulations, and internal ethical standards, continuously fulfilling its commitment to responsible marketing.

Governance

CanSinoBIO practices responsible marketing and strictly abides by local laws, regulations, and industry guidelines where it operates, including the *Drug Administration Law of the People's Republic of China*, the *Vaccine Administration Law of the People's Republic of China*, and the *Advertising Law of the People's Republic of China*, ensuring the compliance of all marketing behaviors. In accordance with the aforementioned regulations, the Company has formulated and implemented internal management systems such as the *Compliance Operation Standard Manual* and the *Responsible Commercial Statement* to comprehensively regulate marketing and communication behaviors.

In terms of management structure, the Company has built a marketing compliance system covering both Chinese and overseas businesses and established the Commercial Operation Center Management Committee (the "COC Management Committee") headed by the Chief Commercial Officer. This committee is responsible for formulating and supervising responsible marketing strategies, reviewing marketing audit reports, and regularly reporting marketing activities to the Board of Directors to ensure the standardization of marketing activities. In 2025, the number of legal lawsuits related to false marketing involving the Company was 0.

In 2025, the number of legal lawsuits related to false marketing involving the Company was

0

Strategy

In 2025, CanSinoBIO optimized its responsible marketing strategy system, building a closed loop management framework. This system is driven by inputs from senior management research interviews and the *Strategic Risk Assessment Analysis*, and centers on interdepartmental collaborative assessment of marketing risks, and quarterly reviews of strategic execution, thereby strengthening its systematic capability to control marketing activities. Looking forward, the Company will continue to dynamically identify marketing risks, conduct comprehensive interdepartmental risk assessments, absorb industry best practices, and refine the control framework for marketing activities. This ensures that marketing activities adhere to the principles of scientific accuracy and safeguard public trust and long-term brand value.

Impact, Risk, and Opportunity Management

CanSinoBIO attaches great importance to responsible marketing. By constructing a marketing risk management system that covers pre-, in-, and post-event stages, the Company integrates compliance requirements into every phase of its marketing activities.

Marketing Risk Management System

Pre-control

Constructed a marketing compliance management system spanning the entire process by establishing sound marketing compliance protocols, conducting regular risk assessments, and providing systematic compliance training.

In-process monitoring

Incorporated marketing compliance performance into the management appraisal system and ensured the standardization and consistency of marketing activities by establishing an interdepartmental joint marketing management mechanism.

Post-event supervision and inspection

Organized annual internal commercial marketing audits across the entire company to review key aspects such as content output and sales codes of conduct, effectively supervising the compliance of marketing activities and the execution effectiveness of risk control measures.

The Company achieved full staff coverage of responsible marketing courses through the E-learning platform and the "Kangmiaoyou+" initiative. In 2025, the Company introduced AI technology to build an intelligent knowledge base and sales scenario simulation functions to enhance employee learning efficiency. Concurrently, it launched the "Baobian Club" special training program to conduct new product training for core sales personnel, implement key projects, and gather frontline feedback, ensuring that marketing behaviors comply with commercial standards and corporate social responsibility requirements.

Metrics and Targets

CanSinoBIO has established targets related to responsible marketing management and continuously tracks various data metrics to ensure the effective advancement of responsible practices. During the reporting period, the number of noncompliant marketing incidents was 0.

During the reporting period, the number of noncompliant marketing incidents was

0



CanSinoBIO Responsible Marketing Target:

In 2025, centered on the construction of the "responsible marketing" system, the Company fully achieved its goals of enhancing responsibility awareness and capabilities across all employees. Key metrics were all met or exceeded as planned, laying a solid foundation for the compliance, integrity, and social value creation of marketing activities.

Key Metrics for Responsible Marketing

Sessions of responsible marketing training

1,600 sessions

Responsible marketing training expenses

874,000 RMB

Total participants in responsible marketing training

1,000 persons

Employee coverage rate of responsible marketing training

100%

Average responsible marketing training hours per employee

5 hours

Medical Health Accessibility

Driven by the vision of Innovation for a Safer World, CanSinoBIO is committed to providing safe vaccines to the public. We support the Doha Declaration, implement fair pricing practices, and engage in depth collaboration with global medical institutions, government organizations, and industry partners to continually enhance the global accessibility and affordability of medicines.

Strategy and Commitment

CanSinoBIO has established a Scientific Advisory Board composed of authoritative experts from various professional fields including public health and infectious diseases. The board regularly conducts discussions on topics such as rare disease research and development, pharmaceutical accessibility, industrialization, and industry trends to provide recommendations for the strategic planning and decision making of the Company regarding pharmaceutical accessibility. Addressing the practical needs of developing countries and low- and middle-income regions, we have formulated differentiated market strategies. Through technology transfer, capacity building, and talent training, we support the development of localized research and manufacturing systems to enhance regional self sufficiency in vaccine supply.

CanSinoBIO commits to:

- Support the *Doha Declaration on the TRIPS Agreement and Public Health*.
- Abide by international and domestic fair pricing principles, incorporate pharmacoeconomic evaluations when determining product prices, and fully consider the actual paying capacity of different markets. By referencing the pricing mechanisms of similar products domestically and internationally, we are dedicated to establishing a differentiated pricing system to ensure that price levels align with the economic conditions of countries with varying income levels. Simultaneously, we actively support healthy generic drug competition, believing that orderly market competition can promote improvements in drug accessibility to better serve global public health needs.

Technology Accessibility

CanSinoBIO actively fulfills its responsibilities and commitments in the global public health sector. Through in depth cooperation with governments and local enterprises in developing countries, we promote the international transfer and application of advanced vaccine technologies.



In 2025, CanSinoBIO

- Obtained formal market authorization approval for MCV4 in Indonesia and completed the submission of registration materials in multiple countries across Southeast Asia, the Americas, and Western Asia.
- Obtained Halal certification for PCV13*i*, laying a crucial qualification foundation for the product.
- Completed GMP compliance audits in several key regions, including an online GMP audit for the COVID-19 XBB variant in Mexico and the on-site audits for MCV4 in Egypt and Malaysia.
- Actively advanced the localized production process of MCV4 in overseas partner countries and simultaneously initiated MCV4 technology transfer cooperation projects in multiple key markets.
- Completed the enrollment of the first subject in the Phase I clinical trial for the inhaled tuberculosis booster vaccine in Indonesia, marking the entry of this project into a new stage of clinical research.
- Formally signed an MCV4 supply agreement with a partner in Saudi Arabia, accelerating the commercialization process of the product in the Middle East.

Furthermore, to elevate healthcare standards in developing countries, the Company has launched multidisciplinary capacity building projects for partners in developing nations such as Malaysia. These projects cover regulatory policies, clinical trial management, pharmacovigilance systems, and specialized product knowledge, thereby enhancing the professional proficiency and independent operational capabilities of local public health systems.

Product Accessibility

CanSinoBIO actively supports localized research and development and production in developing countries to help build a global immune barrier. Strictly complying with domestic and international regulatory requirements, including GMP and GSP, as well as standards set by the FDA, PICS, and WHO, the Company relies on professional pharmaceutical cold chain logistics service providers to establish a stable and reliable pharmaceutical distribution network in key regions such as Southeast Asia, the Middle East, and Latin America. This ensures the continuous accessibility of vaccines and critical medical supplies in resource limited areas. We have completed risk validation and optimization for key logistics channels in Morocco, Mexico, and Indonesia. Meanwhile, to guarantee product quality, safety, and traceability, the Company established a GS1 traceability system that meets international standards. By utilizing intelligent packaging coding technology, we achieve full chain information traceability from production to circulation. Ultimately, this enables an efficient, stable, and sustainable international market supply of medicines under the premise of ensuring quality compliance and safety control.

Ensuring the "Last Mile" Vaccine Delivery by CanSinoBIO

To improve the equity and accessibility of public health services in remote areas, CanSinoBIO has continued to strengthen its nationwide vaccine cold chain distribution network. In 2025, the Company completed the establishment of 11 regional warehouses in Gansu, Ningxia, Xinjiang, Guizhou, and other locations, covering traditionally underserved distribution areas in Northwest and Southwest China and achieving 100% coverage of the national regional distribution network. We use specialized refrigerated transport equipment and real-time temperature monitoring systems, together with a multimodal "road + air" transportation solution, to effectively address challenges such as long transport distances and inadequate infrastructure in remote areas. At the same time, logistics service providers have established emergency response mechanisms for contingencies such as vehicle or equipment failures and extreme weather, including nearby vehicle redeployment, emergency support, and mutual assistance agreements with other enterprises, thereby ensuring the quality and safety of vaccine distribution.

Knowledge Accessibility

CanSinoBIO remains committed to public health education. Through active participation in high-level industry exchanges and public science outreach initiatives, we translate scientific research achievements into health knowledge that is accessible to the public.

Participation in the Seminar on Pediatric Bacterial Vaccines

On July 5, 2025, the Company was invited to attend an industry seminar on pediatric bacterial vaccines held in Tianjin, where it joined experts from multiple fields to discuss child health protection. During the seminar, the Company shared insights on the application characteristics and value of various vaccines in preventing pediatric diseases, contributing to the scientific dissemination of vaccine-related health knowledge and actively supporting greater public awareness of infectious disease prevention in children.

Participation in the Industry Seminar on Pediatric Bacterial Vaccines

03

Value Creation

Upholding a People-Centered Approach and Fulfilling Social Responsibility

CanSinoBIO regards talent as the cornerstone of corporate value creation. By strengthening our talent development strategy, optimizing our training system, and enhancing our compensation and benefits framework, we provide a strong talent foundation for the Company's fulfillment of its social responsibilities.

Employment and Rights Protection

CanSinoBIO strictly complies with national labor laws and regulations as well as international human rights standards, ensuring fair employment opportunities and lawful rights and interests for employees. We continuously improve our institutional framework and democratic management mechanisms to foster a workplace environment that respects differences and supports inclusive development.

Protection of Employee Rights

CanSinoBIO adheres to the philosophy of "putting people first and respecting human rights," placing a high priority on safeguarding its workforce. The Company strictly complies with laws and regulations including the *Labor Law of the People's Republic of China*, the *Labor Contract Law of the People's Republic of China*, and the *Provisions on the Prohibition of Child Labor*, while actively adhering to international labor and human rights principles such as the *Ten Principles of the United Nations Global Compact*. Through the systematic review, formulation, and rigorous implementation of a series of compliant, standardized, and efficient internal policies, including the *Employee Handbook*, the *Labor Contract Management Procedures*, and the *Attendance, Overtime and Leave Management System*, the Company continues to strengthen a full-process, comprehensive institutional management system. With standardized management as the foundation, CanSinoBIO protects the lawful rights and interests of job applicants, current employees, and departing employees in accordance with the law, fosters a fair, transparent, stable, and orderly employment environment, and enhances both corporate governance and employees' sense of belonging. In 2025, the Company did not record any incidents involving child labor or forced labor and actively encouraged suppliers and business partners to uphold the same commitments.

In 2025, the Company did **not** record any incidents involving child labor or forced labor and actively encouraged suppliers and business partners to uphold the same commitments.

Measures to Protect Employee Rights

Equal Employment

We have zero tolerance for any improper conduct such as discrimination, offense, or insult based on nationality, race, place of origin, gender, sexual orientation, economic status, political beliefs, or religious faith.

We prohibit all forms of discrimination in employment and occupation and uphold equal pay for equal work.

Prohibition of Child Labor and Forced Labor

We implement a full-process review mechanism covering the stages before hiring, during recruitment, and after onboarding. Through clearly defined recruitment requirements, third-party background checks, and verification of onboarding documents, we eliminate the risk of child labor at the source.

We fully respect employees' willingness in work assignment, establish a scientific and well-regulated division of labor system, and prohibit all forms of forced labor.

Anti-Harassment

We have zero tolerance for any form of harassment, including but not limited to physical harassment, sexual harassment, psychological harassment, verbal harassment, or any other form of inappropriate conduct.

Collective Bargaining

We uphold employees' freedom of association and protect their right to collective bargaining.

Reasonable Working Hours

We updated the *Comprehensive Working Hours Management Procedures* and optimized the logic for working hours calculation based on business needs.

By improving the approval process, we promoted more reasonable management of attendance irregularities, overtime headcount, and overtime hours.

Supported by a well-established internal reporting and investigation mechanism, the Company clearly requires all employees to promptly report any violations involving child labor, forced labor, discrimination, or harassment through designated channels such as the Human Resources Department or their direct supervisors. The Company ensures that all investigations are conducted in accordance with fair and transparent procedures and that the identity of whistleblowers is kept strictly confidential, thereby effectively protecting employee rights and maintaining organizational credibility.

Aon's 2025 China Best ESG Employer

In 2025, the Company received Aon Group's "2025 China Best ESG Employer" award for the fourth consecutive year, fully reflecting our industry-leading performance in protecting employee rights as well as in ESG governance and practice across all dimensions.

Employee Recruitment

In 2025, CanSinoBIO continued to regard talent as a core driver of corporate innovation and sustainable development and actively advanced the optimization of its talent structure and the intelligent upgrading of its recruitment system. Through diversified and efficient recruitment mechanisms, we attracted outstanding talent and injected momentum into the Company's strategic execution and long-term development.

With respect to the recruitment of technical talent, the Company brought in 11 professionals from the biopharmaceutical sector with strong academic backgrounds and extensive industry experience, further enhancing its R&D and innovation capabilities in the vaccine field and laying a solid foundation of high-caliber talent for future development.

In terms of employer branding and university-enterprise collaboration, the Company entered into a strategic partnership with McGill University in Canada and launched an international internship exchange program. Under this initiative, the Company plans to recruit outstanding students from leading overseas universities in 2026 for several months of internship experience in China, with a view to strengthening its international talent pipeline.

With respect to internal recruitment, the Company formulated and implemented the *Internal Application Management Procedures* in 2025, publicly released relevant vacancies, and provided employees with consultation services on internal applications. Employees are encouraged to apply for open positions across departments or subsidiaries, thereby opening internal channels for talent mobility.

In terms of recruitment process digitalization, the Company's online recruitment system introduced AI-enabled functions to support résumé screening, improving the efficiency and accuracy of initial screening. At the same time, the system's AI interview assistant helps structure and standardize the interview process by providing interviewers with intelligent question prompts and competency assessment support, thereby enhancing the rigor and scientific basis of recruitment.

As of the end of the reporting period, the Group had a total of

1,134 employees

The overall employee turnover rate was

6.97%

The Group's Employment in 2025

Indicator		2025 Data
Total Employees (Persons)		1,134
Newly contracted Employees (Including Those Who Joined and Left) (Persons)		110
Internally Recruited Employees (Persons)		5
Labor Contract Signing Rate (%)		100
By Gender (Persons)	Male	539
	Female	595
By Gender (%)	Male	47.53
	Female	52.47
By Age (Persons)	Under 30	183
	Aged 30 to Under 50	933
	Aged 50 and Above	18
By Age (%)	Under 30	16.14
	Aged 30 to Under 50	82.28
	Aged 50 and Above	1.58
By Employee Level (Persons)	Senior Management	16
	Middle Management	158
	General Staff	960

Indicator		2025 Data
By Employee Level (%)	Senior Management	1.41
	Middle Management	13.93
	General Staff	84.66
Female Employees in Management	Female Employees in Senior Management	3
	Female Employees in Middle Management	75
By Job Category (Persons)	Management Personnel	145
	R&D Personnel	273
	Quality Personnel	139
	Production Personnel	209
	Sales Personnel	342
	Finance Personnel	26
By Job Category (%)	Management Personnel	12.79
	R&D Personnel	24.07
	Quality Personnel	12.26
	Production Personnel	18.43
	Sales Personnel	30.16
	Finance Personnel	2.29

Indicator		2025 Data
By Educational Background (Persons)	Doctoral Degree and Above	22
	Master's Degree	258
	Bachelor's Degree	602
	Associate Degree and Below	252
By Educational Background (%)	Doctoral Degree and Above	1.94
	Master's Degree	22.75
	Bachelor's Degree	53.09
	Associate Degree and Below	22.22
By Ethnicity (Persons)	Han Ethnicity	1,080
	Ethnic Minorities	44
	Foreign Employees	10
By Ethnicity (%)	Han Ethnicity	95.24
	Ethnic Minorities	3.88
	Foreign Employees	0.88
By Nationality (Persons)	Chinese Employees (Including Hong Kong, Macau, and Taiwan)	1,124
	Foreign Employees	10
By Nationality (%)	Chinese Employees (Including Hong Kong, Macau, and Taiwan)	99.12
	Foreign Employees	0.88

Indicator		2025 Data
Employee Turnover (Persons)[8]		85
Total Employee Turnover Rate (%)		6.97
Turnover by Gender (Persons)	Male	46
	Female	39
Turnover Rate by Gender (%)	Male	7.86
	Female	6.15
Turnover by Age (Persons)	Under 30	21
	Aged 30 to Under 50	62
	50 and Above	2
Turnover Rate by Age (%)	Under 30	10.29
	Aged 30 to Under 50	6.23
	50 and Above	10.00
Turnover by Employee Level (Persons)	Senior Management	1
	Middle Management	13
	General Staff	71
Turnover Rate by Employee Level (%)	Senior Management	5.88
	Middle Management	7.60
	General Staff	6.89

[8] The statistical scope of employee turnover headcount and turnover rate metrics includes only voluntary turnover personnel.

Diversity and Inclusion

CanSinoBIO provides equal employment opportunities for employees of different nationalities, races, skin colors, places of origin, genders, sexual orientations, ages, economic backgrounds, political beliefs, religious beliefs, ethnic groups, regions, or disability status, and is committed to fostering a diverse and inclusive working environment.

To support the development of female employees, the Company strictly implements statutory benefits such as maternity leave, childcare leave, and maternity insurance, while also providing marriage and childbirth gifts and continuously improving initiatives that support women. To help female employees during pregnancy and lactation better balance work and family responsibilities, the Company has established dedicated mother and baby rooms that are private, hygienic, and conveniently accessible. On International Women's Day, the Company organizes holiday celebration activities and provides female employees with benefit packages covering beauty products, daily necessities, health, and fitness-related items. As of the end of the reporting period, CanSinoBIO had 78 female managers, representing 44.83% of all management personnel, and 595 female employees, accounting for 52.47% of the total workforce.

CanSinoBIO had **78** female managers

representing **44.83%** of all management personnel

and **595** female employees

accounting for **52.47%** of the total workforce

Notice of CanSinoBIO Women's Day Employee Benefits Activity

Supporting the Employment and Development of Persons with Disabilities

CanSinoBIO remains committed to implementing the *Three-Year Action Plan for Supporting Employment of People with Disabilities (2025-2027)* and continues to provide people with disabilities with employment and development opportunities to help them realize their self-worth. As of the end of the reporting period, the Company had provided employment to 9 people with disabilities.

Democratic Management

The labor union of CanSinoBIO follows the principles of democratic management and ensures employees' right to be informed of and participate in the Company's operational and welfare policies. Centered on employee service and support for development, the labor union plays a substantive role in key areas such as communicating major decisions, collecting and responding to employee concerns, and coordinating efforts in corporate culture development, thereby establishing institutionalized channels for employee participation. In 2025, the Company held 4 labor union meetings and successfully completed the reelection of the union committee.

Employees' Representative Meeting

In 2025, the labor union of CanSinoBIO convened an Employees' Representative Meeting to review, with a focus on the proposed adjustments to the Company's annual business targets and the plan to enhance the employee welfare system. During the meeting, union representatives engaged in in-depth discussions on topics including the optimization of core business processes, the allocation of skills training resources, and support for parent-child benefits, and voted on the relevant proposals on site, incorporating employees' suggestions into the Company's decision-making.

Employee Communication

CanSinoBIO has established diversified and effective communication channels to ensure that employee views are heard promptly and addressed effectively. The Company has clearly defined employee complaint and grievance mechanisms and, while strictly safeguarding confidentiality, effectively protects employee rights and interests.

Employee Communication Channels

Communication Channel	Communication Content
Human Resources Business Partner (HRBP)	Based on employee engagement survey results, timely improvement measures are taken for low-scoring dimensions. A full-cycle communication mechanism for new employees has been established, with dialogue conducted at key stages such as onboarding and probation to promptly follow up on their needs and suggestions. Exit interviews are conducted with 100% of departing employees, and effective feedback is translated into management improvement actions through analysis. Regular communication is carried out with managers and employees to provide timely support in response to business needs and employee concerns, while also exploring innovative approaches such as cross-position incentives.
Values Workshop	Customized workshops are conducted with a focus on strengthening team collaboration and clarifying technology development pathways, thereby promoting cross-departmental coordination and technological advancement. Annual Values Stars are selected and recognized at the townhall meeting, reinforcing the guiding role of the Company's values.
Human Resources Assistant	Through the introduction of the Feishu intelligent agent, the Company has digitally upgraded its people and administrative service system across the entire process, creating an employee self-service platform that integrates intelligent knowledge base Q and A, connected HR and administrative services, and automated business processing. At the same time, the employee notification and information delivery mechanism has been upgraded to achieve precise, timely, and comprehensive service response, providing all employees with efficient, convenient, and one-stop personnel and administrative support. Since its launch on August 25, 2025, the platform has processed a total of 1,520 requests.
Townhall	An interactive platform has been established with dedicated sessions in which management responds to employees' key concerns, with a view to enhancing both the breadth and depth of employee participation in corporate governance.

In June 2025, CanSinoBIO launched its annual employee engagement survey, covering 7 dimensions including alignment with strategic objectives and cultural values, resource support, recognition and incentives, leadership effectiveness, performance management, employer brand perception, and level of commitment and engagement. The questionnaire response rate reached 85%, with an overall average score of 4.29 out of 5. Four dimensions scored above the overall average, namely commitment and engagement, employer brand perception, alignment with strategy and cultural values, and leadership effectiveness. Based on the survey results, the Company promptly formulated an improvement plan with a focus on strengthening the recognition and incentive system, optimizing resource support mechanisms, and improving the performance management system, to respond effectively to employee needs and concerns.

In accordance with the *Employee Handbook*, the Company has established an employee grievance mechanism. Where employees believe their rights or interests have been adversely affected, they may submit written grievance materials through designated channels. Upon receipt of a grievance, the Company will promptly initiate an investigation process and handle the matter with rigor and impartiality, while keeping management informed of the progress and outcome of the investigation in a timely manner. The Company places a high priority on privacy protection and keeps complainants' personal information strictly confidential to ensure the security of their privacy, while also ensuring that the handling outcome is communicated to employees in a timely manner.

Employee Compensation and Benefits

CanSinoBIO has optimized its compensation and performance management system, strengthened employee care initiatives, and established a multi-dimensional communication mechanism to respond effectively to employee feedback and enhance the protection of employee rights and interests as well as organizational cohesion.

Compensation Incentives and Performance Evaluation

CanSinoBIO has formulated and refined its *Compensation and Benefits Management Policy* to strengthen compensation compliance management, continue providing allowances, and optimize its long-term incentive framework. In 2025, the Company conducted a market benchmarking study on employee compensation levels to align with industry standards, scientifically assess the competitiveness and internal fairness of its compensation practices, and provide data support for subsequent compensation adjustments and labor cost budgeting. At the same time, the Company continued to provide employees with a range of allowances, including off-site work assignment allowances, overseas hardship project allowances, and position-based allowances.

With respect to performance evaluation, the Company follows its *Performance Management Policy* and, while maintaining the overall framework of its performance management approach, has further strengthened requirements for management capability development. The Company requires managerial personnel to include team management indicators with a weighting of no less than 20% in their performance objectives and enhances their management capabilities through targeted coaching in multiple areas, with a view to continuously improving team effectiveness and managerial leadership. The Company also continued to advance the development of its long-term incentive mechanism by implementing an employee share ownership plan for key core personnel, covering approximately 23.02% of employees.

Employee Care

CanSinoBIO has established a comprehensive welfare support system for full-time employees, part-time personnel, and outsourced personnel. The Company strictly ensures that all employees are entitled to statutory benefits, including social insurance and the housing fund, annual leave, and sick leave, so that every employee receives consistent care and protection. On this basis, the Company has introduced a range of non-statutory benefits and care programs covering multiple areas. In 2025, the total value of employee benefits distributed by the Company amounted to RMB 73.12 million.

Employee Care Measures

Non-statutory Benefits and Assistance

The Company provides full-time employees with non-statutory leave benefits, including company annual leave and fully paid sick leave, and in certain regions applies the more favorable standard for marriage leave and paternity leave.

The Company also provides assistance to employees in financial hardship by granting monthly subsidies to eligible employees and offers home visits and condolence payments to employees suffering from serious illness.

Physical and Mental Well-being

The Company provides employees with commercial insurance coverage above the market average and also offers medical insurance and free vaccinations for employees' children.

The Company has established a 24/7 psychological support hotline and launched EAP psychological courses to safeguard employees' mental health.

The Company has optimized the points circulation and claims functions of its flexible benefits platform to enhance employees' experience in selecting benefit plans and products.

Employee Training and Development

CanSinoBIO has improved its career development pathways and established a tiered and category-based training system to advance talent pipeline development, provide employees with full-cycle growth support from onboarding to promotion, and strengthen the talent foundation for the Company's innovation-driven development.

Promotion Pathways

CanSinoBIO upholds a talent philosophy of fairness, transparency, and development, and is committed to building a scientific and well-structured promotion mechanism. In 2025, the Company systematically optimized its promotion framework and strengthened the rigor of promotion decisions by establishing a structured assessment system and a closed-loop management process.



Career Development Pathways for Managerial and Specialist Talent

Key Measures for Optimizing the Promotion Mechanism in 2025

Institutional and Process Standardization	The Company issued and implemented the *Promotion Management Procedures*, which clarify promotion criteria, review procedures, and the responsible parties at each stage, thereby enhancing the transparency of the promotion process and the credibility of promotion decisions.
Innovation in the Review Mechanism	The Company established a review committee composed of business, human resources, and cross-functional leaders, and adopted a competency model-based assessment approach together with an anonymous voting mechanism to ensure objective and fair evaluations.
Strengthened Post-promotion Management	The Company introduced a post-promotion debriefing process, requiring promoted employees to present their team development plans and objectives, thereby achieving closed-loop management from promotion assessment to follow-up on performance in role.
Organizational Collaboration and Capability Building	Through the participation of cross-functional reviewers and the application of competency models, the Company has aligned internal capability standards and promoted the enhancement of managers' systematic thinking and management capabilities.

Talent Development System

In 2025, guided by a forward-looking talent development philosophy, CanSino continued to optimize its *Training Management System* and established a progressive training system covering senior executives, middle and junior managers, and all employees. Closely aligned with regulatory compliance requirements and emerging technology trends, the system focuses on core capabilities such as leadership, digital skills, ESG management, and new product knowledge. Through an integrated online and offline learning model, it systematically enhances the employees' overall capability to respond to change and drive innovation. In 2026, the Company plans to identify the key capability development priorities for talent at each level, integrate existing course resources in a targeted manner, optimize program content, and build a full-cycle talent development and training system.

At the same time, the Company encourages employees to actively apply for professional title accreditation. As of the end of the reporting period, the Company had supported 27 employees in applying for professional titles, including 12 at the associate senior level, 7 at the intermediate level, 7 at the assistant level, and 1 at the entry level. In 2025, the Company invested RMB 1.83 million in employee training, with average training hours per employee reaching 34.48 hours and training coverage reaching 100%.

In 2025, the Company invested

RMB **1.83** million in employee training

with average training hours per employee reaching

34.48 hours

training coverage reaching

100%

CanSinoBIO's Employee Training System and Key Programs

Executive Coaching	As a supporting program under the "Leadership Program," the Company engaged external coaches for senior executives to enhance leadership and personal influence.
Frontline Manager Development Camp	The Company launched foundation and advanced programs for middle and junior management talent, adopting a closed-loop model of "micro-learning for guided preparation + in-person instruction + practical application." The program covers topics such as role awareness, performance management, and change leadership, and incorporates a learning points system and team-based competition mechanism. During the reporting period, the program recorded 43 participant attendances and a cumulative duration of 900 hours.
New Hire Orientation Training	The Company adopted a model combining "online foundational learning + department-based on-the-job training." Through the E-learning platform, new hires complete mandatory content such as corporate culture, compliance, and safety requirements to ensure rapid integration into the organization. During the reporting period, based on training completion dates, a total of 190 new hires (including interns) completed onboarding training through the E-learning platform.
General Skills Training	Relying on the E-learning platform, the Company provides online courses to all employees and uses digital tools to send learning progress reminders and disclose training data, thereby linking training with talent development programs. During the reporting period, the program covered 1,181 employees.
Digital Skills Training	The Company organized organization-wide training on digital applications centered on office systems such as Feishu, covering topics including efficient meetings and agile collaboration, to enhance employees' digital workplace capabilities. During the reporting period, online and offline training sessions reached 138 participant attendances.
Product Knowledge Training	The Company organized product-related learning sessions and quiz-based interactive activities for all employees to promote product knowledge and strengthen employees' understanding of the Company's products.
ESG Special Training	The Company conducted ESG project kickoff and training sessions in both online and offline formats to strengthen employees' awareness of ESG management and practice. During the reporting period, ESG training coverage reached 100%.

Product Knowledge Training for iPneucia®

In 2025, following the official launch of the new product iPneucia®, CanSinoBIO organized a company-wide online learning and quiz-based interactive program. Through online courses, the Company systematically introduced the product's features, technological advantages, and clinical application value, and incorporated interactive quiz sessions to reinforce learning outcomes. A total of 1,191 employees participated in the training, with cumulative learning time reaching 140 hours. In the quiz-based interactive sessions, 707 employees actively participated, laying an internal foundation for the product launch and subsequent market promotion.

A total of **1,191** employees participated in the training

with cumulative learning time reaching **140** hours

In the quiz-based interactive sessions, **707** employees actively participated

Feishu Efficiency Pioneer Camp

In 2025, CanSinoBIO launched the "Feishu Efficiency Pioneer Camp" digital intelligence capability development program. By organizing AI application competitions, the Company encouraged key employees to explore highly efficient digital workplace solutions for typical business scenarios, including real-time data monitoring, end-to-end process automation, and efficient knowledge management through AI applications. The program included 5 dedicated training sessions, covering 400 participant attendances, and received a total of 50 submitted cases, effectively enhancing the Company's office productivity and level of intelligent operations.

The program included **5** dedicated training sessions

covering **400** participant attendances

received a total of **50** submitted cases

CanSinoBIO Employee Training Statistics in 2025

Employee Training Indicators		Employee Training Data
Average training hours per employee (hours)		34.48
Average training hours per employee by employment type	Average training hours per senior management employee (hours)	14.62
	Average training hours per middle management employee (hours)	51.66
	Average training hours per frontline employee (hours)	31.99
Average training hours per employee by gender	Average training hours per male employee (hours)	34.26
	Average training hours per female employee (hours)	34.69
Percentage of employees trained (%)		100
Percentage of employees receiving training by employment type	Percentage of senior management employees receiving training (%)	100
	Percentage of middle management employees receiving training (%)	100
	Percentage of frontline employees receiving training (%)	100
Percentage of employees receiving training by gender	Percentage of male employees receiving training (%)	100
	Percentage of female employees receiving training (%)	100

Occupational Health and Safety

CanSinoBIO advances occupational health and safety management in a comprehensive manner by improving its management system, strengthening risk assessment and hazard identification, conducting systematic training and emergency drills, and reinforcing whole-process oversight of contractors, thereby safeguarding the occupational health and workplace safety of every employee.

Occupational Health and Safety Management

CanSinoBIO complies with the *Law of the People's Republic of China on Work Safety*, the *Law of the People's Republic of China on the Prevention and Control of Occupational Diseases*, and other applicable national laws and regulations. The Company has established its occupational health and safety management system with reference to relevant International Labour Organization guidelines and the ISO 45001 standard. During the year, the Company carried out a systematic enhancement of its EHS management framework, issuing 2 new documents and revising 11 existing documents, including the *EHS Objectives and Responsibilities Management Policy* and the *EHS Rewards and Punishment System*. These updates further clarified key requirements for the assessment of EHS responsibilities and the corresponding rewards and penalties, as well as safety controls throughout production processes, while training was provided to ensure effective communication and implementation of the relevant policies. During the reporting period, the Company recorded no major or serious incidents, incurred no administrative penalties related to occupational health and safety, reported zero occupational health and safety injury incidents, and maintained a work-related fatality rate of 0%.

Specific Occupational Health and Safety Measures

EHS objectives and performance assessment

- Safety accountability statements for all positions for 2025 were prepared and signed, achieving a **100%** signing completion rate.
- Conducted the mid-year 2025 and annual safety responsibility performance evaluations, with overall scores **all meeting the standards**.

Emergency drills

- A total of 42 emergency drills were completed, covering emergency rescue, fire safety, chemicals, biosafety, and other areas, with **1,086** participant attendances in total.

Risk assessment and hazard remediation

- The annual risk assessment was completed, identifying 883 risks, including 45 major risks, 325 general risks, and 513 low risks, with a **100%** remediation completion rate.
- Multi-level hazard inspections were conducted, covering external inspections, BP inspections, and departmental self-inspections. The annual hazard remediation rate reached **99.22%**. For the small number of hazards not yet rectified, long-term remediation plans and interim control measures were established.

Occupational health protection

- All production areas completed periodic monitoring of occupational hazard factors, and all monitoring results **met applicable standards**.
- Annual occupational health examinations covered active employees, departing employees, and pre-employment personnel, with **no** target diseases or occupational contraindications identified.

Internal and external audits

- Internal special audits were conducted in accordance with the annual plan, and all identified issues were **fully rectified**.
- The Company underwent 18 external health and safety audits and inspections, during which 34 issues were identified. No major non-conformities were found, and all issues were **fully rectified**.

Safety awareness communication

- In accordance with the annual plan, 12 EHS training sessions were completed, covering safety awareness, laws and regulations, management policies, and special operations, with a total of **7,161** participant attendances and a **100%** pass rate in the assessments.
- The Company conducted 3 skills enhancement training sessions for members of the EHS safety team, and **93** participants attended.
- A cumulative total of 335 department-level safety training sessions were conducted, with **7,092** participant attendances. All new employees and frontline personnel **completed** the relevant induction and safety assessments.
- A total of **288** EHS-related videos and knowledge-sharing materials were disseminated through channels including the Company's WeChat work groups.

Occupational Health and Safety Training Data

Occupational health and safety training indicator	Occupational health and safety training data
Employee training coverage (%)	100
Average training hours per employee for all employees (hours)	12.36
Total number of training sessions (sessions)	341
Total training attendances (attendances)	14,382
Male employee training attendances (attendances)	7,760
Female employee training attendances (attendances)	6,622
Senior management training attendances (attendances)	24
Middle management training attendances (attendances)	1,968
General staff training attendances (attendances)	12,390

Contractor Safety Management

CanSinoBIO optimized its contractor safety management system and, in 2025, revised the *Contractor Safety Management Procedures* to further standardize safety management across the entire contractor work process. At the same time, the Company continued to incorporate contractors into its overall safety target management system and adopted multiple measures, including a combination of digital platforms and site-based supervision, to ensure the safety of contractor operations. During the reporting period, the Company recorded no contractor-related EHS incidents.

Key Measures for Contractor Safety Management

Integration into safety targets

Contractor safety management performance indicators were incorporated into the assessment of responsible departments and aligned with the Company's overall safety targets.

Digital management

Leveraging the government's digital management platform, the Company created account profiles for 96 contractors and achieved full-process online management covering plant entry applications, pre-commencement preparation, process supervision, and completion acceptance.

On-site supervision

The Company carried out end-to-end supervision of contractor operations, including daily entry review, pre-work inspection, in-process inspection, and completion acceptance, while also conducting daily random safety inspections to ensure safe contractor operations.

Training and drills

Contractor emergency evacuation drills were incorporated into the Company's annual drill plan. Throughout the year, the Company organized 120 contractor safety training sessions, covering 652 participant attendances, with a 100% training pass rate.

Community Development and Public Welfare

CanSinoBIO actively fulfills its social responsibilities, places strong emphasis on the dissemination of healthcare knowledge, and continues to invest in public welfare initiatives in support of the strategic objectives of comprehensive rural revitalization.

Public Welfare and Philanthropy

CanSinoBIO actively carried out a range of initiatives, including disability support, medical assistance, and care for children with special needs, contributing to the advancement of public welfare and the well-being of vulnerable groups.



Family Day Disability Support Initiative

In 2025, during its annual Family Day event, CanSinoBIO partnered with Chuangmei Disability Support Organization to purchase more than RMB 6,500 worth of handicrafts made by people with disabilities and used them as event prizes. While enriching the Family Day program, the Company also provided tangible support for the employment of people with disabilities.

Family Day Event

World Meningitis Day Public Welfare Initiative "Adding Protection with Love"

During World Meningitis Day 2025, CanSinoBIO joined hands with the Ai You Foundation to launch a public welfare initiative supporting children affected by meningitis. The initiative provided RMB 200,000 in medical expense assistance for children aged 0 to 17 from low-income families suffering from meningococcal meningitis and carried out public education activities on the disease. By combining financial assistance with health education, the Company helped ease the medical burden for affected children from disadvantaged families and enhanced public awareness of meningococcal disease prevention.

Caring for Children with Autism

In 2025, CanSinoBIO visited the Hangu Autism Rehabilitation Center to extend care and support, delivering rehabilitation supplies and other materials to children with autism, and exchanged views with the center's staff on rehabilitation support for children with autism, contributing to improvements in the rehabilitation environment for these children.

Hangu Autism Rehabilitation Center

Rural Revitalization

CanSinoBIO has incorporated agricultural support initiatives into its corporate social responsibility practices. Through multidimensional measures including industry empowerment, the Company continues to support agricultural modernization and rural development and contributes through concrete actions to the achievement of the goals of comprehensive rural revitalization.

Procurement of Agricultural Support Products from Dafang County, Guizhou

Ahead of the Mid-Autumn Festival, the Company carried out a dedicated agricultural support procurement initiative in Dafang County, Guizhou, purchasing more than RMB 100,000 of locally distinctive agricultural and sideline products in total. This initiative not only enriched holiday benefits for employees, but also provided tangible support for local industrial development, fostering a positive cycle in which employees benefit and farmers increase their income.

Procurement of Farmer-supporting Products

04

Strengthening Governance

Improving Governance Systems and Empowering Stable Development

CanSino Biologics regards compliance as the foundation of its corporate growth. Guided by business integrity as a core principle, the Company has established and continues to refine a comprehensive risk management and audit system covering the entire value chain. We continuously optimize supply chain processes to ensure strict compliance throughout operations, while placing strong emphasis on information security management to safeguard data assets and trade secrets. These efforts provide a solid foundation for the Company's sustainable development.

Corporate Governance

CanSino Biologics has established a sound corporate governance structure and continues to optimize its decision-making processes and execution mechanisms in order to effectively enhance overall operational efficiency and organizational effectiveness.

Governance Structure

CanSino Biologics strictly complies with the *Company Law of the People's Republic of China*, the *Securities Law of the People's Republic of China*, the *Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited*, the *Rules Governing the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange*, and other applicable laws, regulations, and regulatory requirements. Through standardized appointment and election procedures for directors, the Company has established a corporate governance structure and operating mechanism centered on the Annual General Meeting of Shareholders and the Board of Directors, forming a scientific, efficient, and sustainable decision making and oversight system that ensures compliant operations and effectively safeguards the interests of all shareholders.

The Board of Directors is responsible for the Company's overall strategic planning and has established the Audit Committee, the Remuneration and Assessment Committee, and the Nomination Committee to assist in the discharge of its governance responsibilities. The Board and its specialized committees jointly guide business planning, oversee implementation, review operational and financial performance, continuously improve the Company's operating efficiency, and support the achievement of its long term and steady development. As of the end of the reporting period, the third session of the Board of CanSino Biologics consisted of three executive directors, one non-executive director, and three independent non-executive directors.

CanSino Biologics Corporate Governance Structure and Responsibilities in 2025

Controlling Shareholder and the Listed Company

- The controlling shareholder of the Company has consistently adhered to regulatory requirements, exercised shareholder rights in accordance with the law, and actively supported the Company's development, while maintaining independence from the Company in terms of business, personnel, assets, organizational structure, and finance.
- The controlling shareholder has strictly complied with corporate governance rules, and there have been no instances of interference in the Company's decision making or business operations through means other than the General Meeting of Shareholders.

Shareholders and the General Meeting of Shareholders

- As the Company's highest authority, the shareholders' meeting is composed of all shareholders and is empowered to elect and replace directors, determine major business policies and investment plans, and adopt resolutions on significant corporate matters.
- The Company strictly implements procedures for the convening, holding, and voting of shareholders' meetings, promotes active shareholder participation, and places particular emphasis on safeguarding the equal rights and status of minority shareholders.

Directors and the Board of Directors

- The Company continues to strengthen the role of external directors in oversight and strategic advisory functions, and fully considers their professional advice on industry trend analysis and risk management in order to enhance the scientific basis and reasonableness of Board decision making.
- The Board of Directors convenes at least four meetings each year to ensure continuity in the Company's operations and timely responses to major decisions.

In 2025, the Company convened a total of **3** shareholders' meetings and **7** Board meetings. The Board committees held **5** Audit Committee meetings, **4** Remuneration and Assessment Committee meetings, and **1** Nomination Committee meeting, respectively.

Board Diversity

CanSinoBIO regards Board diversity as a core pillar supporting the Company's sustainable development. To this end, the Company has formulated and implemented the *Board Member Diversity Policy*, under which a range of factors are comprehensively considered in the selection of new directors, including gender, age, cultural background, educational background, ethnicity, professional capabilities, industry experience, qualifications, professional integrity, as well as willingness and ability to devote sufficient time to the discharge of duties. Members of the Board possess extensive professional knowledge and substantial practical experience in areas such as healthcare, finance and accounting, corporate management, and risk control. Their skills are complementary and enable efficient collaboration. In addition, Board members continue to pursue ongoing learning and professional development, providing strong support for the Company's strategic decision making. As of the end of the reporting period, the third session of the Board comprised seven members, including two female directors, representing 28.57% of the Board.[7]

Members of the Third Session of the Board of Directors

Director Category

Executive Directors	Non-executive Director	Independent Non-executive Directors
3	1	3

Gender

Male Directors	Female Directors
5	2

Cultural and Educational Background

Directors with Doctoral Degrees	Directors with Master's Degrees
2	5

Age

Directors aged 40 to 49	Directors aged 60 to 69
2	5

Investor Relations

CanSino Biologics has formulated and implemented the *Investor Relations Management Policy*, adhering to the principles of information disclosure that are truthful, accurate, complete, timely, and efficient, and establishing an open and equal two-way communication mechanism. Through diversified channels such as investor communication platforms, shareholders' meetings, and results presentations, the Company proactively communicates its operating philosophy, presents its business achievements, and explains its development strategy to investors, thereby continuously strengthening market recognition of and confidence in the intrinsic value of CanSinoBIO. In 2025, the Company communicated with investors on hundreds of occasions, published 10 records of investor relations activities, responded to nearly 60 inquiries on SSE E-Interaction (online platform), and answered more than 160 calls through the investor hotline.

The Eleventh Stop of the Listed Companies New Quality Productive Forces Research Tour Visited CanSinoBIO

On November 13, 2025, the eleventh stop of the Advancing Innovation and Pursuing Quality and Long-Term Growth, Listed Companies New Quality Productive Forces Research Tour, jointly organized by Shanghai Securities News, China Southern Fund, and Huatai Securities, was held at CanSinoBIO. Nearly 40 institutional investors participated in the event. Through in-depth discussions with the Company's management team and on-site visits, participants gained a comprehensive understanding of CanSinoBIO's exploration, achievements, and practical approach in the field of new quality productive forces.

CanSinoBIO Hosted the "I Am a Shareholder" Listed Company Visit Event

On September 11, 2025, the "I Am a Shareholder" listed company visit event, organized by the Bohai Securities Investor Education Base, was successfully held at CanSino Biologics. Representatives from the Listed Companies Association of Tianjin, the Tianjin Securities Association, Bohai Securities, and related investors participated in the event. Accompanied by the management team and the IR team, guests visited the corporate culture exhibition hall and the innovative vaccine research and development center. They also received presentations on the Company's vaccine products, research and development processes, and the layout of its Tianjin manufacturing site, gaining insight into the Company's core capabilities and technical expertise in research and development, production, and quality control. The event effectively established an efficient and transparent communication bridge between the Company and investors, enabled face to face dialogue with management, and enhanced investors' understanding and recognition of the Company's core competitiveness and growth potential.

[7] Information regarding the members of the Board of Directors can be found in the 2025 Annual Report, Company announcements, and circulars.

Compliance Development

CanSinoBIO is committed to continuously deepening compliant operations, comprehensively strengthening operational management capabilities, upholding compliance values and standards, and laying a solid foundation for the Company's long-term and steady development.

Governance

CanSinoBIO strictly complies with the *Company Law of the People's Republic of China* and other relevant laws and regulations. The Company has established the *CanSinoBIO Compliance Management Manual* and revised relevant policies and procedures, including the *Management Review Procedure for the Compliance Management System and Anti-Bribery Management System* and the *Compliance Management Procedure for Channel Partners*, in order to advance the improvement and effective implementation of compliance management.

CanSinoBIO continues to optimize and enhance its compliance management system. In 2025, the Company further refined its compliance governance structure by upgrading the highest decision-making body for compliance management from the Risk and Internal Control Management Committee to the Executive Committee under the direct leadership of the General Manager, thereby improving decision-making efficiency and strategic responsiveness.

CanSinoBIO Compliance Governance Structure

Governance Level — Executive Committee

- As the highest decision-making body for compliance management, the Executive Committee operates under the direct leadership of the General Manager.
- Responsible for approving major compliance policies, systems, and annual reports, and for determining response plans for major compliance risks.

Management Level — Legal and Compliance Department

- As the core lead department, the Legal and Compliance Department is responsible for establishing and maintaining the compliance management system, organizing risk identification, assessment, early warning, and response activities, and handling anti-corruption matters, whistleblowing investigations, and follow-up on corrective actions.

Implementation Level — Heads of Departments and Centers

- The head of each department serves as the primary person responsible for compliance management within that department, ensuring the implementation of compliance work plans, organizing compliance risk identification, early warning, and response activities, conducting departmental compliance training, and promoting the development of a compliance culture within the department.

- All Employees

  Proactively identify and report compliance risks and comply with the Company's compliance requirements.

- Suppliers and Business Partners

  Comply with the Company's compliance policies, standards, and prohibited matters to ensure compliance in business cooperation.

Strategy

In 2025, CanSinoBIO continued to improve the operating mechanisms of its compliance management system, with a focus on key areas. The Company dynamically identified changes in compliance obligations and risks, updated lists of compliance obligations, risk registers, and follow-up monitoring measures for relevant areas in a timely manner and formulated targeted compliance policies for identified high-risk areas to strengthen management measures and execution mechanisms. During the reporting period, CanSinoBIO had no incidents of non-compliance. Looking ahead, CanSinoBIO plans to continue advancing and improving the operation of a forward-looking compliance control system to ensure safe operations within the Company's global regulatory framework. The Company places importance on upholding business ethics, helping reduce systemic risks, and creating strategic value that enhances long-term competitiveness, thereby promoting the deep integration of compliance management with ESG governance and the Company's core values.

Impact, Risk and Opportunity Management

The Company continued to improve its compliance management system centered on the *Compliance Obligations and Compliance Risk Assessment Procedures*. Through external database tracking, research through official channels, and other means, it dynamically identified compliance obligations and issued internal briefings such as the *Compliance Monthly Newsletter* to guide business departments in identifying and implementing compliance requirements. A systematic risk assessment is conducted every six months. Based on dynamically updated risk ratings and combined assessments of inherent risk and residual risk, the Company strengthened process controls. In key areas such as engineering, procurement, marketing, and information security, the Company established dedicated risk assessment checklists and embedded compliance requirements into business processes through cross-functional collaboration. In 2025, the Company successfully passed surveillance audits for both the ISO 37301 Compliance Management System and the ISO 37001 Anti-Bribery Management System, and continued to enhance the effectiveness of system operation through risk-based thinking and the PDCA cycle.

To strengthen compliance governance, the Company established an integrated risk control and audit oversight system covering beforehand prevention, in-process control, and afterwards supervision, and revised the *Internal Control Management Policy* and the *Internal Audit Management System* to further improve internal control and audit mechanisms. The Company also carried out a systematic upgrade of its document management system. Centered on its business structure, it comprehensively reviewed, consolidated, and optimized policy documents, established a standardized document structure and centralized management mechanism, reviewed more than 330 documents during the year, and completed the drafting or revision of approximately 170 items, thereby improving the applicability, guidance value, and management efficiency of its documentation.

In 2025, in accordance with requirements under such regulations as the *Application Guidelines for Enterprise Internal Control*, the Company implemented a three-year full-coverage audit mechanism and systematically advanced audit oversight across all business segments. In the area of procurement management, the Company conducted a full-process internal control special audit with a focus on business ethics risks. Through document matching, process testing, data analysis, and other methods, it carried out in-depth reviews of suppliers, and no fraudulent conduct was identified during the audit period. The Company will continue to improve its supply chain oversight mechanism and plans to conduct a special audit of the supplier management system. In the area of marketing and sales, the Company worked with the compliance department to optimize inspection standards and completed the quarterly review of more than 9,400 supporting documents. At the same time, it conducted a special audit of the sales and collections cycle, carrying out a comprehensive assessment from the perspectives of internal control effectiveness, business authenticity, and coordination between business and finance, thereby promoting the optimization of business processes and the integration of control measures. In addition, the Company carried out special audits in key areas including import and export, funds management, seal management, major matters, and financial transactions involving key personnel. Through risk identification, reporting, and closed-loop remediation, related issues have been rectified, effectively strengthening the internal control system and providing systematic support for the Company's steady operations.

Metrics and Targets

CanSinoBIO has set a target of zero major compliance risk incidents and continues to enhance its risk management capabilities by monitoring relevant indicators, including employee participation in compliance training. The Company adopts a tiered and targeted training approach and carries out initiatives across the workforce to strengthen risk awareness and operational compliance standards. During the year, it organized a total of 17 specialized compliance training sessions, effectively enhancing employees' compliance awareness and risk identification capabilities.

CanSinoBIO Launches Its Fourth Compliance Promotion Month

In September 2025, under the theme "Compliance Lays the Foundation, Innovation Drives the Future," CanSinoBIO held its Compliance Awareness Month campaign for the fourth consecutive year, covering all four major business segments of the Company. Through a range of formats including senior management addresses, specialized training, and thematic workshops, the campaign promoted a deeper understanding of compliance across the organization and advanced the shift from conceptual recognition to shared governance.

Highlights of CanSinoBIO's Compliance Management Performance

Indicator	Unit	2025 Performance
Participation rate in compliance training for the Board of Directors and management	%	100
Employee participation rate in compliance training	%	100
Average compliance training hours per Board member	Hours	3
Average compliance training hours per employee[8]	Hours	14

[8] The statistics cover senior and middle management, as well as frontline employees.

Business Ethics

CanSinoBIO continued to strengthen its business ethics framework, strictly complied with national laws and regulations, systematically improved its anti-corruption management system, and established an anti-corruption governance mechanism covering the entire value chain. The Company provided regular and diversified anti-corruption communications and training for employees, suppliers, and partners, while continuously optimizing whistleblowing procedures and reporting channels to strengthen the effective operation of its oversight mechanisms.

Governance

CanSinoBIO strictly complies with the *Anti-Monopoly Law of the People's Republic of China*, the *Anti-Unfair Competition Law of the People's Republic of China*, the *Anti-Money Laundering Law of the People's Republic of China*, and other applicable laws and regulations, and firmly opposes all forms of corruption and unfair competition. To continuously improve its business ethics management, the Company has formulated and implemented relevant policies including the *Conflict of Interest Management Policy* and the *Employee Receiving Gift Management Process*, and revised the *Anti-Corruption and Anti-Fraud Management System* to comprehensively enhance the standardization and effectiveness of business ethics management.

CanSinoBIO Business Ethics Governance Structure

Executive Committee

- Oversees the Company's business ethics and compliance management strategy
- Reviews and decides on major compliance risk matters

Legal and Compliance Department

- Manages whistleblowing mechanisms related to corruption, bribery, and fraud, and formulates relevant procedures
- Maintains reporting channels, receives reports, and conducts investigations

Heads of Departments

- Bear direct management responsibility for anti-corruption, anti-bribery, and anti-fraud matters within their respective departments
- Promptly report actual or potential violations

To strengthen the management of business ethics among suppliers, the Company updated its Supplier Code of Conduct in 2025, explicitly incorporating core business ethics requirements such as anti-corruption and integrity in business operations into the standards for supplier onboarding and ongoing cooperation. Together with the *Integrity Agreement* and the *Confidentiality Agreement*, this code forms an essential document framework for supplier cooperation and promotes the alignment of business ethics and compliance development across the supply chain.

Strategy

Grounded in institutional frameworks and guided by its corporate culture, CanSinoBIO has progressively advanced the systematic development of its business ethics and anti-corruption and anti-bribery management system, with a focus on compliant operations and risk prevention and control. In this process, the Company has actively engaged in industry dialogue and cross-sector collaboration, continuously drawing on external feedback and experience to enhance its governance capabilities. Looking ahead, while continuing to improve its institutional framework, the Company will strengthen governance execution, further embed ethical principles into its operations, and deepen exchanges and cooperation with industry associations, regulatory authorities, and international platforms, thereby promoting the steady evolution of business ethics development from rules-based compliance to values-based leadership.

Impact, Risk and Opportunity Management

CanSinoBIO continued to advance the optimization and development of its business ethics framework. In 2025, the Company focused on promoting systematic reviews of anti-bribery management across core business areas, covering nine key functions including research and development, supply chain, marketing, human resources, and finance. Through in-depth internal interviews, end-to-end process analysis, and reviews of policy documents, the Company comprehensively assessed the effectiveness of its existing anti-bribery management system in practical business operations. In response to the continuous evolution of pharmaceutical regulatory policies, the compliance team promptly identified and consolidated new requirements relating to anti-commercial bribery and other relevant matters, translated them into specific control measures, further strengthened the Company's ability to prevent and control corruption risks in key areas, and effectively promoted the integration of the compliance system with business operations.

During the year, the Company successfully passed the annual external surveillance audit for the ISO 37001 Anti-Bribery Management System, reflecting the effectiveness of its strategic efforts to advance the development of its business ethics framework.

CanSinoBIO actively promotes a culture of integrity and compliance, encourages internal reporting of corruption and violations of business ethics, and receives relevant information through multiple public channels including a hotline, a dedicated email address, and written correspondence. The Company has established a 24-hour monitoring mechanism to ensure that every report and lead is responded to and handled in a timely manner. In accordance with internal policies such as the *Management Procedure for Compliance Reporting, Whistleblowing and Internal Investigations*, the Company strictly implements a protection mechanism for the information of named whistleblowers and effectively safeguards their lawful rights and interests. At the same time, the Company has established the *Reward Process for Non-Compliance Reporting* to provide appropriate rewards to individuals who submit verified and valid reports, thereby strengthening company-wide oversight and continuously fostering a clean operating environment.

Main reporting channels of CanSinoBIO

- Reporting hotline: 022-58213600-6218
- Reporting email: compliance@cansinotech.com
- Mailing address: Rongsheng Building, 185 South Street, West District, Tianjin Economic and Technological Development Zone

In 2025

CanSinoBIO participated in a number of industry exchange and cooperation activities relating to compliance, internal control, and business ethics.

In March 2025

the Company attended an in-person conference organized by EverPro on contract review and compliance risk prevention in the healthcare industry.

In April 2025

the Company attended the Second Pharmaceutical Compliance Promotion Conference organized by the Hainan Yuanchuang Institute for Proactive Health Industry Development.

In August 2025

the Company attended the seminar *Compliance Safeguards Growth, Intelligence Shapes the Future: Legal Practice and Frontier Issues for Pharmaceutical Enterprises*, organized by Zhong Lun Law Firm.

In September 2025

the Company attended the 2025 Pharmaceutical Industry Compliance Digital Intelligence Innovation Forum, jointly organized by the Shanghai Pharmaceutical Profession Association and the Association of China Compliance Professionals.

In December 2025

the Company attended an event organized by the Tianjin Arbitration Commission on the interpretation of the *Arbitration Law of the People's Republic of China*.

In December 2025

the Company attended the 11th Annual Compliance Forum organized by the Association of China Compliance Professionals.

Metrics and Targets

CanSinoBIO has set a target of zero material anti-corruption incidents throughout the year. The Company also treats employee participation rate, coverage rate, and pass rate for business ethics training as key monitoring indicators, and continues to track and improve performance against these metrics.

The Company has established a business ethics and anti-corruption training system that covers all employees, and has incorporated completion of compliance training into the employee performance evaluation system. For new hire onboarding, all new employees are required to complete mandatory courses including the *Compliance Manual* and *Conflict of Interest Compliance Training* through the online learning platform, enabling them to systematically learn core compliance requirements such as anti-corruption and anti-fraud. For management, the Company has introduced a dedicated mandatory course, *Management Responsibilities for Anti Corruption, Anti Fraud, and Anti Commercial Bribery*, to strengthen compliance leadership and accountability. In addition, the Company requires 100 percent of all employees (including interns and contract staff) to sign the *Anti Corruption and Business Ethics Commitment Letter*, thereby jointly building an internal line of defense founded on integrity and self discipline.

CanSinoBIO Business Ethics Indicators

Indicator	Unit	2025 Performance
Employee signing rate for the Anti Corruption and Business Ethics Code of Conduct commitment letter	%	100
Supplier signing rate for confidentiality agreements and integrity agreements[9]	%	100
Litigation or cases related to corruption, violations of business ethics, or unfair competition	Cases	0
Number of business ethics and anti corruption training sessions	Sessions	9
Average training hours per person at the Board level	Hours	0.5
Average training hours per person at the management level	Hours	5
Average training hours per person for all employees	Hours	6.5

[9] Scope of signing covers all domestic suppliers.

Party Building Leadership

CanSinoBIO leverages high quality Party building to drive high quality development, innovates collaborative Party building models, strengthens the foundations of Party building, and promotes mutual reinforcement between Party building and business operations.

Joint government enterprise Party building creates a new collaborative platform connecting government, experts, and enterprises

In 2025, the Party Committee of CanSinoBIO used Party building as a link to establish an exchange platform connecting government, experts, and enterprises. During the year, it organized more than ten joint learning and co-building activities, involving more than 20 experts from health commissions, centers for disease control and prevention, hospitals, and industry associations. It also received more than 100 visits in total from relevant national authorities, Tianjin drug regulatory institutions, centers for disease control and prevention from multiple provinces and cities, and participants in high level talent training programs for research and inspection visits.

it organized more than **10** joint learning and co-building activities

It also received more than **100** visits in total from relevant national authorities

Pioneering leadership and branch coordination strengthen the foundation

To implement the guiding principles of the 20th National Congress of the Communist Party of China, the Company's Party Committee launched the Party Member Vanguard Post selection at the end of 2025. A total of 18 individuals were recognized, and their exemplary achievements were widely publicized across the Company to set a model of diligent and practical performance. Each Party branch also carried out a range of distinctive activities aligned with business operations, including seminars and essay activities on the spirit of the Central Eight-point Regulations and the guiding principles of the Third Plenary Session of the 20th Central Committee. These activities promoted the integration of Party building and business operations and enhanced organizational cohesion.

The Party Committee of CanSinoBIO coordinates and advances the normalization and institutionalization of theoretical study

In 2025, the Company's Party Committee focused on implementing the decisions and arrangements of higher level authorities, continuously strengthening theoretical grounding and political guidance. It identified the spirit of the Central Eight-point Regulations, the guiding principles of the Fourth Plenary Session of the 20th Central Committee, and accelerating the development of Healthy China as key annual study topics, and systematically organized thematic learning activities. By integrating learning with practice, the Company effectively strengthened the role of Party branches as strongholds of action and the vanguard role of Party members, providing solid political assurance and organizational support for the successful completion of annual tasks.

Party Member Training

Responsible Supply Chain

CanSinoBIO integrates sustainable development principles throughout the entire supply chain management process. Based on stringent supplier admission requirements and ongoing evaluation mechanisms, the Company promotes shared responsibility across the upstream and downstream value chain. Through a systematic supply chain governance structure and risk identification mechanisms, we are committed to building, together with our partners, a responsible supply chain system that is transparent and compliant, operationally efficient, resilient, and mutually beneficial.

Governance

CanSinoBIO strictly complies with *the Civil Code of the People's Republic of China*, the *Bidding Law of the People's Republic of China*, and other laws and regulations. The Company has established the *Supplier Management Regulations* and refined and updated related institutional documents including the *Supplier Management Procedures*, the *Standard Operating Procedures for Supplier Audits*, and *Supplier Performance Management*, in order to define and implement supply chain management requirements, standards, and procedures. The Company has established a Procurement Committee and, in light of the specific characteristics of different procurement functions, has also formulated supporting subordinate management policies internally to better address the management needs of various business scenarios.

Strategy

CanSinoBIO has established a systematic and well developed supply chain management system covering the full process from supplier admission, tiered evaluation, and ongoing audits to dynamic exit, while also actively promoting joint capability building with suppliers. On this basis, the Company will continue to strengthen its strategic focus on sustainable supply chain management and extend responsible practices toward the front end of the value chain. In response to global supply chain trends and changes in the external environment, the Company has developed a procurement strategy that balances short term assurance with long term autonomy and controllability. Through the ongoing advancement of material substitution and risk control, the Company has already achieved initial results and expects to realize more significant cost optimization and improvements in supply stability in the future.

The Company actively implements a localized procurement strategy and gives priority to high quality local enterprises during supplier selection and development, in order to strengthen regional collaboration and promote mutually beneficial development. In 2025, all three framework agreements signed for R&D material platform suppliers were concluded with local distributors.



Impact, Risk, and Opportunity Management

CanSinoBIO places strong emphasis on full life cycle supplier management and has developed systematic strategies across four core stages including admission, classification, review, and exit, thereby achieving comprehensive supplier oversight and closed loop control.



In accordance with the *Supplier Admission Management Procedures*, shortlisted supplier eligibility is determined based on supplier questionnaires and comprehensive evaluation results, and suppliers that pass the review are required to sign an integrity agreement, a confidentiality agreement, and the Supplier Code of Conduct.

The Company has also formulated the *Supplier Management Procedures* and the *Standard Operating Procedures for Supplier Audits*, which systematically standardize admission assessments across three modules including commercial, technical, and qualification review. These procedures comprehensively examine suppliers' lawful operating qualifications, quality management systems, and related policies and processes. Admission is completed through system submission and approval of the *Qualified Supplier List for Logistics Services*.

Based on two dimensions including supply risk and supply value, suppliers are categorized into four groups including strategic, leverage, bottleneck, and routine, with differentiated management strategies applied to each category.

On an ongoing basis, and based on annual performance evaluation results, suppliers are further assigned to five grades including A, B, C, D, and E. Supplier capabilities in key categories are also subject to more granular classification in order to enhance the precision and effectiveness of management.

In daily assessments, the Company focuses on suppliers' routine performance, incoming quality, delivery timeliness, and service levels to ensure that they continue to meet cooperation requirements.

For suppliers of critical raw materials and consumables, the Company organizes on site factory inspections to conduct in depth assessments of their production and management capabilities.

As part of annual assessments, the Company conducts comprehensive evaluations of suppliers by material category across multiple dimensions including delivery, quality, service, and price. Together with quarterly KPI communication and annual quality audits, this enables a systematic assessment of overall supplier performance throughout the year.

In accordance with the *Procedures for Supplier Freezing, Unfreezing, and Exit Management*, suppliers that fail audits are eliminated directly.

Suppliers that fail annual evaluations and do not cooperate with corrective actions are removed.

The Company closely monitors internal supplier risk assessment reports, and if any material risk item arises, cooperation is terminated immediately.

CanSinoBIO has established and continues to refine a supplier risk management system covering the full process of identification, prevention, management, and correction, and applies differentiated and refined management measures to different types of suppliers. In the risk identification and due diligence stage, the Company uses the *Commercial Supply Survey Form* and a regular audit mechanism to systematically identify potential risks. For key suppliers of production materials, the Company completed annual quality audits of 22 suppliers during the year, including on site audits of 21 suppliers, and dynamically included 3 new suppliers in the audit scope as needed. For logistics service providers, the Company carried out 19 special quality audits covering key processes including transportation and warehousing. For overseas suppliers, audit evaluations of 8 suppliers were completed through questionnaires.

In terms of risk prevention and management, the Company has established a normalized monitoring and response mechanism. Through regular reviews of material inventory and usage, the Company promptly identifies risks of slow-moving inventory or material shortages and coordinates responses with suppliers and internal user departments. At the same time, the Company has established emergency and urgent procurement procedures and activates a tiered emergency response mechanism based on the urgency of the event and the procurement amount, thereby systematically enhancing supply chain resilience and responsiveness.

In the correction stage, the Company prepares rectification documentation and audit reports for all audit findings, driving suppliers to implement improvement measures and ensuring closed loop management.

Supply Chain ESG Management

CanSinoBIO attaches great importance to suppliers' ESG performance and is committed to building a green and sustainable responsible supply chain. During the year, the Company fully incorporated core requirements relating to environmental protection, health and safety, and business ethics into the *Supplier Code of Conduct*, gave priority to the procurement of low carbon and environmentally friendly products and services, and formulated targeted control measures for potential environmental and social risks in supplier operations, continuously promoting the overall optimization and sustainable development of supply chain management.

Basic requirements

100% of domestic suppliers have signed the *Supplier Code of Conduct*.



Certification requirements

Under equivalent conditions, priority is given to suppliers certified under management systems such as ISO 9001, ISO 14001, ISO 45001, and OHSAS 18000.

Health and safety requirements

Suppliers are required to establish mechanisms for the prevention, management, tracking, and reporting of occupational injuries and diseases, and are encouraged to adopt corresponding corrective measures.

Suppliers are required to provide employees with systematic health and safety training, eliminate relevant hazards at the source, and protect employees' lawful rights and interests in accordance with the law, including statutory benefits and paid leave.

Labor rights requirements

Suppliers are required to strictly comply with laws and regulations relating to the protection of employee rights and interests, the prohibition of child labor and forced labor, and anti discrimination, so as to ensure full compliance in their operations.

Suppliers are expected to fully respect employees' rights to freedom of association and collective bargaining, safeguard their lawful rights and interests, firmly eliminate workplace discrimination arising from factors such as race, gender, age, and religious belief, and actively foster a fair and inclusive working environment.

Business ethics requirements

All suppliers are required to sign the *Integrity Agreement* and the *Confidentiality Agreement* in order to prevent corrupt practices and strictly protect the Company's technical materials and intellectual property rights.

Suppliers are required to help build a fair and transparent business environment, and any improper competition, fraud, money laundering, or similar misconduct is strictly prohibited so as to ensure compliant and orderly cooperation.

Environmental protection requirements

Suppliers are expected to minimize energy consumption and are encouraged to use renewable energy. The concepts of reuse and recycling are promoted as priorities.

Suppliers are expected to make every effort to optimize product packaging, minimize fuel and water consumption, reduce greenhouse gas emissions, and avoid the use of hazardous raw materials.

Suppliers are required to assess and control business activities that pose environmental risks and strive to meet environmental management system standards recognized by national or international institutions.

Supplier Training

CanSinoBIO has established a multi-tiered and targeted supplier training system. This system disseminates compliance requirements via centralized online training, while conducting systematic oversight of supplier quality through annual audits and semi-annual quality communication meetings. These meetings mandate the participation of key supplier managers, and are followed by post-meeting self-assessments and improvement plans. This ensures that the company's annual training comprehensively covers relevant regulations, policies, and operating procedures. Through this dual-track mechanism of audits and meetings, the Company continuously disseminates its high-quality standards and fosters collaborative improvement throughout the supply chain. For supplier-specific issues, CanSinoBIO also engages in targeted, point-to-point communication, resolving practical cooperation challenges through one-on-one dialogue. This approach effectively assists suppliers in enhancing their capabilities and ensures the full implementation of the Company's requirements.

Metrics and Targets

CanSinoBIO has established clear management objectives and evaluation metrics for its supply chain. The Company has set "zero major supplier responsibility incidents" as its core objective and continues to enhance its supplier selection, evaluation, and collaboration mechanisms. At the same time, by tracking quantitative indicators such as the total number of suppliers, the number of suppliers subject to annual dynamic management, and the proportion of suppliers certified under key management systems including ISO 14001 and ISO 45001, the Company systematically promotes steady improvement in supplier quality, compliance, and sustainability performance, and works jointly with suppliers to build a resilient, reliable, and continuously optimized supply chain ecosystem. In materials and capital management, the Company continues to refine its control mechanisms and, through ongoing benchmarking and process improvement, has significantly enhanced inventory turnover efficiency and capital utilization while ensuring supply security. During the reporting period, CanSinoBIO did not have any situation in which its accounts payable balance exceeded RMB 30 billion or accounted for more than 50% of total assets.

CanSinoBIO Supplier Data

Indicator	Unit	2025 Performance
Suppliers in mainland China	Number	1,202
Suppliers in Hong Kong, Macao, and Taiwan, China	Number	8
Overseas suppliers	Number	95
Suppliers certified under quality management systems (e.g., ISO 9001) as of the end of the reporting period	Number	154
Suppliers certified under health and safety management systems (e.g., ISO 45001) as of the end of the reporting period	Number	62
Suppliers certified under environmental management systems (e.g., ISO 14001, ISO 14064) as of the end of the reporting period	Number	62

Information Security

CanSinoBIO complies with the *Cybersecurity Law of the People's Republic of China*, the *Data Security Law of the People's Republic of China*, and other applicable laws and regulations. The Company has revised its *Information Security Management Procedures* and *Information Digital Systems Management Procedures*, and has separately formulated the *Information Security Management Procedures for the Deployment and Application of AI Large Models*. By clearly defining principles for information processing, standards for data transmission, and mechanisms to safeguard the rights of personal information subjects, the Company has systematically established a data security management framework that is responsive to technological developments and provides strong support for business innovation and compliant operations.

The Company has established an information security governance system and built a five-tier governance structure consisting of the decision-making level, management level, execution level, employees and partners, and supervision level, thereby forming an organizational safeguard system with clear responsibilities and orderly operation.

CanSinoBIO Information Security Management Structure

Decision-making level	• Formulate information security management objectives and policies • Make decisions on critical information security incidents	**Supervision level** • Supervise the actual implementation of the Company's information security policies • Monitor information security risks and issue early warnings • Organize and carry out information security audits
Management level	• Develop information security management plans • Standardize management operations at all levels	
Execution level	• Implement specific information security management measures • Conduct information security risk assessments	
Employees and partners	• Comply with and implement information security requirements • Report information security risks in a timely manner	

In 2025, the Company conducted two dedicated internal information security audits to ensure that all information security risks and vulnerabilities were promptly rectified. In addition, the Company successfully obtained Level III certification under the Multi-Level Protection Scheme for information systems in the People's Republic of China.

During the year, the Company achieved systematic progress in process automation, intelligent collaboration, data security, cybersecurity, and system disaster recovery.

Process automation

The Company deployed RPA[10] digital employees at scale across a range of high frequency business scenarios, including finance and supply chain, driving automated operations across related processes. This initiative improved operational efficiency by approximately 40%, with processing accuracy exceeding 99.5%.

AI powered collaboration and enhanced decision making

The Company successfully launched the Feishu AI project, deeply integrating artificial intelligence capabilities into daily operations. Through the development of an intelligent knowledge base, the introduction of a meeting assistant, and the use of AI driven business data analysis, the Company enabled real time cross departmental collaboration and strengthened intelligent decision support.

Strengthening of the cybersecurity framework

The Company completed security enhancement and MLPS certification for its industrial control systems and core business platforms, and continued to strengthen its capabilities in proactive defense and real time threat detection.

System disaster recovery management

The Company established a multi center, end to end disaster recovery system, completed offsite disaster recovery deployment for core business systems and production databases, and implemented full data backup. This system enables fault detection within minutes and business switchover within seconds. Multiple disaster recovery drills were conducted throughout the year, and the system recovery success rate remained at 100%.

To comprehensively enhance employees' information security awareness and response capabilities, the Company delivered information security training and assessments to all employees through its E-Learning platform. At the same time, the Company regularly organized phishing email simulation exercises and red team blue team practical drills, effectively strengthening employees' security awareness and real-world defensive capabilities. In 2025, the Company organized four information security and privacy protection training sessions, achieving 100% employee coverage.

[10] RPA stands for Robotic Process Automation.

Content Index of ESG Reporting Code of Hong Kong Stock Exchange

Subject Area	Aspect	KPIs	Corresponding Chapters
Environmental	A1 Emissions	General Disclosure: Information on the policies; and compliance with relevant laws and regulations that have a significant impact on the issuer relating to air emissions, discharges into water and land, and the generation of hazardous and non-hazardous waste.	Waste Management
		A1.1 The types of emissions and respective emissions data	Waste Management ESG Data Summary
		A1.3 Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Waste Management ESG Data Summary
		A1.4 Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Waste Management ESG Data Summary
		A1.5 Description of emission target(s) set and steps taken to achieve them.	Waste Management
		A1.6 Description of how hazardous and non-hazardous wastes are handled, and a description of waste reduction target(s) set and steps taken to achieve them.	Waste Management
	A2 Use of Resources	General Disclosure: Policies on the efficient use of resources, including energy, water and other raw materials.	Resource Use
		A2.1 Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in' 000s) and intensity (e.g. per unit of production volume, per facility).	Use of Resources ESG Data Summary
Environmental	A2 Use of Resources	A2.2 Water consumption in total and intensity (e.g. per unit of production volume, per facility).	Resource Use ESG Data Summary
		A2.3 Description of energy use efficiency target(s) set and steps taken to achieve them.	Resource Use
		A2.4 Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set, and steps taken to achieve them.	Resource Use
		A2.5 Total packaging material used for finished products (in tonnes) and, where appropriate, with reference to per unit produced.	Resource Use ESG Data Summary
	A3 The Environment and Natural Resources	General Disclosure: Policies on minimizing the issuer's significant impact on the environment and natural resources.	Environmental Management
		A3.1 Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	Environmental Management
Social	B1 Employment	General Disclosure Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	Employment and Rights Protection Employee Compensation and Benefits Employee Training and Development
		B1.1 Total workforce by gender, employment type (for example, full or part-time), age group and geographical region.	Employment and Rights Protection
		B1.2 Employee turnover rate by gender, age group and geographical region.	Employment and Rights Protection

Subject Area	Aspect	KPIs	Corresponding Chapters
Social	B2 Health and Safety	General Disclosure: Information on (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	Occupational Health and Safety
		B2.1 Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	Occupational Health and Safety
		B2.2 Lost days due to work injury.	Occupational Health and Safety
		B2.3 Description of occupational health and safety measures adopted, how they are implemented and monitored.	Occupational Health and Safety
	B3 Development and Training	General Disclosure Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	Employee Training and Development
		B3.1 The percentage of employees trained by gender and employee category (e.g., senior management, middle management).	Protection of Employee Rights
		B3.2 The average training hours completed per employee by gender and employee category.	Protection of Employee Rights
	B4 Labour Standards	General Disclosure Information on: the policies; and compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour.	Protection of Employee Rights
		B4.1 Description of measures to review employment practices to avoid child and forced labour	Protection of Employee Rights
		B4.2 Description of steps taken to eliminate such practices when discovered.	Protection of Employee Rights
Social	B5 Supply Chain Management	General Disclosure Policies on managing environmental and social risks of the supply chain.	Responsible Supply Chain
		B5.1 Number of suppliers by geographical region.	Responsible Supply Chain
		B5.2 Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	Responsible Supply Chain
		B5.3 Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	Responsible Supply Chain
		B5.4 Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	Responsible Supply Chain
	B6 Product Responsibility	General Disclosure Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labeling and privacy matters relating to products and services provided and methods of redress.	Product Safety and Quality Customer Service and Pharmacovigilance Responsible Marketing
		B6.1 Percentage of total products sold or shipped subject to recalls for safety and health reasons.	Product Safety and Quality
		B6.2 Number of products and service-related complaints received and how they are dealt with.	Customer Service and Pharmacovigilance
		B6.3 Description of practices relating to observing and protecting intellectual property rights.	Product Innovation and R&D
		B6.4 Description of quality assurance process and recall procedures.	Product Safety and Quality
		B6.5 Description of consumer data protection and privacy policies and how they are implemented and monitored.	Information Security

Subject Area	Aspect	KPIs	Corresponding Chapters
Social	B7 Anticorruption	General Disclosure Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	Business Ethics
		B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	Business Ethics
		B7.2 Description of preventive measures and whistleblowing procedures, and how they are implemented and monitored.	Business Ethics
		B7.3 Description of anti-corruption training provided to directors and staff.	Business Ethics
	B8 Community investment	General Disclosure Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure that its activities take into consideration the communities' interests.	Community Development and Public Welfare
		B8.1 Focus areas of contribution (e.g., education, environmental issues, labour needs, health, culture and sport).	Public Welfare and Philanthropy
		B8.2 Resources contributed (e.g. money or time) to the focus area	Public Welfare and Philanthropy

Climate-related disclosures

Climate-related disclosures	Governance	Governance	Addressing Climate Change
	Strategy	Climate-related risks and opportunities	Addressing Climate Change
		Business model and value chain	Addressing Climate Change
	Strategy	Strategy and decision-making	Addressing Climate Change
		Financial position, financial performance and cash flows	Addressing Climate Change
		Climate resilience	Addressing Climate Change
		Financial impacts of climate-related risks and opportunities	Addressing Climate Change
	Risk Management	Risk management	Addressing Climate Change
	Metrics and Targets	Greenhouse gas emissions	Addressing Climate Change ESG Data Summary
		Climate-related transition risks	Addressing Climate Change
		Climate-related physical risks	Addressing Climate Change
		Climate-related opportunities	Addressing Climate Change
		Capital deployment	Addressing Climate Change
		Internal carbon prices	Addressing Climate Change
		Remuneration	Addressing Climate Change
		Industry-based metrics	Addressing Climate Change
		Climate-related targets	Addressing Climate Change
		Cross-industry metrics and applicability of cross-industry metrics	Addressing Climate Change

Shanghai Stock Exchange Index

Dimension	Number	Topic	Relevant Provisions	Corresponding Chapters
Environment	1	Climate change tackling	Article 21-28	Addressing Climate Change
	2	Pollutant discharge	Article 30	Waste Management
	3	Waste disposal	Article 31	Waste Management
	4	Ecosystem and biodiversity protection	Article 32	Environmental Management
	5	Environmental compliance management	Article 33	Environmental Management
	6	Energy usage	Article 35	Resource Use
	7	Usage of water resources	Article 36	Resource Use
	8	Circular economy	Article 37	Resource Use
Social	9	Rural revitalization	Article 39	Community Development and Public Welfare
	10	Contributions to the society	Article 40	Community Development and Public Welfare
	11	Innovation-driven	Article 42	Product Innovation and R&D
Social	12	Ethics of science and technology	Article 43	Clinical Trial Ethics
	13	Supply chain security	Article 45	Responsible Supply Chain
	14	Equal treatment to small and medium-sized enterprises	Article 46	Responsible Supply Chain
	15	Safety and quality of products and services	Article 47	Product Safety and Quality
	16	Data security and customer privacy protection	Article 48	Information Security
	17	Employees	Article 50	Employment and Rights Protection Employee Compensation and Benefits Employee Training and Development
Sustainability-related governance	18	Due diligence	Article 52	ESG Governance System, Responsible Supply Chain
	19	Communications with stakeholders	Article 53	Stakeholder Communication
	20	Anti-commercial bribery and anti-corruption	Article 55	Business Ethics
	21	Anti- unfair competition	Article 56	Business Ethics

GRI Content Index

Statement of use	CanSinoBIO has reported in accordance with the GRI Standards for the period January 1, 2025 to December 31, 2025.	
GRI 1 used	GRI 1: Foundation 2021	
Disclosure issue/ disclosure item	**Disclosure**	**Corresponding Chapters**
GRI 2: General Disclosures 2021		
The organization and its reporting practices		
2-1	Organizational details	About CanSinoBIO
2-2	Entities included in the organization's sustainability reporting	About CanSinoBIO
2-3	Reporting period, frequency and contact point	About the Report
2-4	Restatements of information	Not applicable
Activities and workers		
2-6	Activities, value chain and other business relationships	About CanSinoBIO, Responsible Supply Chain
2-7	Employees	Employment and Employee Rights Protection
2-8	Workers who are not employees	Employment and Rights Protection
Governance		
2-9	Governance structure and composition	Corporate Governance
2-10	Nomination and selection of the highest governance body	Corporate Governance
2-11	Chair of the highest governance body	Corporate Governance
2-12	Role of the highest governance body in overseeing the management of impacts	Corporate Governance
2-13	Delegation of responsibility for managing impacts	Corporate Governance
2-14	Role of the highest governance body in sustainability reporting	Corporate Governance
2-15	Conflicts of interest	Corporate Governance
2-16	Communication of critical concerns	Corporate Governance
2-17	Collective knowledge of the highest governance body	Corporate Governance
2-19	Remuneration policies	Corporate Governance
2-20	Process to determine remuneration	Corporate Governance
Strategy, policies and practices		
2-22	Statement on Sustainable Development Strategy	ESG Governance System
2-23	Policy commitments	ESG Governance System
2-25	Processes to remediate negative impacts	ESG Governance System
2-26	Mechanisms for seeking advice and raising concerns	ESG Governance System
2-27	Compliance with laws and regulations	ESG Governance System
Stakeholder engagement		
2-29	Approach to stakeholder engagement	Stakeholder Communication
GRI 3: Material Topics 2021		
3-1	Process to determine material topics	Dual Materiality Assessment
3-2	List of material topics	Dual Materiality Assessment
3-3	Management of material topics	Dual Materiality Assessment

Economic		
GRI 201: Economic Performance		
201-2	Financial implications and other risks and opportunities due to climate change	Addressing Climate Change
201-3	Defined benefit plan obligations and other retirement plans	Employee Compensation and Benefits
GRI 205: Anti-corruption		
205-1	Operations assessed for risks related to corruption	Business Ethics
205-2	Communication and training about anti-corruption policies and procedures	Business Ethics
205-3	Conffrmed incidents of corruption and actions taken	Business Ethics
GRI 206: Anti-competitive Behavior 2016		
206-1	Legal actions for anti-competitive behavior, anti-trust and monopoly practices	Business Ethics
Environmental		
GRI 101: Biodiversity 2024		
101-1	Policies to halt and reverse biodiversity loss	Environmental Management
101-2	Management of biodiversity impacts	Environmental Management
101-3	Access and benefit sharing	Environmental Management
101-4	Identifying biodiversity impacts	Environmental Management
101-5	Locations with biodiversity impacts	Environmental Management
101-6	Direct drivers of biodiversity loss	Environmental Management
101-7	Changes in the state of biodiversity	Environmental Management
101-8	Ecosystem services	Environmental Management

GRI 302: Energy 2016		
302-1	Energy consumption within the organization	ESG Data Summary
302-2	Energy consumption outside of the organization	ESG Data Summary
302-3	Energy intensity	ESG Data Summary
302-4	Reduction of energy consumption	Addressing Climate Change
302-5	Reductions in energy requirements of products and services	Addressing Climate Change
GRI 303: Water and Effluents 2018		
303-1	Interactions with water as a shared resource	Resource Use
303-2	Management of water discharge related impacts	Resource Use, Waste Management
303-3	Water withdrawal	ESG Data Summary
303-4	Water discharge	ESG Data Summary
303-5	Water consumption	ESG Data Summary
GRI 304: Biodiversity 2016		
304-1	Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas	Environmental Management
304-2	Significant impacts of activities, products and services on biodiversity	Environmental Management
304-3	Habitats protected or restored	Environmental Management
GRI 305: Emissions 2016		
305-1	Direct (Scope 1) GHG emissions	Addressing Climate Change, ESG Data Summary
305-2	Energy indirect (Scope 2) GHG emissions	Addressing Climate Change, ESG Data Summary

305-3	Other indirect (Scope 3) GHG emissions	/
305-4	GHG emissions intensity	Addressing Climate Change, ESG Data Summary
305-5	Reduction of GHG emissions	Addressing Climate Change, ESG Data Summary
305-7	Nitrogen oxides (NO_x), sulfur oxides (SO_x), and other significant air emissions	Waste Management, ESG Data Summary
GRI 306: Waste 2020		
306-1	Waste generation and significant waste related impacts	Waste Management
306-2	Management of significant waste related impacts	Waste Management
306-3	Waste generated	Waste Management
306-4	Waste diverted from disposal	Waste Management, ESG Data Summary
306-5	Waste directed to disposal	Waste Management, ESG Data Summary
GRI 308: Supplier Environmental Assessment		
308-1	New suppliers that were screened using environmental criteria	Responsible Supply Chain
308-2	Negative environmental impacts in the supply chain and actions taken	Responsible Supply Chain
Social		
GRI 401: Employment		
401-1	New employee hires and employee turnover	Employment and Rights Protection
401-2	Benefits provided to full time employees that are not provided to temporary or part time employees	Employee Compensation and Benefits
401-3	Parental leave	Employment and Rights Protection
GRI 403: Occupational Health and Safety		
403-1	Occupational health and safety management system	Occupational Health and Safety
403-2	Hazard identification, risk assessment and incident investigation	Occupational Health and Safety
403-3	Occupational health services	Occupational Health and Safety
403-4	Occupational health and safety matters: worker participation, consultation and communication	Occupational Health and Safety, Employment and Rights Protection
403-5	Worker training on occupational health and safety	Occupational Health and Safety
403-6	Promotion of worker health	Occupational Health and Safety
403-7	Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	Occupational Health and Safety
403-8	Workers covered by an occupational health and safety management system	Occupational Health and Safety
403-9	Work related injuries	Occupational Health and Safety
403-10	Work related ill health	Occupational Health and Safety
GRI 404: Training and Education		
404-1	Average hours of training per year per employee	Employee Training and Development
404-2	Programs for upgrading employee skills and transition assistance programs	Employee Training and Development
404-3	Percentage of employees receiving regular performance and career development reviews	Employee Training and Development
GRI 405: Diversity and Equal Opportunity		
405-1	Diversity of governance bodies and employees	Employment and Rights Protection, Corporate Governance
GRI 406: Non-discrimination		
406-1	Incidents of discrimination and corrective actions taken	Employment and Rights Protection

GRI 407: Freedom of Association and Collective Bargaining		
407-1	Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk	Employment and Rights Protection
GRI 408: Child Labor		
408-1	Operations and suppliers at significant risk for incidents of child labor	Employment and Rights Protection
GRI 409: Forced or Compulsory Labor		
409-1	Operations and suppliers at significant risk for incidents of forced or compulsory labor	Employment and Rights Protection
GRI 413: Local Communities		
413-1	Operations with local community engagement, impact assessments, and development programs	Community Development and Public Welfare
GRI 414: Supplier Social Assessment		
414-1	New suppliers that were screened using social criteria	Responsible Supply Chian
GRI 416: Customer Health and Safety 2016		
416-1	Assessment of the health and safety impacts of product and service categories	Customer Service and Pharmacovigilance
416-2	Incidents of non compliance concerning the health and safety impacts of products and services	Customer Service and Pharmacovigilance
GRI 417: Marketing and Labeling 2016		
417-1	Requirements for product and service information and labeling	Responsible Marketing
417-2	Incidents of non compliance concerning product and service information and labeling	Responsible Marketing
417-3	Incidents of non compliance concerning marketing communications	Responsible Marketing
GRI 418: Customer Privacy		
418-1	Substantiated complaints concerning breaches of customer privacy and losses of customer data	Information Security

List of Internal Policies[11]

Policy Name	Corresponding HKEX ESG Guide
Environmental Management Policy	Aspect A1 Emissions, Aspect A2 Use of Resources, Aspect A3 The Environment and Natural Resources, Climate related Disclosures
Management Policy for Environmental Protection Equipment and Facilities	Aspect A1 Emissions, Aspect A3 The Environment and Natural Resources
EHS Targets and Accountability Management Policy	Aspect A1 Emissions, Aspect A3 The Environment and Natural Resources
EHS Rewards and Penalties Management Policy	Aspect A1 Emissions, Aspect A3 The Environment and Natural Resources
Wastewater Management Procedures	Aspect A1 Emissions
Waste Gas Management Procedures	Aspect A1 Emissions
Energy Management Procedures	Aspect A2 Use of Resources
Energy Management Policy	Aspect A2 Use of Resources
Operating Procedures for Gas Boiler	Aspect A2 Use of Resources
Emergency Response Plan for Heavy Pollution Weather	Climate related Disclosures, Aspect B2 Health and Safety
Emergency Management Procedures for Water Supply Interruption, Water Leakage and Steam Supply Interruption	Climate related Disclosures, Aspect B2 Health and Safety
Board Member Diversity Policy	Aspect B1 Employment
Employee Handbook	Aspect B1 Employment, Aspect B4 Labour Standards
Employee Rights Protection Statement	Aspect B1 Employment
Attendance, Overtime and Leave Management System	Aspect B1 Employment
CanSino Occupational Health Management Policy	Aspect B2 Health and Safety

[11] This table only includes internal systems and key systems relating to each ESG topic disclosed in the Report as the part of the Company's all internal system lists.

Labor Protection Supplies Management Policy	Aspect B2 Health and Safety
EHS Objectives and Responsibilities Management Policy	Aspect B2 Health and Safety
EHS Rewards and Punishment System	Aspect B2 Health and Safety
Special Equipment Safety Management Policy	Aspect B2 Health and Safety
Hazardous Chemicals Safety Management Policy	Aspect B2 Health and Safety
SOP-SFY-032 Hazardous Chemicals Management Policy	Aspect B2 Health and Safety
Training Management System	Aspect B3 Development and Training
Supplier Management Regulations	Aspect B5 Supply Chain Management
Supplier Management Procedures	Aspect B5 Supply Chain Management
Standard Operating Procedures for Supplier Audits	Aspect B5 Supply Chain Management
Supplier Performance Management	Aspect B5 Supply Chain Management
Supplier Admission Management Procedures	Aspect B5 Supply Chain Management
Qualified Supplier List for Logistics Services	Aspect B5 Supply Chain Management
Procedures for Supplier Freezing, Unfreezing, and Exit Management	Aspect B5 Supply Chain Management
Supplier Code of Conduct	Aspect B5 Supply Chain Management
Laboratory Animal Management Procedures	Aspect B6 Product Responsibility
Feed and Bedding Management Procedures	Aspect B6 Product Responsibility
Changing Procedures for Animal Facility Personnel	Aspect B6 Product Responsibility
Standard Operating Procedures for Environmental Management of Animal Facilities	Aspect B6 Product Responsibility
Standard Operating Procedures for the Entry and Exit of Items into and out of Animal Facilities	Aspect B6 Product Responsibility
Standard Operating Procedures for Laboratory Animal Quarantine	Aspect B6 Product Responsibility
Deviation Management Procedures	Aspect B6 Product Responsibility
Constitution of the Drug Safety Committee	Aspect B6 Product Responsibility
Major Safety Incidents Handling Procedures	Aspect B6 Product Responsibility
Nonconforming Product Management Procedures	Aspect B6 Product Responsibility
Vaccine Traceability System Management Procedures	Aspect B6 Product Responsibility
Marketed Product Recall Management Procedures	Aspect B6 Product Responsibility
Quality Manual	Aspect B6 Product Responsibility
Responsibilities of the Head of Quality Management	Aspect B6 Product Responsibility
Responsibilities of the Qualified Person	Aspect B6 Product Responsibility
GMP Training Management Procedures for Personnel	Aspect B6 Product Responsibility
Training Management Procedures for Sampling Personnel	Aspect B6 Product Responsibility
Intellectual Property Management Policy	Aspect B6 Product Responsibility
Intellectual Property Emergency Response Plan	Aspect B6 Product Responsibility
Copyright Management Procedures	Aspect B6 Product Responsibility

Trademark Management Procedures	Aspect B6 Product Responsibility
Patent Management Procedures	Aspect B6 Product Responsibility
Technical Secret Management Procedures	Aspect B6 Product Responsibility
Patent and Invention Reward Procedures	Aspect B6 Product Responsibility
Management Procedures for Complaints of Marketed Products	Aspect B6 Product Responsibility
Handling Process for Insurance Compensation of Adverse Events Following Immunization	Aspect B6 Product Responsibility
Collecting Process for Suspected Adverse Events Following Immunization	Aspect B6 Product Responsibility
Handling Process for Suspected Adverse Events Following Immunization	Aspect B6 Product Responsibility
Measures for Compensation for Adverse Events Following Immunization	Aspect B6 Product Responsibility
Responsible Commercial Statement	Aspect B6 Product Responsibility
Compliance Operation Standard Manual	Aspect B6 Product Responsibility
Conflict of Interest Management Policy	Aspect B7 Anti corruption
Employee Receiving Gift Management Process	Aspect B7 Anti corruption
Anti-Corruption and Anti-Fraud Management System	Aspect B7 Anti corruption
Integrity Agreement	Aspect B7 Anti corruption
Confidentiality Agreement	Aspect B7 Anti corruption
Management Procedure for Compliance Reporting, Whistleblowing and Internal Investigations	Aspect B7 Anti corruption
Reward Process for Non-Compliance Reporting	Aspect B7 Anti corruption
Donation Management Policy	Aspect B8 Community Investment
Information Security Management Procedures	Aspect B6 Product Responsibility
Information Digital Systems Management Procedures	Aspect B6 Product Responsibility
Information Security Management Procedures for the Deployment and Application of AI Large Models	Aspect B6 Product Responsibility

ESG Data Summary

Environmental				
Indicator	**Unit**	**2025**	**2024**	**2023**
Energy Use				
Total GHG emissions (Scope 1 and Scope 2)	tCO_2e	43,873.91	31,075.31	31,726.94
Total GHG emissions per unit floor area of production and auxiliary facilities[12]	tCO_2e per square meter	0.38	0.46	0.46
GHG emissions per unit of floor area for all premises[13]	tCO_2e per square meter	0.36	/	/
Natural gas	tCO_2e	1,915.77	1,176.73	3,140.18
Gasoline	tCO_2e	118.53	13.46	166.11
Diesel	tCO_2e	4.09	5.30	3.98
Refrigerants	tCO_2e	82.62	668.61	1,035.19
Purchased electricity	tCO_2e	21,254.66	17,485.91	17,196.19
Purchased steam	tCO_2e	20,495.95	11,725.30	10,185.30
Emissions				
Total wastewater discharge	tonnes	269,989.00	221,776.80	293,485.00
Suspended solids	tonnes	0.94	3.60	1.43
Chemical oxygen demand	tonnes	2.55	10.05	15.82

[12] Floor areas of the Company's projects under construction and R&D projects not included.

[13] To better demonstrate CanSinoBIO's environmental protection practices, starting in 2025, the Company began disclosing certain environmental intensity indicators based on all sites. All sites include the Group's projects under construction and R&D projects.

Ammonia nitrogen	tonnes	0.10	1.09	1.76
Total wastewater pollutant discharge	tonnes	3.59	14.74	19.01
Wastewater pollutant discharge intensity per unit of floor area for wastewater discharge premises[14]	tonnes/m²	0.00004	0.00017	0.00021
Total waste gas emissions	m³	574,446,672.00	462,312,072.00	486,347,470.00
Nitrogen oxides	tonnes	1.16	1.48	1.97
Non methane hydrocarbons	tonnes	2.28	2.66	2.30
Particulate matter	tonnes	0.08	0.13	0.02
Waste gas pollutant emissions per production batch	tonnes/batch	0.0109	0.0118	0.0077
Total non hazardous waste generated	tonnes	51.00	84.89	180.24
Non-hazardous waste intensity per unit of floor area for production and ancillary premises	tonnes/m²	0.0008	0.0013	0.0026
Total hazardous waste generated	tonnes	170.77	216.42	573.43
Hazardous waste generated per production batch	tonnes/batch	0.53	0.60	1.03
Resource and Energy Consumption				
Natural gas	m³	876,092.00	537,603.00	1,434,630.00
Gasoline	liters	54,708.00	6,191.61	76,397.60
Diesel	liters	1,547.00	2,000.00	1,500.00
Refrigerants	kg	54.00	437.00	464.50
Purchased electricity	kWh	40,057,792.00	28,180,350.00	30,152,880.00
Purchased steam	tonnes	70,312.00	40,224.00	34,941.00
Total energy consumption	MWh	123,601.88	76,161.28	82,917.68
Energy consumption per unit of floor area for production and ancillary premises	MWh/m²	1.07	1.13	1.20
Energy consumption per unit of floor area for all premises[15]	MWh/m²	1.02	/	/
Municipal water supply	tonnes	446,517.00	210,136.00	341,713.00
Water consumption per unit of floor area for production and ancillary premises	tonnes/m²	3.16	3.12	4.93
Water consumption per unit of floor area for all premises[15]	tonnes/m²	3.69	/	/
Packaging materials used	tonnes	102.00	296.77	220.86
Packaging material intensity[16]	tonnes/batch	0.85	0.82	0.40

[14] All wastewater from the company's various plant sites is centrally collected and treated at a single sewage treatment station, with discharge density calculated based on the drainage plant area.

[15] To better demonstrate CanSinoBIO's environmental protection practices, the Company began disclosing this indicator in 2025.

[16] The amount of packaging materials used corresponds to 120 batches of products. The remaining products do not require packaging materials during production, sales, or other processes.

Social

Indicator	Unit	2025	2024	2023
Employment				
Total number of employees	persons	1,134	1,105	1,494
Number of new employees under labor contracts (including those who joined and left during the year)	persons	110	91	214
Number of employees by gender				
Male	persons	539	537	735
Female	persons	595	568	759
Proportion of employees by gender				
Male	%	47.53	48.60	49.20
Female	%	52.47	51.40	50.80

Number of employees by employment category				
Senior management	persons	16	17	30
Middle management	persons	158	182	248
General staff	persons	960	906	1,216
Proportion of employees by employment type				
Senior management	%	1.41	1.54	2.01
Middle management	%	13.93	16.47	16.60
General staff	%	84.66	81.99	81.39
Number of employees by age				
Under 30	persons	183	216	380
Aged 30 and above and under 50	persons	933	871	1,084
Aged 50 and above	persons	18	18	30
Proportion of employees by age				
Under 30	%	16.14	19.55	25.44
Aged 30 and above and under 50	%	82.28	78.82	72.55
Aged 50 and above	%	1.58	1.63	2.01
Number of employees by region				
China	persons	1,124	1,095	1,476
Overseas	persons	10	10	18
Proportion of employees by region				
China	%	99.12	99.10	98.80
Overseas	%	0.88	0.90	1.20

Employee turnover[17]				
Overall employee turnover rate	%	6.97	7.53	13.14
Employee turnover rate by gender				
Male	%	7.86	8.36	14.83
Female	%	6.15	6.73	11.44
Employee turnover rate by age group				
Under 30	%	10.29	11.84	18.80
Aged 30 and above and under 50	%	6.23	6.44	11.22
Aged 50 and above	%	10.00	5.26	3.23
Employee turnover rate by region				
China	%	6.89	7.53	13.28
Overseas	%	0.08	0	0
Employee turnover rate by business function				
Commercial	%	12.29	12.68	15.42
R&D	%	3.70	3.93	7.74
Functional	%	12.77	15.07	11.11
Technical operations and product supply	%	2.07	1.95	16.97
Employee Health and Safety				
Number of work related fatalities	persons	0	0	0
Rate of work related fatalities	%	0	0	0

[17] Data includes only employees who left voluntarily.

Lost hours due to work related injuries	hours	88[18]	0	1,120
Employee Development and Training				
Average training hours per employee	hours	34.48	37.8	72.70
Percentage of trained employees by gender				
Male	%	100	100	100
Female	%	100	100	100
Average training hours per employee by gender				
Male	hours	34.26	39.19	76.33
Female	hours	34.69	36.48	69.18
Percentage of trained employees by employee category				
Senior management	%	100	100	100
Middle management	%	100	100	100
General staff	%	100	100	100
Average training hours per employee by employee category				
Middle and senior management	hours	48.25	33.92	79.20
General staff	hours	31.99	38.65	71.21
Supplier Management				
Number of suppliers by region				
Chinese Mainland	suppliers	1,202	1,089	1,148
Hong Kong, Macao and Taiwan, China	suppliers	8	8	10
Overseas	suppliers	95	89	71

Supplier certifications				
Supplier with quality management system certification (ISO 9001, etc.)	suppliers	154	135	150
Supplier with environmental management system certification (ISO 14001, ISO 14064, etc.)	suppliers	62	46	55
Supplier with health and safety management system certification (ISO 45001, etc.)	suppliers	62	33	55
R&D and Innovation				
R&D investment	RMB 100 million	3.71	5.11	6.62
Cumulative patents granted	items	57	70	61
Anti-Corruption				
Anti-corruption training hours for all employees	hours/person	6.5	4.5	4.69
Anti-corruption training hours for Board members and senior management	hours/person	0.5	1	1
Participation rate of Board members in anti-corruption training	%	100	100	100
Corruption litigation cases	cases	0	0	0
Community Welfare				
Total charitable donations	RMB ten thousand	87.46	44.77	41.30
Hours contributed to charitable and public welfare activities	hours	908	311	/

[18] In 2025, lost working hours due to work-related injury were incurred because of an employee sustaining injuries in a traffic accident.

Definition

Term	Definition
HKEX	The Stock Exchange of Hong Kong Limited
NMPA	The National Medical Products Administration of China or, where the context so requires, its predecessor, the China Food and Drug Administration or CFDA
Vaccine	An active immunity preparation for the prevention of infectious diseases, which is made of pathogenic microbes (such as bacteria, rickettsia, viruses, etc.) and their metabolites through detoxification, inactivation, or genetic engineering
Antigen	Substances that can cause immune responses in humans and animals, can not only produce antibodies and primed lymphocytes by stimulating the immune system to have specific immune responses but also combine and react with antibodies and primed lymphocytes. It is usually a protein, but polysaccharides and nucleic acids can also be used as antigens
Conjugate vaccines	The polysaccharide-protein conjugate vaccine was prepared by containing polysaccharides conjugated to the carrier protein by chemicals
mRNA	Messenger RNA
mRNA vaccine	A vaccine which is based on the mRNA structure corresponding to antigen protein in the pathogen, transmitted to human cells through different transmission approaches and after translation, which can stimulate cells to produce antigen protein and produce specific immune responses
Ad5-nCoV	Ad5-nCoV Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), including two types of products, Convidecia® and Convidecia® Air® (Ad5-nCoV for inhalation)
Convidecia®	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for intramuscular injection, whose trade name is Convidecia®
Convidecia® Air® or "Ad5-nCoV for Inhalation"	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for inhalation
COVID-19	The disease caused by a new coronavirus called SARS-CoV-2
PBPV	A globally innovative, serotype-independent protein-based pneumococcal vaccine being developed by us

Term	Definition
PCV13	13-Valent pneumococcal conjugate vaccine, 13-valent vaccine primarily used for the prevention of invasive pneumococcal diseases
PCV13*i*	An improved pneumococcal polysaccharide conjugate vaccine being developed by us
PCV24	24 valent pneumococcal polysaccharide conjugate vaccine (CRM197/TT)
PPV23	23-valent pneumococcal polysaccharide vaccine, used for the prevention of invasive pneumococcal disease in children aged above two years of old and adults
Recombinant Poliomyelitis Vaccine	A VLP-based poliomyelitis vaccine developed by the Company
Recombinant Zoster Vaccine	The Recombinant Zoster Vaccine (Adenovirus Vector) developed by the Group in cooperation with Barinthus Biotherapeutics (UK) Limited (formerly known as Vaccitech (UK) Limited)
MCV	Meningococcal conjugate vaccine, used to prevent infection caused by meningococcal bacteria
MCV2	Groups A and C MCV, a vaccine used for the prevention of N. meningitides (Lta)
MCV4	Groups A, C, Y and W135 MCV, a vaccine used for the prevention of N. meningitides (Lta)
Menhycia®	Trade name of Groups A, C, Y and W135 MCV, a vaccine used for the prevention of N. meningitides (Lta)
Menphecia®	Trade name of Groups A and C MCV, a vaccine used for the prevention of N. meningitides (Lta)
iPneucia®	The trade name of 13 valent pneumococcal polysaccharide conjugate vaccine (CRM197/TT) used to prevent invasive pneumococcal disease
DPT	Diphtheria, Pertussis, Tetanus
Pertussis	Commonly known as whooping cough, a respiratory tract infection characterized by a paroxysmal cough

Term	Definition
DTcP	Diphtheria, tetanus and acellular pertussis (components) combined vaccine, each pertussis antigen of DTcP vaccines is purified individually and are subsequently combined in a defined ratio, hence ensuring a fixed and consistent composition
DTcP Infant	DTcP vaccine for infants and toddlers (under 2 years old)
DTcP-Hib-MCV4 Combined Vaccine	Absorbed diphtheria, tetanus and acellular pertussis (components) Haemophilus Influenzae Type b (Conjugate) – Group ACYW135 Meningococcal (Conjugate) combined vaccine
Tdcp Adolescent and Adult	A vaccine being developed by us for adolescents and adults (above 6 years old) that protects against pertussis, containing slightly increased amount of TT antigen to DTcP vaccine candidate for infants, but reduced amounts of pertussis and DT antigens
Hib	Haemophilus Influenzae Type b Conjugate Vaccine, Freeze-dried
Tetanus Vaccine	Adsorbed Tetanus Vaccine
GMP	Good Manufacturing Practice, guidelines and regulations from time to time issued pursuant to the *Drug Administration Law of the People's Republic of China* as part of quality assurance which aims to minimize the risks of contamination, cross contamination, confusion and errors during the manufacture process of pharmaceutical products and to ensure that pharmaceutical products subject to these guidelines and regulations are consistently produced and controlled in conformity to quality and standards appropriate for their intended use
EHS	Environment, Health, and Safety for short
CRM197	A well-defined diphtheria toxin mutant protein, in which one of its amino acids is mutated from glutamic acid to glycine
Clinical trial	Systematic research on drugs in the human body (patients or healthy volunteers) to confirm or reveal the effects, adverse reactions and/or absorption, distribution, metabolism, and excretion of experimental drugs, aiming to determine the effectiveness and safety of experimental drugs
ICH	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
Adjuvant	Substances that can assist antigen response and modulate immune reactions
Immunogenicity	The ability of a particular substance, such as an antigen, to provoke an immune response in the body of a human and other animal

Reader's Feedback

Thank you for reading the *2025 Environmental, Social and Governance (ESG) & Sustainability Report of CanSino Biologics Inc.*. We highly value your opinion of the Report. To improve the Company's performance in the environment, society, and governance, we welcome your opinions and suggestions on the Report, so that we can further improve the Report.

1. Your overall comment on the Report

☐ Excellent ☐ Good ☐ Ordinary ☐ Not Good ☐ Bad

2. Your comment on the readability of the Report

☐ Excellent ☐ Good ☐ Ordinary ☐ Not Good ☐ Bad

3. Your comment on the structural arrangement of the Report

☐ Excellent ☐ Good ☐ Ordinary ☐ Not Good ☐ Bad

If you have any questions or suggestions regarding this Report, please contact us via the following communication channels:

Address: Rongsheng Building, 185 South Street, West District, Tianjin Economic and Technological Development Zone, Tianjin, China

Tel: 022-58213766

Email: ir@cansinotech.com

Address: Rongsheng Building, 185 South Street, West District, Tianjin Economic and Technological Development Zone, Tianjin, China

Tel: 022-58213766

Email: ir@cansinotech.com